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The research scope encompasses the creation of novel bioactive composite scaffolds 
consisting of polycaprolactone (PCL) physically blended with 20 % tricalcium phosphate 
(TCP) particles. The supposition was for these scaffolds to be superior bone substitutes 
than the first generation pure PCL scaffolds due to its likeness to the living bone in terms 
of its composition. An additional perception was for these scaffolds to serve 
simultaneously as protein delivery systems to further augment its bone regenerative 
capacity. After the formulation of the concept and fabrication process, the scaffolds were 
subjected to both in vitro and in vivo experiments to test their efficacy. The scope of this 
thesis ended with animal studies, a stage just before preclinical trials.  
PCL-TCP scaffolds loaded with osteoblasts sustained osteogenic expression in vitro. The 
osteoblasts readily colonized the surfaces, rods and pores of the scaffolds while 
maintaining their osteogenic phenotype for four weeks. The addition of recombinant 
human bone morphogenetic protein-2 (rhBMP-2) enhanced the differentiated function of 
these osteoblasts that resulted in accelerated mineralization, followed by their death as 
they underwent terminal differentiation. Hence, the scaffolds were (1) capable of 
facilitating the process from cellular attachment to differentiation to mineral, (2) not toxic 
to the cells and (3) its 3D-architecture and porosity allowed for the infiltration of cells 
and loading of proteins. 
The protein release profile is a function of the degradation of the scaffolds. The objective 
was to characterize the in vitro degradation behavior of PCL-TCP scaffolds, paying 
special attention to how the inclusion of TCP would affect the degradation properties. 
Based on weight loss, water uptake and pH measurements, it was found that PCL-TCP 
 6 
scaffolds were degraded slowly in phosphate buffered saline (PBS).  A calcium-rich layer 
was nucleated on the scaffold’s surface that finally resulted in hydroxyapatite 
precipitation after 2 weeks of immersion in simulated body fluid (SBF) as verified by X-
ray diffraction, scanning electron microscopy and biochemical analysis.  
The effectiveness of PCL-TCP scaffolds as protein delivery systems for a single 
osteoinductive factor was evaluated. Pure PCL scaffolds of similar architecture were 
adopted as controls to investigate if the addition of TCP resulted in disparate release 
profiles. Protein retention was 49.1 % ±  for PCL-TCP scaffolds. The scaffolds were 
loaded with rhBMP-2 in fibrin sealant and immersed in PBS for 4 weeks. The rhBMP-2 
particles were distributed uniformly on the rods’ surfaces of PCL-TCP scaffolds. Bi- and 
tri-phasic burst-like release profiles were observed for scaffolds loaded with 10 and 20 
µg/ml rhBMP-2 respectively. PCL-TCP scaffolds retained rhBMP-2 longer than pure 
PCL scaffolds. The stability and bioactivity of eluted proteins were verified as well to 
ensure that the released growth factor could still execute its primary function of 
stimulating tissue regeneration. 
To evaluate the efficacy of the scaffolds as delivery systems for multiple 
growth factors, platelet-rich plasma (PRP) was used. The buffers sufficed as 
important determinants of the release profiles obtained for transforming growth factor 
and platelet derived growth factor. PBS-soaked scaffolds manifested a tri-phasic burst-
like profile that was absent in SBF. SBF-soaked scaffolds showed sustained release of the 
growth factors and total release was not achieved, whereas total release was realized for 
PBS-soaked scaffolds. Only release profiles for SBF-soaked scaffolds were growth factor 
mediated in terms of their amounts and sizes. The ultimate goal of obtaining the 
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release profile of growth factors was to correlate the protein release to the 
stages of bone regeneration observed from subsequent in vivo studies.    
We hypothesized that delivery of autologous PRP within a structural scaffold would 
promote more rapid early revascularization of the defect region and enhance longer-term 
functional bone repair. To test this hypothesis, we quantified the effects of PRP delivery 
within PCL-TCP scaffolds on vascularization, mineralization, and mechanical properties 
of large segmental defects in the rat femur. The in vivo study demonstrated that (1) PCL-
TCP scaffolds were effective at promoting bone formation within critically-sized femoral 
defects, (2) PRP delivery promoted early vascularization within bone repair constructs, 
and (3) micro-CT imaging techniques may be used to evaluate both vascularization and 
mineralization in a challenging in vivo test bed of bone regeneration strategies.  
The application of our bone regenerative strategy to a canine model and for a longer-term 
period was investigated. The research showed that PRP loaded PCL-TCP scaffolds could 
facilitate the placement of dental implants, shorten wound healing time and stimulate 
mandibular bone regeneration simultaneously in mongrels. PRP-treated defects had 98.3 
and 58.3 % higher bone volume than controls at 6 and 9 months respectively. New bone 
trabeculae were observed in close apposition to the dental implants and penetrated the 
defect site. The scaffolds experienced 33 % degradation from 6 to 9 months, finally 
occupying only 46.9 % of the cross-sectional area. 
In conclusion, the work presented in the thesis showed for the first time that three-
dimensional, bioactive polycaprolactone scaffolds can serve effectively as protein 
delivery systems for bone regeneration and has the potential for clinical applications. 
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Figure 1.1       Schematic diagram of research scope 
 
Figure 2.1       Generalized structural nature of connective tissue depicting common 
components (www.ptei.org/stuff/chapter 4_4_bone_te.pdf). 
 
Figure 2.2       A schematic representation of bone structure (www.ptei.org/stuff/chapter 
4_4_bone_te.pdf). 
        
Figure 2.3      The general sequence of bone fracture repair 
(www.ptei.org/stuff/chapter 4_4_bone_te.pdf). 
 
Figure 2.4      (a) Lay-down pattern of 0/60/120° forming triangular honeycomb 
pores viewed in the –Z direction of the FDM build process. (b) Alignment 
of filaments in scaffold specimens with a 0/60/120° lay-down pattern. In 
the OL orientation, the filaments are aligned in the XY-plane. In both ILV 
and ILH orientations, the filaments are aligned in the XZ-plane and YZ-
plane, respectively. (c) Cross-section viewed in the XZ plane of the FDM 
build process. Symbols are denoted as RW: road width, FG: fill gap, ST: 
slice thickness, LG: layer gap [31]. 
 
Figure 2.5      Mechanism of the activation of BMP receptors and signal transduction by    
Smad1, Smad4 and probably other Smads, exist as homotrimers [62]. 
 
Figure 2.6       Steps in the preparation of platelet-rich plasma [67]. 
Figure 3.1       Schematic diagram of research objectives. 
Figure 4.1       Scanning electron micrograph of empty PCL-TCP scaffolds revealed 
interconnecting pores of 400-600µm in diameter. 
   
Figure 4.2       Cell viability and proliferation was assayed by Alamar-Blue test. Cell 
density used was 3 x 105 cells/scaffold. Controls were cell/scaffold 
constructs without rhBMP-2. The other groups constituted of cell/scaffold 
constructs with 10, 100 and 1000 ng/ml rhBMP-2 (n = 4, ± SD). 
 
Figure 4.3       Confocal micrographs of osteoblasts stained with 2 µg/ml of FDA and 
100 µg/ml of PI after (a) 3 h, (b) 1 and (c) 20 days. FDA stained viable 
cells green while PI stained nuclei of necrotic cells red.  
 
Figure 4.4       Phase contrast light microscopy showing osteoblasts loaded PCL-TCP 
scaffolds at (a) 3 h, (b) 1 and (c) 20 days. All pictures were reproduced at 
4 x magnification. 
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Figure 4.5       Scanning electron micrographs of osteoblast adhering onto PCL-TCP 
scaffolds 2 weeks after cell loading. (a) Control (scaffold/cell constructs 
without rhBMP-2) (b) Scaffold/cell constructs with 10 ng/ml rhBMP-2 (c) 
Scaffold/cell constructs with 100 ng/ml of rhBMP-2 (d) Scaffold/cell 
constructs with 1000 ng/ml of rhBMP-2.   
 
Figure 4.6       Extracellular matrix production as assessed by osteocalcin assay. The 
results are shown as osteocalcin (ng/ml) as a function of days. On day 7, 
cells were stimulated with differentiation medium (refer to text). Control 
was scaffold/cell constructs without rhBMP-2. The other groups 
constituted of scaffold/cell constructs with 10, 100 and 1000 ng/ml of 
rhBMP-2, respectively (n = 4, ± SD). 
 
Figure 4.7      Extracellular matrix production as assessed by Von Kossa assay at day 20. 
Brownish-black deposits indicate extent of mineralization on the surfaces 
of culture wells (arrows). (a) Control (scaffold/cell constructs without 
rhBMP-2), (b) Scaffold/cell constructs with 10 ng/ml, (c) 100 ng/ml and 
(d) 1000 ng/ml of rhBMP-2. All pictures were reproduced at 4 x 
magnification. 
 
Figure 4.8      The percent of water absorbed by PCL-TCP composite scaffolds after 
immersion in simulated body fluids (SBF) and phosphate buffered saline 
(PBS) over a time period of 21 days (n = 2, ± SD). 
 
Figure 4.9      The pH of supernatant collected from PCL-TCP composite scaffolds 
immersed in simulated body fluids as a function of time (Real line: trend 
line) (n = 2, ± SD). 
Figure 4.10    Calcium/phosphate ratio of the supernatant collected from PCL-TCP 
composite scaffolds immersed in simulated body fluids as a function of 
time (n = 2, ± SD). 
Figure 4.11   Phase contrast micrographs of the calcium precipitates on the surface of a 
representative PCL-TCP composite scaffold after immersion in simulated 
body fluids for (a) 1 and (b) 4 weeks and stained with Von Kossa as 
described in manuscript. 
Figure 4.12    Scanning electron micrographs of the calcium precipitates on the surface 
of PCL-TCP composite scaffolds immersed in simulated body fluids for 
(a) 2, (b) 3 and (c) 4 weeks. Figure (d) is a higher magnification of (c) that 
illustrates the unique globoid and needle-like structures manifested by the 
calcium precipitates on the surface of PCL-TCP scaffolds after immersion 
in simulated body fluids for 4 weeks. 
Figure 5.1    SEM micrographs of 3-dimensional (A) PCL and (B) PCL-TCP scaffold 
structure produced by fused deposition modeling and having a 0/60/120° 
lay down pattern. Both pictures represent the top view, displaying a 
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typical array of equilateral triangles. TCP was evident as particles on the 
walls of the PCL scaffold. 
 
Figure 5.2       SEM micrograph of PCL-TCP scaffolds before (A & C) and 
after (B & D) 
hydrolysis in lipase solution for 3 days. 
 
Figure 5.3    Protein retention of PCL-TCP composite scaffolds after pretreatment in 
simulated body fluid (SBF) and phosphate buffered saline (PBS) over time 
(n = 2, ±  SD). 
 
Figure 5.4    SEM micrographs of (A) Control (PCL-TCP-fibrin scaffolds), (B) PCL-
fibrin and (C) PCL-TCP-fibrin scaffolds loaded with 10 µg/ml of rhBMP-
2. 
 
Figure 5.5       The amount of rhBMP-2 released from experimental groups in vitro as a 
function of time. Released medium was removed at 2 h, followed by 1, 2, 
4, 7, 10, 14 and 21 days and quantified by ELISA (n = 4, mean ± SD). 
Group 1: PCL-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 2: 
PCL-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Group 3: PCL-TCP-
fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 4: PCL-TCP- 
fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Controls showed no 
release of rhBMP-2 at all time points. 
 
Figure 5.6      The cumulative in vitro release of rhBMP-2 from experimental groups as a 
function of time. Released medium was removed at 2 h, followed by 1, 2, 
4, 7, 10, 14 and 21 days and quantified by ELISA (n = 4, mean ± SD). 
Group 1: PCL-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 2: 
PCL-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Group 3: PCL-TCP-
fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 4: PCL-TCP-fibrin 
scaffolds loaded with 20 µg/ml rhBMP-2. Controls showed no release of 
rhBMP-2 at all time points. 
 
Figure 5.7      The amount of total protein release from experimental groups in vitro as a 
                        function of time. Released medium was removed at 2 h, followed by 1, 2, 
4, 7, 10, 14 and 21 days and quantified by protein BioRad Assay (n = 4, 
mean ± SD). Group 1: PCL-fibrin scaffolds loaded with 10 µg/ml rhBMP-
2. Group 2: PCL-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Group 
3: PCL-TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 4: 
PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Control 1: 
PCL-fibrin scaffolds alone. Control 2: PCL-TCP-fibrin scaffolds alone. 
 
Figure 5.8    ALP histochemistry of hOB incubated with eluted supernatant 
from 2 h from (A) PCL-fibrin scaffolds alone, (B) PCL-fibrin 
scaffolds loaded with 10 µg/ml rhBMP-2, (C) PCL-fibrin 
scaffolds loaded with 20 µg/ml rhBMP-2, (D) PCL-TCP-fibrin 
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scaffolds loaded with 10 µg/ml rhBMP-2 and (E) PCL-TCP-
fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Blue-stained 
granules within the cytoplasm of cells represent sites of 
phosphatase activity. All pictures are reproduced at • 20 
magnification.  
 
Figure 5.9    SDS-PAGE represents rhBMP-2 elution from (A) PCL-fibrin and PCL-
TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Lane 1: protein 
molecular weight markers. Lane 2: positive control. Lanes 3-6: eluted 
rhBMP-2 from PCL scaffolds loaded with 10 µg/ml rhBMP-2 at 2 h, days 
2, 7 and 16. Lanes 7-9: eluted rhBMP-2 from PCL-TCP scaffolds loaded 
with 10 µg/ml rhBMP-2 at 2 h, days 1 and 14. (B) PCL-fibrin and PCL-
TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Lane 1: protein 
molecular weight markers. Lane 2: positive control. Lanes 3-6: eluted 
rhBMP-2 from PCL scaffolds loaded with 20 µg/ml rhBMP-2 at 2 h, days 
2, 7 and 16. Lanes 7-9: eluted rhBMP-2 from PCL-TCP-fibrin scaffolds 
loaded with 20 µg/ml rhBMP-2 at 2 h, days 10 and 21. RhBMP-2 suffices 
as a 30 kDa band. 
 
Figure 6.1       Scanning electron (A) and phase contrast (B) micrographs of platelet-rich 
plasma loading onto PCL–TCP composite scaffolds. PRP mixture formed 
an interconnected network that extended across the pores, while remaining 
rooted to the rods of the composites. 
 
Figure 6.2       Amount of total protein release from platelet-rich plasma-
loaded PCL–TCP composite scaffolds  immersed in simulated 
body fluid (SBF) and phosphate buffered saline (PBS) as a 
function of time (days). Control, that is PCL–TCP composite 
scaffolds loaded with thrombin solution alone, showed no 
release (n = 4, ± SD). 
 
Figure 6.3      Amount of TGF-β1 released from PRP-loaded PCL–TCP composite 
scaffolds immersed in simulated body fluid (SBF) (A) and phosphate 
buffered saline (PBS) (B) as a function of time (days). Control, that is 
PCL–TCP composite scaffolds loaded with thrombin solution alone, 
showed no release (n = 4, ± SD). A trendline with polynomial equation 
could be extrapolated for SBF immersed scaffolds. 
 
Figure 6.4      Amount of PDGF-BB released from PRP-loaded PCL–TCP composite 
scaffolds immersed in simulated body fluids (SBF) (A) and phosphate 
buffered saline (PBS) (B) as a function of days. Control, that is PCL–TCP 
scaffolds loaded with thrombin solution alone, showed no release (n = 4, ± 




Figure 6.5       Amount of IGF-1 released from PRP-loaded PCL–TCP composite 
scaffolds immersed in simulated body fluid (SBF) and phosphate buffered 
saline (PBS) as a function of time (days). Control, that is PCL–TCP 
composite scaffolds loaded with thrombin solution alone, showed no 
release (n = 4,  ± SD). 
Figure 7.1       Two-dimensional radiographs of both control (PCL-TCP scaffold 
alone)(A-C) and treated (PRP-loaded PCL-TCP scaffolds) (D-F) femurs, 
at three weeks after surgery (A and D), eight weeks after surgery (B and 
E) and 12 weeks after surgery (C and F). Note the bone union in PRP-
loaded PCL-TCP treated femurs and gap in control femurs. 
 
Figure 7.2       Quantitative assessment of vascular volume fraction (VVF) at week 3 as 
determined by micro-CT analysis at a threshold of 100. N = 5 for each 
treatment group. Results are expressed as mean ± standard error. § 
indicates a statistical trend (P = 0.08). 
 
Figure 7.3       Representative week 3 post-surgery micro-CT images of control (PCL-
TCP alone) (A-C) and treated (PRP-loaded PCL-TCP) (D-F) femurs. A 
and D: bone and vasculature. B and E: bone only. C and F: vasculature 
only.  
 
Figure 7.4       Quantitative assessment of bone volume fraction (BVF) at week 3 as 
determined by micro-CT analysis at a threshold of (A) 100 and (B) 75. N 
= 11 for each treatment group. Results are expressed as mean ± standard 
error. * indicates statistical significance (P < 0.05). 
 
Figure 7.5      Quantitative comparison of bone volume fraction (BVF) at weeks 3 and 12 
as determined by micro-CT analysis at a threshold of 100. N = 11 for each 
treatment group at week 3. N = 6 for each treatment group at week 12. 
Results are expressed as mean ± standard error. * indicates statistical 
significance (P < 0.05). 
 
Figure 7.6      Representative week 12 post-surgery micro-CT images of control (PCL-
TCP alone) (A-B) and treated (PRP-loaded PCL-TCP) (C-D) femurs. Note 
the bone union and callus formation in PRP-loaded PCL-TCP treated 
femurs and gap in control femurs. 
 
Figure 7.7       A plot of torque against angular displacement obtained for a 
representative PRP-loaded PCL-TCP treated femur that experienced bone 
union. 
 
Figure 7.8       The correlation between (A) maximum torque and (B) stiffness with bone 
volume fraction (BVF) as determined by biomechanical evaluation. The 
data was pooled from both control (PCL-TCP alone) and treated (PRP-
loaded PCL-TCP) femurs (N = 10). 
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Figure 7.9       (A) Representative week 12 post-surgery histological images of PRP-
loaded PCL-TCP treated femurs. Sections 1: New bone spanning the 
entire defect site (brown/black) at 4 x magnification. Sections 2: 
Connective tissue with vasculature (red) and collagen fibers (blue). 
Sections 3: Active resorption sites in new bone. Sections 4: Vascular 
structures interspersed between new bone. Sections 5: Bone marrow filled 
up cavities between new bone. Sections 2-5 are light micrographs taken at 
20 x magnification. 
(B) Representative week 12 post-surgery histological images of control 
(PCL-TCP alone) femurs. Sections 1: New bone spanning the entire defect 
site (brown/black) at 4 x magnification. Sections 2: Connective tissue with 
vasculature (red) and collagen fibers (blue). Sections 3: Active resorption 
sites in new bone. Sections 4: Vascular structures interspersed between 
new bone. Sections 5: Bone marrow filled up cavities between new bone. 
Sections 2-5 are light micrographs taken at 20 x magnification. 
 
Figure 8.1       Digital photographs of implanted PCL-TCP scaffolds with titanium 
implants (A) loaded with platelet-rich plasma (PRP), (B) without PRP and 
empty defect (controls). 
 
Figure 8.2       Segmentation using VGStudio Max software. (A) Segmented bone (light 
grey), scaffold (dark grey) with titanium implants (blue) and (B) 
Separation of segmented regions.  
 
Figure 8.3      Quantitative assessment of bone volume fraction (BVF) at 6 and 9 months 
as determined by micro-CT analysis. (A) shows the differences between 
PRP loaded PCL-TCP scaffolds and controls. (B) illustrates the 
differences between frontal and caudal situated PRP-loaded PCL-TCP 
scaffolds. Results are expressed as mean ± standard error. * indicates 
statistical significance (p < 0.05). 
 
Figure 8.4      Representative three-dimensional micro-CT images of a PRP-treated group 
at 9 months examined slice by slice to determine if bony ingrowth was 
present throughout the defect site. The proximal (A), distal (B) and middle 
(C) section of the defect site are shown. 
 
Figure 8.5       Representative histological section of platelet-rich plasma-treated defect at 
6 months. The two dental implants and scaffold remnants appeared black 
and dark brown respectively. The section was stained with Haematoxylin 
and eosin, which stains nuclei blue-purple, erythrocytes bright pink to red 
and cytoplasm and other tissue elements various shades of pink. I: 
Implant, S: Scaffold. (Original magnification: (A) x 20, (B and C) x 40). 
 
Figure 8.6       Representative histological section of platelet-rich plasma-treated defect at 
6 months. The two dental implants and scaffold remnants appeared black 
and dark brown respectively. The section was stained with Von Kossa, 
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which stains calcium salts brown and non-mineralized tissue pink. Implant 
= I, Scaffold = S. (Original magnification: (A) x 20, (B and C) x 40). 
 
Figure 8.7       Representative histological section of platelet-rich plasma-treated defect at 
9 months. The two dental implants and scaffold remnants appeared black 
and dark brown respectively. The section was stained with Haematoxylin 
and eosin, which stains nuclei blue-purple, erythrocytes bright pink to red 
and cytoplasm and other tissue elements various shades of pink. Implant = 
I, Scaffold = S. (Original magnification: (A) x 20, (B and C) x 40). 
 
Figure 8.8      Representative histological section of platelet-rich plasma-treated defect at 
9 months. The two dental implants and scaffold remnants appeared black 
and dark brown respectively. The section was stained with Von Kossa, 
which stains calcium salts brown and non-mineralized tissue pink. Implant 
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CHAPTER 1: INTRODUCTION 
 
1.1   BACKGROUND 
This chapter aims to provide background information regarding the current available 
treatments for the repair of bone defects and their corresponding drawbacks that lead the 
author to pursue a bone tissue engineering strategy. 
 
1.1.1 Current treatments for bone defects 
Bone tissue, by itself, possesses highly regenerative repair capability. For example, new 
bone is formed at a fracture site if appropriate reduction and fixation are provided. This is 
followed by union of the bone and almost complete restoration within several months, 
with the shape of the new bone similar to the original. However, there is a limit to this 
regenerative capacity. In the event of a severely comminuted fracture or incorrect 
treatment, bone union cannot be achieved and this condition is termed nonunion. 
Similarly, if the bone defect is the result of an extraction of a bone tumour, bone can only 
be repaired by natural processes if it is a small defect, but not if the bone defect is 
sufficiently large or critical-sized [Saoto, 2003]. Nonunions and large bone defects cause 
major dysfunctions and pain to the patient and are an increasingly serious health problem 
[AAOS, 2003; NOF, 2003; ACS, 2003]. Current clinical treatments for critical-sized 
defects are inadequate and often yield poor healing due to the complicated anatomy and 
physiology of bone tissue as well as limitations of present medical technology.  
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The “gold standard” treatment for healing bone defects at the moment is the 
transplantation of natural bone tissue from the patient known as autografts. This 
technique does not cause an immunological reaction because the patient’s own bone is 
used and activates the regenerative capacity of bone. However, several problems surfaced 
with the usage of autografts, namely: (1) insufficient sites where bone may be harvested 
without any loss of function [Enneking, 1980; Brown, 1982], (2) alleviated effectiveness 
in irregularly-shaped defects, (3) bone resorption prior to complete healing and (4) 
emergence of potential complications such as infections, fractures, pain, paresthesia, 
nerve injuries and donor-site morbidities [Younger, 1989; Gitelis, 2002]. Another 
commonly used bone graft material is allografts derived from cadavers. Severe concerns 
regarding the use of unprocessed allografts are mainly disease transmission and 
immunologic rejection. Processed allografts, on the other hand, for instance 
demineralized bone matrix, lack osteoinductive factors necessary for stimulating bone 
repair [Bostrom, 1997]. Xenografts or bone grafts obtained from a different species are 
also a poor alternative due to the possibilities of disease transmission or immunological 
rejection [Erbe, 2001]. The inadequacies of the current treatment options for bone defects 
has digressed our attention to bone tissue engineering as a potential substitute method. 
 
1.1.2 Bone Tissue Engineering strategies 
Tissue engineering has been defined as the application of scientific principles to the 
design, construction, modification and growth of living tissues using biomaterials, cells 
and factors, alone or in combination [Bostrom, 1997]. A plethora of newspaper headlines 
have captured the public (and scientific) imagination as to the potential of skeletal tissue 
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engineering for bone regeneration. Skeletal tissue engineering requires, essentially, an 
osteoconductive scaffold to facilitate cell attachment and maintenance of cell function, 
together with a rich source of osteoprogenitor cells in combination with selected 
osteoinductive factors. However, to date, a fully vascularised and mechanically 
competent osteoconductive/inductive bone construct remains to be documented [Rose, 
2002]. 
With respect to this thesis, the term osteoinduction refers to the formation of bone 
through the guided differentiation of uncommitted mesenchymal cells, whereas 
osteoconduction is the process of bone growth on surfaces which act as scaffold for bone 
regeneration [Sykaras, 2001]. Understanding how cells function and form matrix as well 
as the fabrication of polymeric materials that provide appropriate scaffolding conducive 
for cell attachment and maintenance of cell function, are key concepts that are currently 
lacking in the field. 
The emergence of bone tissue engineering offers a promising alternative approach for 
healing bone injuries by utilizing the body’s own physiological response to tissue damage 
in conjunction with engineering principles. Tissue engineering strategies can be 
categorized into cell [Bancroft, 2001], growth-factor [Tabata, 2003] and scaffold-based 
strategies [Ratner, 2004]. In practice, however, all three components are needed to 
achieve a solution that works. A credible bone tissue-engineered construct should fulfill 
the respective design criteria collated below [Mistry, 2005]: 
• Provide temporary mechanical strength to the affected area. 
• Act as a substrate for osteoid deposition and growth. 
• Contain a porous architecture to allow for vascularisation and bone ingrowth. 
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• Encourage bone cell migration into a defect and enhance cell activity for 
regeneration and repair. 
• Degrade in a controlled manner to facilitate load transfer to developing bone 
and to allow bone growth into the defect. 
• Degrade into non-toxic products that can safely be removed by the body. 
• Not cause a significant inflammatory response. 
• Be capable of sterilization without loss of bioactivity. 
Growth factor and scaffold-based strategies were implemented for the work presented in 
this thesis. Growth factors are signaling polypeptide molecules that regulate a multitude 
of cellular functions including proliferation, differentiation, migration, adhesion and gene 
expression [Linkhart, 1996; Schliephake, 2002]. A growth factor may be produced by a 
variety of cell types and the same growth factor can act on different cell types with a 
diverse range of effects. A great deal of research is being conducted on growth factors 
and their associated delivery mechanisms that can transfer the factors, maintain them at 
the site of implantation and optimize their release [Sheridan, 2000; Whitaker, 2001; 
Ziegler, 2002]. For bone applications, most work is focused on osteoinductive factors 
[Boden, 1999]. Major players in the skeletal tissue engineering are members of the TGF-
β superfamily notably the bone morphogenetic proteins. It must be noted that growth 
factors promoting vascularisation are of equal significance [Murphy, 2000; Orban 2002].  
Growth factor-based strategies provide the osteogenic and osteoinductive components of 
a potential treatment for severe bone injury or loss. However, the importance of a 
scaffold biomaterial must not be overlooked. It is essential for filling a critical-sized 
defect and simultaneously as a carrier for the growth factors used to heal the defect.  The 
 28 
main function of the scaffold is to direct the growth of cells migrating from surrounding 
tissue (tissue conduction). The scaffold must therefore provide a suitable substrate for 
cell attachment, proliferation, differentiated function and in certain cases, cell migration 
[Thomson, 2000]. The scaffold should also provide temporary mechanical support, 
osteoconductivity, porous architecture, controlled biodegradation, biocompatibility of 
itself and its degradation products and sterilizability as highlighted above.  
Several points need to be considered when incorporating growth factors for release from 
such scaffolds [PTEI, 2005]: 
• Loading capacity defined as the amount of growth factor that can be mixed into 
the scaffold 
• Load distribution as the growth factor needs to be dispersed evenly throughout 
the scaffold 
• Binding affinity defined as how tightly the growth factor binds the scaffold and 
the binding must be sufficient to allow release 
• Release kinetics that needs to be controlled to allow the appropriate dose of 
growth factor to reach the cells over a given period of time  
• Long term stability which refers to the stability of the growth factors when 
incorporated within the scaffold at physiological temperature and growth factors 
need to maintain their structure and activity over a prolonged period of time. 
 
1.2   RESEARCH OBJECTIVES 
The aim of this work was to investigate whether the three-dimensional, bioactive 
polycaprolactone scaffolds can serve as effective protein delivery systems for the repair 
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of bone tissue. The merit of the work was that the PCL-based scaffolds could serve not 
only as a template for bone growth but also as a delivery vehicle for osteoinductive 
factors so as to eventually improve the quality of the bone regenerated in terms of the 
amount/volume of bone formed, infiltration of vascular networks and bone unions. 
 





Figure 1.1: Schematic diagram of research scope 
 
 
The research scope (Fig 1.1) encompasses the formulation of a concept followed by a 
succession of testings for its validity. The concept was the creation of second generation 
bioactive composite scaffolds consisting of PCL physically blended with 20 % TCP. The 
supposition was for these scaffolds to be superior bone substitutes than the first 
generation pure PCL scaffolds due to its likeness to the living bone in terms of its 
composition. An additional perception was for these scaffolds to serve simultaneously as 
growth factor delivery systems to further augment its bone regenerative capacity. After 
the formulation of the concept and material fabrication process, the scaffolds were 
subjected to both in vitro (Chapters 4-6) and in vivo (Chapters 7-8) experiments to 
understand and test its efficacy. The scope of this thesis ended at the preclinical stage, 
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which were animal studies. The detailed description of each research objective can be 
found in Chapter 3.  
 
CHAPTER 2: LITERATURE REVIEW 
2.1   BONE PHYSIOLOGY 
The reconstruction of bone requires prior in depth knowledge of the natural anatomy and 
physiology of the bone tissue. Bone is a subset of a large and diverse group of tissues 
collectively referred to as connective tissue. Despite exhibiting rather varied functions in 
the body, connective tissues share certain structural properties. Their extensive 
extracellular matrix imparts a number of physical advantages that enables them to 
withstand mechanical stresses better than any other tissue. Connective tissues consist of 
three elements, namely, ground substance, fibers and cells. Ground substance is an 
unstructured material that occupies the space between cells and contains interstitial fluid, 
cell adhesion proteins and proteoglycans. The fluid serves as a medium for diffusion of 
essential substances, while the other two components provide anchoring attachments for 
cells and mechanical properties for the matrix. The fibers of connective tissue are 
typically composed of protein and confer support and resistance to physical stresses. 
Collagen is one of the most abundant proteins in animals and is often organized into 
fibers that permeate many connective tissues. The mechanical properties of the tissue are 
greatly influenced by the composition, abundance, and organization of the fibers. Figure 
2.1 represents a generalized scheme depicting the varying components of a typical 
connective tissue. 
Bone tissue appears to contain five main cell types: 
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• Osteogenic cells - generally located in tissue contacting the endosteum or 
periosteum (inner and outer connective tissue linings of bone respectively), they 
respond to trauma, giving rise to osteoblasts and osteoclasts that can reform and 
remodel bone. 
• Osteoblasts - bone-forming cells that synthesize and secrete unmineralized 
ground substance, generally abundant in areas of high bone metabolism such as 
under the periosteum and next to the medullary cavity. 
• Osteocytes - mature cells that have secreted bone tissue around themselves; they 
maintain bone health through enzymatic secretions, by influencing mineral 
content, and by regulating calcium release into the blood. 
• Osteoclasts - large, multinuclear cells that enzymatically break down bone tissue, 
influencing bone growth, remodeling, and healing. 
• Bone-lining cells - found along the surface of many adult bones, thought to 
regulate the movement of calcium and phosphate into and out of the bone matrix. 
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Figure 2.1: Generalized structural nature of connective tissue depicting common 
components (Pittsburg Tissue Engineering Initiative). 
 
The chemical composition of bone consists of both organic and inorganic matrix 
components. The osteoblasts secrete proteoglycans, glycoproteins and collagen fibers that 
form the organic osteoid. These molecules contribute to bone structure and are primarily 
responsible for the limited flexibility and great tensile strength of bone. The inorganic 
component of bone consists mainly of mineral salts known as hydroxyapatites, which are 
largely made up of calcium phosphates. Tiny crystals of these salts lie in and around the 
collagen fibers in the extracellular matrix, producing the hardness that is so characteristic 
of bone. The proper combination of the fibers and salts allows bones to be both strong 
and durable without being brittle. Surprisingly, healthy bone rivals steel in resisting 
tension and is roughly half as strong in resisting compression. Bone has the added 
advantage of being able to repair and remodel itself in response to physical stresses. 
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As stated previously, these bone components appear to be organized in two ways. There 
exists a greater degree of order in compact or dense bone, which results in a higher 
degree of mineralization. At a perfunctory glance, compact bone may appear to be very 
dense, though a more intimate inspection would reveal significant porosity. As 
demonstrated in Figure 2.2, numerous canals and other passageways create channels for 
nerves, blood vessels, and lymph vessels. These passages also result in a lower bone mass 
and density, an important concern for motile animals. 
The repeated structural unit of compact bone is called the osteon or Haversian system. 
Each of these osteons exists as an elongated cylinder running parallel to the long axis of 
the bone where they act as weight-bearing pillars. In true fact, each osteon is a group of 
hollow tubes of bone matrix or lamellae that is arranged like the rings of a tree trunk. 
Through the center of each osteon is a canal referred to as the Haversian canal, which 
 





contains small blood vessels and nerve fibers. If these canals are to successfully supply 
interior bone cells, it stands to reason that extra canals must extend from these central 
canals into the thin connective tissue membrane containing both osteoblasts and 
osteoclasts. Lastly, mature bone cells (osteocytes) reside in small cavities, called lacunae, 
at the junctions between lamellae. Hair-like canals called canaliculi serve to connect the 
lacunae to each other and to the central canal. 
In contrast to the apparent internal regularity of compact bone, spongy 
or cancellous bone appears far less organized with a greater amount of 
porosity as well. Spongy bone consists of thin plates of bone known as 
trabeculae, which contain irregularly arranged lamellae and osteocytes 
inter-connected by canaliculi. It is noted that no osteons are present and 
hence nutrients must reach the osteocytes by diffusing through the 
canaliculi from the marrow spaces between the trabeculae. 
As seen in Figure 2.3, bone has a remarkable ability to repair structural damage. A crucial 
part of this repair mechanism involves the regeneration of new bone. It is hoped that 
tissue engineering strategy will be able to replicate this normal regenerative ability, 









2.2   BIOMATERIALS SELECTION 
2.2.1   Polycaprolactone (PCL)-based scaffolds 
Characterization 
PCL is a semicrystalline, biodegradable polymer belonging to the aliphatic polyester 
family. The repeating molecular structure of PCL homopolymer consists of five nonpolar 
methylene groups and a single relatively polar ester group [Perninand, 1997]. It has a low 
glass-transition temperature of –60 Û&DPHOWLQJSRLQWRIÛ&DQGDKLJKGHFRPSRVLWLRQ
temperature of 350 Û& ZLWK D ZLGH range of temperatures that allow extrusion. This 
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imparts a rubbery characteristic to the material that results in its high permeability for 
gases and fluids, a property that has been exploited for the delivery of low molecular 
weight drugs [Coombes, 2004].  
 
Fabrication method 
The major requirement of any proposed polymer processing technique is not only the 
utilization of biocompatible materials, but that the process should in no way affect the 
biocompatibility of the polymer. The processing technique should also allow the 
manufacture of scaffolds with controlled porosity and pore size, both crucial factors for 
bone tissue regeneration. Pore size plays a critical role in both tissue ingrowth and the 
internal surface area available for cell and protein attachment. A highly porous scaffold is 
desirable to allow adequate cell or protein seeding, followed by its migration throughout 
the material.  
The method of synthesis was described in detail in recent literature [Hutmacher, 2001]. 
The first step is filament fabrication. Pellets of PCL (catalog no. 440744) from Aldrich 
Chemical Co., Inc. (Milwaukee, WI) are used. The polymer has an average number-
average molecular weight (Mn) of 80,000 with a melt index of 1.0 g/10 min. The polymer 
pellets are kept in a desiccator prior to usage. Filament fabrication is performed with a 
fiber-spinning machine (Alex James & Associates Inc., Greensville, SC). The pellets are 
melted at 190 °C in a cylinder with an external heating jacket. After a hold time of 15 
min, the temperature is lowered to 140 °C and the polymer melt is extruded through 
spinnerets with a die exit diameter of 0.064 in. (1.63 mm). Each batch of PCL pellets 
weighs about 30 ± 1 g. The piston speed is set at 10 mm/min. The extrudate is quenched 
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in chilled water placed 40 mm below the die exit. The combination of temperature, piston 
speed and height drop to water quenching settings produces a filament diameter of 1.70 ± 
0.10 mm. The PCL filaments are fabricated to have a consistent diameter to fit the drive 
wheels of the Fused Deposition Modeling (FDM) system. The filaments are vacuum-
dried and kept in a desiccator prior to usage. 
The next step is scaffold design and fabrication [Hutmacher, 2000; Zein, 2002] (Fig 2.4). 
The PCL filaments are fed into a FDM 3D Modeler RP system from Stratasys Inc. (Eden 
Prairie, MN). Stratasys QuickSlice software is manipulated to produce the desired 
dimensions. The head speed, fill gap, and raster angle for every layer are programmed 
through this software and saved in the Slice file format. Lay-down patterns of 0/60/120° 
are used to give a honeycomb, fully interconnected matrix architecture and mechanical 
properties suitable for rapid vascularization and maintenance of the structural integrity of 
tissue engineered bone grafts in load-bearing applications [Hutmacher, 2001; Schantz, 
2002; Schantz, 2003]. The use of the highly reproducible and computer-controlled FDM 
technique allows the fabrication of bone grafts that can be designed based on computed 




Figure 2.4: (a) Lay-down pattern of 0/60/120° forming triangular honeycomb pores 
viewed in the –Z direction of the FDM build process. (b) Alignment of filaments in 
scaffold specimens with a 0/60/120° lay-down pattern. In the OL orientation, the 
filaments are aligned in the XY-plane. In both ILV and ILH orientations, the filaments 
are aligned in the XZ-plane and YZ-plane, respectively. (c) Cross-section viewed in the 
XZ plane of the FDM build process. Symbols are denoted as RW: road width, FG: fill 
gap, ST: slice thickness, LG: layer gap [Zein, 2002]. 
 
Biodegradation                                                                                                              
Many biocompatible materials can be potentially used to construct scaffolds. However, a 
biodegradable material is usually desired because the role of the scaffold is usually only a 
temporary one. The meaning and definition of the word biodegradable which is often 
used misleadingly in the tissue engineering literature is of importance to discuss the                         
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rationale, function as well as chemical and physical properties of polymer-based 
scaffolds. With respect to this thesis, the polymer properties are based on the definitions 
given by Vert et al. Biodegradable refers to solid polymeric materials and devices which 
break down due to macromolecular degradation with dispersion in vivo but no proof for 
the elimination from the body. Biodegradable polymeric systems or devices can be 
attacked by biological elements so that the integrity of the system and in some cases but 
not necessarily of the macromolecules themselves, is affected and gives fragments or 
other degradation by-products. Such fragments can move away from their site of action 
but not necessarily from the body. 
Woodard et al have extensively studied the intracellular degradation of PCL. Their work 
provided perhaps the most comprehensive details on the biocompatibility of PCL 
throughout the degradation process using as animal model. During the first stage (non-
enzymatic bulk hydrolysis), the implant became encapsulated by collagen filaments 
containing only occasional giant cells. Significant weight loss of the implant was not 
observed during the first stage that lasted about 9 months. After this time period, the 
molecular weight decreased to about 5000, followed by the onset of the second stage of 
degradation. The rate of chain scission slowed, the hydrolytic process began to produce 
short chain oligomers and weight loss was observed. Eventually the implant was 
observed to fragment into a powder. The degradation of fragmented PCL was observed 
inside the phagosomes of macrophages and giant cells. Inside these cells, the degradation 
was rapid, requiring only 13 days for complete absorption in some cases. It should be 
noted that PCL fibers were susceptible to enzymatic degradation as well [Hayashi, 2002]. 
A lipoprotein lipase was adopted as the hydrolase and it resulted in the gradual surface 
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degradation of PCL fibers as indicated by the reportedly deteriorating weight loss, 
mechanical properties and surface morphology.                                 
 
Biocompatibility                                                                                                                   
In general, the scaffold should be fabricated from a highly biocompatible material which 
does not have the potential to elicit an immunological or clinically detectable primary or 
secondary foreign body reaction [Hutmacher, 2000]. Numerous works have proven the 
biocompatibility of the PCL material, from in vitro to in vivo as well as clinical trials. 
This has resulted in the Food and Drug Administration (FDA) approval for its usage in 
various medical applications, namely sutures and drug delivery systems. The in vitro 
biocompatibility of PCL scaffolds was investigated by Dietmar et al. It was found that 
both human fibroblasts and osteoblasts colonized the struts and bars and formed a cell-to 
cell and cell-to-extracellular matrix interconnective network throughout the entire 3D 
honeycomb-like architecture. In an in vivo study, intramedullary pins made of PCL were 
implanted into a rat humerus osteotomy model [Lowry, 1997]. Gross post mortem 
examination revealed normal soft tissue and callus formation. Nonunion, 
lymhadenopathy, infection and sinus drainage were not seen in any of the PCL 
specimens. Histology verified the absence of osteolytic regression around the implant site 
and foreign body giant cell reactions. Decalcified humeri demonstrated osteoblastic and 
osteoclastic activity. The clinical use of Capronor (a PCL capsular delivery system for 
delivery of levonorgestrel contraceptive) with 48 women for approximately 40 weeks 
revealed that the device was well tolerated with no adverse systemic side effects observed 
[Darney, 1989]. Hence, based on a large number of tests, the monomer, ε-
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polycaprolactone and the polymer PCL are currently regarded as non-toxic and tissue 
compatible materials.  
            
2.2.2   Rationale for composite biomaterials                                                                          
Synthetic scaffolds when implanted into bone defects are generally encapsulated by a 
fibrous tissue and become isolated from the surrounding bone. Consequently, they do not 
adhere to bone and this has been a critical problem in their use in bone repair [Kokubo, 
2003]. This evoked the development of bioactive composite materials comprising of a 
biodegradable polymeric phase and a bioactive inorganic phase that can spontaneously 
bond to and integrate with living bone.  Within this interesting bioactive category, we 
find a wide range of calcium phosphate ceramics and bioactive glass ceramics [Wang, 
2004]. These materials possess the common characteristic of generating a carbonated 
hydroxyapatite layer that is equivalent chemically and structurally to the biological 
mineral of bone. This is known to be the determining step for the biointegration [Hench, 
1971; Kokubo, 2003; Wang, 2004].                                                    
Pure ceramics have their limitations which the composite approach can circumvent for 
example it offsets the problems of brittleness and the difficulty of shaping hard ceramic 
materials to fit bone defects [Liu, 2004]. Alternatively, ceramics possess several desirable 
traits that can be imparted to the biodegradable polymer component. The inorganic phase 
may compensate for the acidic release from the polymer through the alkaline calcium 
phosphate [Blaker, 2003; Maquet, 2004]. A problem with biodegradable polyesters is 
acidosis caused by the (chemically unavoidable) release of acidic degradation products. 
Careful in vivo and in vitro measurements of pH in bone chambers have shown that the 
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pH drop is only 0.2 units near the eroding polyesters, but the actual degree of local 
acidity is still debated [Ciapetti, 2003].  
Ceramics exhibit a high binding affinity for proteins mainly via electrostatic interactions 
and are widely used as carriers for growth factors [Matsumoto, 2004]. For example, 
ELRUHVRUEDEOH -tricalcium-phosphate (TCP) particles are common carriers for 
recombinant bone morphogenetic protein-2 (rhBMP-2) and this combination augmented 
bone repair [Niedhart, 2003; Liu, 2004; Ruhe, 2004].  
A composite material would also improve biocompatibility in a way that ceramic 
particles, which are embedded into the polymer matrix, allow for increased initial flash 
spread of serum proteins compared to the more hydrophobic polymer surface 
[Hutmacher, 2000]. Finally, the addition of ceramics dispersed throughout the polymeric 
matrix results in a superior compressive strength of the composite compared to non-
reinforced materials [Blaker, 2003; Kokubo, 2003]. Bioactive composite scaffolds have 
therefore a variety of potential biomedical applications namely, guided bone regeneration 
and drug delivery systems [Blaker, 2003; Wang, 2004].  
The above described factors instigated our research team to fabricate novel, three-
dimensional bioactive composite scaffolds consisting of 80 % PCL with 20 % TCP as the 
second generation product. The synthesis method was similar to as described elsewhere 
except that the PCL pellets were physically blended with TCP granules prior to filament 
fabrication. The evaluation of these novel scaffolds forms the basis of this thesis. It is 
hypothesized that PCL-TCP scaffolds would surpass the first generation PCL scaffolds as 
a graft material and protein delivery system for bone engineering applications.   
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2.2.3   Fibrin sealant biomatrix technology 
Fibrinogen has a molecular weight between 330 000 and 340 000 and is composed of a 
dimer of three peptide chains of three different types, α, β, and γ, connected through 
disulfide bridges. Upon blood coagulation activation, fibrinogen is polymerized into a 
fibrin network in which blood cells and proteins are physiologically trapped. Fibrinogen, 
a plasma protein (2-5 mg/ml in blood) is clotted by thrombin (activated prothrombin). 
Thrombin, a proteolytic enzyme releases 2 molecules each of fibrinopeptides A and B, 
which are split off from the resulting fibrin monomer. These monomers aggregate mainly 
because of hydrogen bonding and thus produce the resulting fibrin matrix. Fibrin 
becomes insoluble by the action of thrombin in the presence of calcium ions. Afterwards, 
fibrin degradation occurs by activation of plasminogen into plasmin [Doillon, 2002]. 
A natural wound-healing matrix, fibrin sealant, is a non-cytotoxic, fully resorbable, 
biologic biomatrix that harnesses the morphogenic potential of human tissue. It consists 
of a bi-component system of the human plasma derivatives fibrinogen and thrombin, 
which when mixed together; stimulate the last stages of the natural coagulation cascade 
to form a structured clot similar to the physiological clot [Basu, 1995]. It is completely 
bioresorbed in 7-10 days through fibrinolysis [Seelich, 1982], has an excellent safety 
profile [Mooney, 1999] and is easy to use with the dual-syringe system. Fibrin sealant has 
been studied in various applications to improve the stability and cell attachment 
properties of other polymer scaffolds [Stark, 1995; Endres, 2003], whilst simultaneously 
delivering cells and/or bioactive agents like polypeptide growth factors [Kawamura, 
1988; Nabeshima, 1995; Sahni, 1998; Elbert, 2000] and recently, non-glycosylated BMPs 
[Schmoekel, 2004] to activate and promote wound healing and tissue regeneration.  
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Fibrin sealant consists of freeze dried powder in a kit together with a solution of human 
fibrinogen (120 mg/ml), thrombin (4 or 500 IU), CaCl2 (40 mM/liter) and aprotinin (3000 
KIU/ml). The substances in the kit are used to prepare two components, namely, the 
sealer and thrombin solution. After preheating at 37 °C, the components are reconstituted 
with their solutions and drawn up in separate syringes. To obtain the sealer solution, 
protein concentrate is dissolved in the stock solution of fibrinolysis inhibitor (aprotinin) 
or a dilution of it, where applicable. Dried thrombin is dissolved in CaCl2 solution to 
yield the thrombin solution. The two components are mixed either immediately before 
application to the recipient surface or in situ with a special dual syringe. The adhesive is 
formed when the fibrin and thrombin compounds come in contact. 
Fibrin sealant was selected as the adhesive material in chapters 4 and 5 as presented in 
this thesis. The purpose of fibrin was to promote the loading efficiency of cells and 
rhBMP-2 onto the scaffolds by immobilizing it [Orban, 2002]. Basically, as the sealant 
was initiated to clot, it enmeshed the cells/proteins within it while adhering to the 
scaffold surface. This provided time and facilitated the interaction of the bioactive 
components with the scaffold material, in particular the TCP particles. Once the fibrin 
network disintegrated, only the factors trapped or physically attached to the scaffold 
remained behind.                                                                                                                                                         
2.2.4    Recombinant bone morphogenetic proteins  
Several families of extracellular signaling molecules are currently administered 
therapeutically to restore form and function to bone, including recombinant forms of 
BMPs [Urist, 1965; Reddi, 1997; Wozney, 2003]. The potent bioactivity of BMPs was 
first applied by Marshall Urist in 1965 to induce ectopic bone formation in muscle 
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pouches of rabbits, rats, mice and guinea pigs. Since then various BMPs have been 
isolated, characterized and cloned [Wozney, 2003]. BMPs are dimeric molecules and 
their conformation is critical for biological actions. Reduction of the single interchain 
disulfide bond results in the loss of biological activity. The mature monomer molecule 
consists of about 120 amino acids with seven canonical cysteine residues. There are three 
intrachain disulfides per monomer and one interchain disulfide bond in the dimer.                                                                                                              
Morphogenesis is a sequential multistep cascade. BMPs regulate each of the key steps: 
chemotaxis, mitosis and differentiation of cartilage and bone and initiate chondrogenesis. 
BMP receptors and signaling cascades are illustrated in Figure 2.5. The BMP and 
cartilage-derived morphogenetic protein (CDMP) family members are dimeric signals 
with a single interchain disulfide bond. The BMP interact with type I and II BMP 
receptors (BMPR I and BMPR II). The BMPR II phosphorylates BMPR I and activates 
the serine/threanine kinase receptor. The BMPR I protein serine/threonine kinase  
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Figure 2.5:  Mechanism of the activation of BMP receptors and signal transduction by 
Smad1, Smad4 and probably other Smads, exist as homotrimers [Reddi, 1997]. 
 
 
phosphorylates cytoplasmic, signaling substrates Smad 1 or Smad 5. This 
phosphorylation is modulated and inhibited by inhibitory Smads 6 and 7. Phosphorylated 
Smads 1 and 5 interact with a common co-Smad 4 and are translocated into the nucleus to 
initiate the transcription of BMP response genes. A Smad interacting protein (SIP) 
modulates binding of Smad 1/4 complex to DNA. The bioavailability of BMP and CDMP 
for interaction with cognate receptors is dependent on BMP-binding proteins and 
antagonists such as noggin and chordin and also extracellular matrix components such as 
collagens I and IV and heparan sulfate [Reddi, 1997].                                                                     
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A particularly well-studied BMP, BMP-2, elicited ectopic bone formation in rats 
[Niedhart, 2003], lead to faster healing of critical size defects in long bone in rats 
[Bessho, 2002] and induced bone healing in rabbits [Matsumoto, 2004]. It was reported 
that BMP-2 is a potent osteoinductive factor as it induced the highest amount of alkaline 
phosphatase activity and mineralization while simultaneously reducing the proliferation 
rate [Linkhart, 1996; Canalis, 2003]. Furthermore, bone regeneration evoked by the 
topical application of various growth factors was best achieved by the use of BMP-2 
[Sheridan, 2000]. Both animal studies and human clinical trials demonstrated the 
osteoinductive properties on par with or better than bone autografts, thus the FDA 
recently approved rhBMP-2 for use in spinal fusion procedures. Given the unequivocal 
evidence for a role of BMP-2 in bone development, it was adopted for our experiments.  
The major requirements of a delivery system for BMPs are listed as follows: 
• To keep the BMPs in place at the site of delivery so that the molecules can exert 
their biologic action and to provide an initial substratum for the growth and 
differentiation of bone-forming cells.  
• Control of the induced bone mass.  
• The biocompatibility of the carrier material should be high and it must not contain 
any toxicity, immunogenicity or carcinogenicity.  
• The carrier must not inhibit the bone formation and repair capability of BMP.  
• The carrier materials should be easy to handle and sterilize and suitable for 
commercial development.  
Atellocollagen is currently considered the “gold standard” for BMP carriers but since this 
collagen is essentially a xenogeneic material, there is a possibility of disease transfer or 
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immunogeneic reactions in clinical use. For this reason, the development of a carrier 
material that is safer and thus superior to collagen is eagerly anticipated [Saoto, 2003]. In 
chapters 4 and 5 of this thesis, PCL-TCP scaffolds were investigated as potential delivery 
vehicles for rhBMP-2. 
 
2.2.5   Platelet-rich plasma 
Platelet rich plasma (PRP) is an autologous source of concentrated platelets that is rich in 
multiple growth factors. The addition of thrombin and calcium chloride activates the 
polymerization of the fibrin component of PRP into an insoluble gel, which causes the 
platelets to degranulate and release the bioactive factors [Weibrich, 2002; Tozum, 2003]. 
This active secretion begins within 10 minutes after clotting and more than 95 % of the 
pre-synthesized growth factors are secreted within 1 hour. The secreted growth factors 
immediately bind to the external surface of cell membranes of cells in the graft or wound 
via transmembrane receptors.  
These receptors in turn induce an activation of an endogenous internal signal protein, 
which causes the expression of a normal gene sequence of the cell such as cellular 
proliferation, matrix formation, osteoid production and collagen synthesis. The 
significance of this knowledge is that the PRP growth factors never enter the cell or its 
nucleus, they are not mutagenic, and they act through the stimulation of normal healing, 
just much faster. Therefore, PRP has no ability to induce tumor formation [Marx, 2004]. 
The growth factors include mainly platelet derived growth factors (PDGF), transforming 
growth factors-beta one (TGF- YDVFXODU HQGRWKHOLDO JURZWK IDFWRr (VEGF) and 
insulin-like growth factor-one (IGF-1).                                                                                                                 
 49 
PDGF is a 30 kDa dimer of A and B polypeptide chains linked by disulphide bonds and it 
is composed of three isoforms, PDGF-AA, PDGF-BB and PDGF-AB.  PDGF is a 
glycoprotein with reported mitogenic, angiogenic, and macrophage activation properties 
[Pfeilschifter, 1990; Oates, 1993; Matsuda, 1992; Hock, 1994; Marx, 1998; Tozum, 
2003]. It is reported that PDGF was first found to be contained in platelets and released 
when blood clots and platelets adhere to blood vessels. It was a stimulator for bone 
fracture healing [Yang, 2000]. Recently, researchers focused their studies on the 
relationship between PDGF and human osteoblasts and some valuable information was 
obtained: (1) PDGF receptor-α was found on the membrane of  human osteoblast, (2) 
PDGF could induce the proliferation of human osteoblasts in vitro  and (3) PDGF-AA is 
an autocrine of normal human adult osteoblasts.                                                                                                                                                                                                                 
The importance of the TGF-β1 molecule is emphasized by the following characteristics:  
• The molecule is highly conserved; there is a high degree of homology between 
human and murine forms with only a single amino acid substitution. The 25 000 
molecular weight homodimer is identical in the human, monkey, bovine, porcine 
and avian forms. The existence of such a highly conserved molecule throughout 
evolution suggests it has a fundamental function in embryogenesis, wound 
healing, matrix formation and skeletal formation and remodeling.  
• A similar structurally related molecule exists in Drosophila that suggests a 
functional equivalent in insects.  
• Many cell types such as fibroblasts, mesothelial cells, osteoblasts and transformed 
cells produce TGFβ.  
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• Almost every cell type studied so far has receptors for and binds TGFβ. Fifth, 
TGF-β1 has dramatic effects on almost every cell type that has receptors for it 
[Bonewald, 1990]. TGF-ZDVVKRZQWRHYRNHFKHPRWD[LVDQGPLWRJHQHVLVRI
osteoblast precursors, promote their differentiation toward mature osteoblasts, 
stimulate deposition of collagen matrix and inhibit osteoclast formation and bone 
resorption [Pfeilschifter, 1990; Matsuda, 1992; Oates, 1993; Marx, 1998; 
Schliephake, 2002; Schmidmaier, 2003].                                                                                                                                  
VEGFs produced in the callus microenvironment take an important part in the angiogenic 
process during fracture healing. It was recently shown that VEGF-induced angiogenesis 
speeds the differentiation and/or maturation of infiltrating osteoblasts and osteoblast 
precursor cells during neo-bone development, perhaps by providing a conduit for delivery 
of osteoinductive soluble signals [Murphy, 2004]. Thus, one possible strategy to promote 
bone regeneration is via induced angiogenesis (by VEGF present in PRP), which could be 
particularly important in larger-sized bone defects where the presence if a vascular supply 
is perhaps more vital. 
IGFs are single chain peptides that exist in two isoforms, IGF-1 (70 amino acids) and 
IGF-II (67 amino acids). IGFs produced by bone cells not only act as acute autocrine and 
paracrine regulators, but also become incorporated into bone  matrix and may be released 
later during resorption. IGF I and IGF II are the most abundant growth factors stored in 
bone matrix.  IGF-1 was reported to be a chemotactic agent for periodontal ligament cells 
and stimulant of bone formation by proliferation and differentiation of fibroblast and 
osteoblasts [Pfeilschifter, 1990; Linkhart, 1996; Schliephake, 2002; Weibrich, 2002; 
Tozum, 2003; Schmidmaier, 2003]. Interestingly, IGF-1 has been reported to increase  
 51 
 
Figure 2.6: Steps in the preparation of platelet-rich plasma [Tozum, 2003]. 
 
osteoclast formation from mouse osteoclast precursors and IGF treatment prolonged 
osteoclast survival in mixed rabbit osteoclast and marrow stromal cells.  Because IGFs 
are small proteins (7.5 kDa), the half-life of systemically administered IGFa is relatively                                                                 
short. However, IGFs exist in vivo in larger protein complexes, bound to IGF binding 
proteins and the half-life of IGFs bound to these complexes is much longer [Linkhart, 
1996].            
Besides releasing multiple growth factors that is an effective way to induce tissue repair 
and regeneration, PRP offers many other advantages. It facilitated graft placement and 
stability [Shanaman, 2001]. PRP decreased the frequency of intraoperative and 
postoperative bleeding at the donor and recipient sites and facilitated more rapid soft-
tissue healing [Tozum, 2003]. Notably, the preparation of PRP is a very simple, two-
centrifugation steps procedure (Fig 2.6). This makes it highly suited for clinical 
applications.                  
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The efficacy of PRP in physiologic systems when added to autogenous bone, inorganic 
bone mineral and organic bone substitutes is increasingly being evaluated. This has 
however resulted in the sparse volume and conflicting nature of present literature [Marx, 
2004, Freymiller, 2004]. The ideal concentration of growth factors in PRP is unknown 
and at certain concentrations, PRP may inhibit bone regeneration. More basic research 
into the exact constituents and optimal concentration of PRP as well as potential carriers 
capable of sustained release is necessary. In addition, reliable and reproducible animal 
models need to be developed followed by well-designed and standardized human trials. 
 
2.2.6 Dental implants 
Dental implants replace the dental root and not the periodontum. They are made of inert 
material, usually titanium, and their placement cannot be considered a tissue engineering 
technique. Nevertheless, their use often involves an increase of the existing osseous 
volume. Alveolar bone exists to support the teeth and this supportive structure begins to 
resorb if a tooth is extracted. Alveolar atrophy can be severe in edentulous patients, but in 
many cases, dental implants are difficult to place. Amongst the most common anatomical 
obstacles are the sinuses and the mandibular dental nerve. But the height of the crest is 
not the only problem, because sufficient width is also necessary. Different forms of tissue 
engineering can be applied in such cases [Miller, 2000]. 
Placement of implants immediately after tooth extraction is a treatment modality used 
increasingly in implant-supported oral rehabilitation. Major difficulties relating to bone 
regeneration that complicate immediate implant procedures: 
• Buccal and/or lingual fenestration. 
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• Primary anchorage of the implants.  
• Protection from functional loading during the osseointegration period. 
• Stability of the implant body during the osseointegration period.  
• Osseointegration at the coronal part of the implant may be of concern.  
• There is always a risk of trauma to the implant-bone interface, which can 
compromise implant success or increase crestal bone loss.  
To overcome these difficulties, various techniques are being investigated and applied, 
and special efforts have been devoted to improving the bone-implant interface by 
















CHAPTER 3: PROPOSED RESEARCH PROGRAM 
3.1 RESEARCH PROGRAM 
The specific research objectives of this thesis are illustrated in figure 3.1. It can be 
grouped into three main categories, namely material characterization, protein delivery 
and animal studies. Each main category can be broken down further into two sub-
categories. The detailed explanation for each are listed below: 
 
 























factors   
PRP 
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3.1.1 Characterization Studies 
Cytotoxicity/Cytocompatibility  
The objective was to periodically monitor the colonization behavior of osteoblasts loaded 
onto PCL-TCP scaffolds and incubated in culture medium for a month. Testing for 
cellular cytocompatibility is pertinent for determining the biocompatibility of a potential 
medical device. Parameters assessed included viability of the cells, their adhesion to the 
material and proliferation of these cells after attachment. In addition, some experimental 
groups were loaded with rhBMP-2 to stimulate differentiation of osteoblasts to deposit 
bone mineral. This was to decipher if the scaffolds were capable of facilitating the entire 
process from cellular attachment to differentiation to mineral. It was also important to 
verify that the scaffolds are not toxic to the cells and that its honeycomb-like architecture 
and porosity allowed for the infiltration of cells. 
 
Biodegradation  
The degradation of first generation PCL scaffolds have been adequately reported in 
literature. Hence, the objective of the current work was to characterize the biodegradation 
behavior of PCL-TCP scaffolds, paying special attention to how the inclusion of TCP has 
affected the degradation properties. Parameters measured were water uptake, weight loss, 
pH and surface morphological changes after immersion in phosphate buffered saline 
(PBS) and simulated body fluids (SBF). Another aim was to detect for the bioactive 
nature, specifically the ability of incorporated TCP to nucleate a hydroxyapatite layer on 
the surface of the PCL polymer.  The scaffolds were immersed in SBF for a month and 
periodically subjected to pH, inorganic calcium/ phosphate ratio, x-ray diffraction and 
 56 
surface morphological analyses.  The information obtained will be useful for future in 
vivo applications. More significantly, these degradation properties will play a role in the 
protein release profile determined in the next objective. 
 
3.1.2    Protein delivery studies 
Single growth factor  
The aim of the next study was to measure the potential of PCL-TCP scaffolds as protein 
delivery systems for a single osteoinductive factor. The growth factor of choice was 
rhBMP-2 for reasons described in Chapter 2. Pure PCL scaffolds were adopted as 
controls to investigate if the addition of TCP affects release profiles. The effect of 
different concentrations of rhBMP-2 loaded on PCL-TCP scaffolds was monitored as 
well. This was to determine if the release profiles were concentration dependent. Release 
profile behavior namely, sustained or burst-like release patterns were recorded. Finally, 
the stability and bioactivity of the eluted protein were verified. This was crucial to ensure 
that the released growth factor can still execute its primary function of stimulating tissue 
regeneration. 
 
Multiple growth factors  
The following study assessed the release profiles of multiple growth 
factors present in PRP loaded on PCL-TCP scaffolds and immersed in 
SBF and PBS. The aims were to evaluate (1) the efficacy of the scaffolds 
as delivery systems for multiple growth factors, (2) if the type of buffer 
used for analysis would affect the release profile obtained and (3) if the 
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type and concentration of growth factors determined the release kinetics. 
The ultimate purpose of obtaining the release profile of growth factors 
present in PRP is so that the protein release can be correlated with the 
stages of wound healing and bone regeneration observed from the 
subsequent in vivo studies.   
 
3.1.3 Animal Studies 
Rat femoral defect model  
Implanting a test device inside the body of a laboratory animal is the most direct means 
of evaluating the material's potential effects on living tissue. A rat nonunion femoral 
defect model together with contrast enhanced micro-computed tomography (micro-CT) 
was adopted for this purpose. The objectives of this short-term in vivo study were (1) to 
investigate the effect of PRP-loaded PCL-TCP scaffolds on tissue regeneration, 
specifically blood vessel and mineralized bone formation and (2) to verify the efficacy of 
the newly developed rat non-union defect model in combination with enhanced micro-CT 
imaging techniques in evaluating tissue regrowth in three dimensional composites. Data 
from micro-CT analyses revealed the vascular volume fraction, bone volume fraction and 
number of bone unions achieved. Additional information on the cellular distribution and 
mechanical properties were obtained by histological and torsional testing methods. 
 
Dog mandible defect model  
The next natural step would be the application of our bone regenerative strategy to a large 
animal model and longer-term period. A large animal model is vital for advancement into 
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clinical trials and a longer time period is required for the acquisition of the in vivo 
degradation properties of the scaffolds and the time required for mature bone deposition 
and remodeling to occur. It would also be interesting to note the efficacy of PRP delivery 
by PCL-TCP scaffolds in bone defect sites other than the femur. With this in mind, the 
present study aimed to investigate the efficacy of PRP loaded PCL-TCP scaffolds in 
facilitating the placement of dental implants, shortening the wound healing time and 
stimulating mandibular bone regeneration in mongrels for a period of 6 and 9 months.  
 




Table 3.1: Schematic diagram of milestones for execution of PhD research 
 
The aims listed in Table 3.1 correspond to the specific objectives described in section 3.1 
of the proposed research program. 
Aim 1 refers to the in vitro cellular cytocompatibility experiments.  
Aim 2 refers to the in vitro characterization of the degradation and bioactivity properties 


















Aim 3 refers to the in vitro protein delivery studies for a single growth factor. 
Aim 4 refers to the in vitro protein delivery studies for multiple growth factors. 
Aim 5 refers to the treatment of rat femoral defects by PRP-loaded PCL-TCP scaffolds. 
Aim 6 refers to the treatment of dog mandible defects by PRP-loaded PCL-TCP 
scaffolds. 
The full report was planned to be written and submitted by the end of the first semester of 




















CHAPTER 4: CYTOCOMPATIBILITY AND BIODEGRADATION 
OF PCL-TCP SCAFFOLDS 
4.1 INTRODUCTION 
The objective of the present thesis is to seek for the ideal bone regenerating device that 
requires an interplay between three components: (i) a 3D scaffold as a pillar of support 
for the cells, (ii) the cells that secrete bone and (iii) bioactive factors that guide the cells 
to form the desired tissue [Wozney, 2003]. A rapid prototyping process called fused 
deposition modeling allows the design and fabrication of highly reproducible 
biodegradable 3D polycaprolactone scaffolds with a fully interconnected pore network 
[Hutmacher, 2000; Hutmacher, 2001; Zein, 2002]. One tissue engineering approach is to 
load osteoprogenitor or osteoblastic cells onto these scaffolds to enhance its 
osteoinductivity [Kasten, 2003]. Cell culture study showed that PCL scaffolds allowed 
the proliferation and differentiation of fibroblasts and osteoblasts [Hutmacher, 2001; 
Schantz, 2002].  
The most important function of osteoblasts is to form mineralized tissue that is regulated 
by many local factors. Among these, bone morphogenetic proteins are one of the most 
potent factors [Younger, 1989]. BMPs have the unique functions of inducing the 
differentiation of cells of the osteoblastic lineage, therefore increasing the pool of mature 
cells, and of enhancing the differentiated function of the osteoblasts [Yamaguchi, 2000; 
Canalis, 2003]. BMPs were originally identified as growth factors that regulate growth 
and differentiation of chondroblast and osteoblast lineage cells in vitro. In accordance to 
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their in vitro effects, BMPs induce bone and cartilage formation when implanted at 
ectopic sites in rats [Urist, 1965; Wozney, 1988; Reddi, 1997].  
Given the unequivocal evidence for a role of BMPs in bone development there has been 
substantial interest in incorporating this cytokine into tissue engineered scaffolds 
[Kawabata, 1998; Boden, 1999; Winn, 1999]. Several points need to be considered when 
incorporating growth factors for release from such scaffolds: loading capacity, load 
distribution, binding affinity, release kinetics and long-term stability [Schmitt, 1999]. 
Several studies of β-TCP as the carrier for extracted rhBMP-2 have been reported 
recently [Whitaker, 2001; Kasten, 2003]. Hence, the combination of BMP with calcium 
phosphate may make bone repair more effective from a clinical point of view [Yuan, 
2001; Jinguishi, 2002]. 
There is an impetus for the development of artificial bone substitute materials that do not 
damage healthy tissue, do not pose any viral or bacterial risk to patients and can be 
supplied at any time in any amount. However, artificial materials implanted into bone 
defects are generally encapsulated by a fibrous tissue and become isolated from 
surrounding bone. Consequently, they do not adhere to bone and this has been a critical 
problem in their use in bone repair. Since the 1970s, this issue has been overcome by 
using bioactive ceramics that spontaneously bond to and integrate with bone in the living 
body [Kokubo, 2003]. In sync with the trend towards bioactive scaffolds, our group 
recently physically blended PCL with 20 % microparticles of β-TCP (Ca3 [PO4]2) to form 
composite scaffolds with both biodegradable and bioactive properties. Combining 
biodegradable polymers with an inorganic bioactive phase were of particular interests as 
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tailored physical, biological and mechanical properties can be obtained [Laurencin, 2000; 
Boccaccini, 2002]. 
An essential requirement for a bioactive synthetic biomaterial is to integrate to host bone 
tissue. A bioactive apatite layer is initiated on its surface when subjected to normal 
physiological conditions. The composition and structure of this surface layer are 
analogous to the inorganic phase in bone and hence forms a bridge between living bone 
and biomaterial.  In vitro, the bioactivity of a synthetic biomaterial can be evaluated by 
monitoring the formation of apatite on its surface when immersed in simulated body 
fluids (SBF) whose ionic composition emulates blood plasma closely [Kokubo, 2003]. As 
yet, little is known about the nature of the calcium rich layer that is formed as the PCL-
TCP scaffolds undergo degradation in body fluids.   
Degradation behaviors of porous scaffolds play an important role in the engineering of 
new tissue, since the degradation rate is intrinsically linked to cell vitality, growth as well 
as host response [Babensee, 1998]. In order for a biodegradable scaffold to be successful 
over the long term, the material must have a rate of degradation that acts in concert with 
the ingrowth of new bone. Ideally the scaffold would degrade slowly enough to maintain 
structural support during the initial stages of bone formation, but fast enough to allow 
space for continuous growth of new bone. It should be noted that the architectural make-
up and physical properties of composites as well as the environmental conditions 
determine the degradation behavior [Wu, 2004].  
The experimental strategy entailed investigating (1) the influence of varied 
concentrations (0, 10, 100 and 1000 ng/ml) of rhBMP-2 on the osteogenic expression of 
canine osteoblasts, loaded onto PCL–20 % TCP composite scaffolds in vitro. It was 
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hypothesized that both osteoconductive and bioactive properties would be inherent in 
PCL-TCP scaffolds and that rhBMP-2 would ameliorate its osteoinductivity. (2) The in 
vitro degradation properties of biodegradable and bioresorbable PCL-TCP composite 
scaffolds immersed in SBF and PBS were investigated. Basically, scaffolds immersed in 
SBF and PBS solutions under physiological conditions were monitored routinely for a 
time period of 4 weeks. Biodegradation parameters assessed were water uptake, weight 
loss and pH measurements. Bioactivity evaluation focused on changes in the surface 
morphology as well as mineral content measurements. 
 
4.2   MATERIALS AND METHODS 
4.2.1   Scaffold design and fabrication 
Scaffold specimens were fabricated with PCL-TCP filaments using a FDM 3D Modeler 
RP system from Stratasys Inc. (Eden Prairie, MN) as described in Chapter 2. Blocks of 
50 x 50 x 3 mm were created directly in Stratasys Quickslice (QS) software. A lay-down 
pattern of 0/60/120 °  was used to give a honeycomb-like pattern of triangular pores and a 
porosity of 70 %. After manufacturing, the specimens were cut with a blade into smaller 
cuboids of dimensions 8 x 8 x 3 mm and 5 x 5 x 3 mm for cellular and degradation 
experiments respectively.  
These cuboids were surface treated in 5M NaOH for 1 h to enhance their hydrophilicity. 
After rinsing 3 x with phosphate buffered saline (PBS, 137 mM NaCL, 2.7 mM KCL, 10 
mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), they were sterilized in 70 % ethanol for 24 h. 
This was followed by rinsing twice in PBS with centrifugation at 1000 rpm for 10 min. 
The scaffolds were dried in humidified atmosphere at 37 °C and 5 % CO2 for 1 h and 
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soaked for 3 h in Dulbecco’s modified Eagle’s medium (DMEM, Sigma, Deisendorf, 
Germany) prior to cell seeding. 
4.2.2   Porosity calculation 
The porosity was calculated through the following method: (1) measuring the weight and 
volume of each sample, (2) from these measurements, the apparent density of the 
scaffolds was calculated using the following formula: ρ * = m (g) / V (cm3) and (3) 
finally, the porosity were obtained using the following porosity = ε = 1- ρ * / ρ x 100 % 
(ρ = 1.17 g/cm3). 
 
4.2.3   Bone morphogenetic protein-2 
The BMP used in the present study was recombinant human BMP-2 (rhBMP-2). It was a 
kind gift from Dr. Chen Fulin from the division of Bioengineering, National University 
of Singapore. The rhBMP-2 was used in concentrations of 10, 100 and 1000 ng/ml. Cell-
loaded scaffolds without rhBMP-2 served as controls. Hence, four experimental groups 
were created. 
 
4.2.4   Cytocompatibility study 
Dog osteoblast culture and cell seeding on PCL-TCP scaffold 
Bilateral extraction of mandibular premolars was performed on a 1, 1/2-year-old female 
dog (Mongrel) weighing 14.8 kg. The removed premolar explants were rinsed in PBS 
containing 2 % penicillin–streptomycin (PS, Sigma, Eschenstr, Germany) and then diced 
into smaller bone chips. Cell culture flasks were filled with the bone chips and incubated 
with DMEM supplemented with 10 % FBS (Hyclone, USA) and 1 % PS in a humidified 
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atmosphere at 37 °C and 5 % CO2. Medium was replaced every 3 or 4 days. Cell 
migration from explant cultures was observed after one week. Primary cultures were 
maintained until they reached 80–90 % confluency and were passaged three times. At this 
stage, cells were trypsinized with 0.25 % trypsin/EDTA (Hyclone, USA), centrifuged, 
resuspended in culture medium and counted with a Neubauer-hemocytometer. 
Canine osteoblasts (third passage, 3 x 105 cells/ml), rhBMP-2 of various concentrations 
and fibrin glue (Tisseel kit, Immuno, Austria) were simultaneously loaded onto the top of 
the porous scaffolds, which were placed in 24-well culture plates. After cell loading, 1 ml 
of fresh culture medium was added to each well and cells were incubated in a humidified 
atmosphere at 37 °C and 5 % CO2 for 4 weeks with medium changes every 3 days. After 
seven days, the osteoblastic phenotype as well as the production of bone extracellular 
matrix was stimulated by supplementing the culture medium with 10mM β- 
glycerophosphate (Sigma, USA), 100 µm ascorbic acid (Sigma) and 10 -7 M 
dexamethasone (Sigma). 
 
Cellular viability and proliferation assays 
Confocal laser microscopy (CLM) and a biochemical assay, the AlamarBlue test assessed 
cellular viability and proliferation. The AlamarBlue (Biosource International Inc, USA) 
test is a non-toxic, water-soluble, colorimetric redox indicator that changes color in 
response to chemical reduction of growth medium as a result of cell growth. Scaffold/cell 
constructs (n = 4) were placed in culture medium with 5 % AlamarBlue solution and 
incubated in a humidified atmosphere at 37 °C and 5 % CO2. After 3 h of incubation, 100 
 66 
µl of solution from each scaffold was transferred to 96-well plates and the optical density 
was measured with a reference filter of 595 nm and measurement filter of 562 nm. 
For CLM, samples were stained with two fluorescent dyes: fluorescein diacetate (Sigma, 
Germany), which stains viable cells green, and propidium iodide (Sigma), which stains 
necrotic and secondary apoptotic cells red. The scaffold/cell constructs were first 
incubated with 2 µg/ml FDA for 30 min at 37 °C. The samples were then rinsed 3 x in 
PBS, placed for 2 min in a 100 µg/ml propidium iodide solution, rinsed again in PBS 
once and viewed under a confocal laser microscope (Olympus 1 x 81, FV500 Fluoview). 
Depth projection images were constructed from 70 horizontal image sections. 
 
Cellular adhesion assay 
Scanning electron microscopy (SEM) and phase contrast light microscopy (PCLM) 
assessed cellular adhesion. For the SEM experiments, samples were fixed in 2.5 % 
gluteraldehyde (Sigma, Germany) at 4 °C overnight. They were then dehydrated in a 
graded ethanol series of 25 %, 50 %, 75 %, 95 % and 100 %, air-dried and gold-sputtered 
with JFC-1200 fine-coater for 70 s at 30 mA under high vacuum. The specimens were 
examined with a Jeol JSM 5600LV SEM operating at 10 kV under high vacuum mode. 
Samples were examined weekly under SEM and PCLM for a month to examine the 
establishment of osteoblast phenotype with intercellular connections. 
Extracellular matrix production 
Mineral as well as osteocalcin content is indicative of extracellular matrix production. 
Von Kossa’s method was used to detect the mineral in bone-like nodules. In brief, the 
specimens were washed 3 x with PBS, fixed in 3.7 % formaldehyde in PBS for 10 min, 
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washed in distilled water 3 x, then incubated in 0.5 % silver nitrate for 1 h. Samples were 
then washed in distilled water 3 x, incubated in 0.3 % sodium thiosulfate pentahydrate for 
3 min, washed in distilled water, dried and viewed under a phase contrast microscope. 
Osteocalcin production was assessed using an ELISA kit (Takara, Shiga, Japan). 
Supernatants were collected weekly (n = 4) and frozen at – 20 °C and then thawed prior 
to analysis. One hundred µl of each sample was used and the assay was performed in 
accordance to the instructions of the manufacturer. Results are presented in ng/ml. 
 
4.2.5   Biodegradation study 
The in vitro degradation properties were evaluated in phosphate buffered saline (PBS) 
and simulated body fluid (SBF) as the release medium. PBS was commercially purchased 
(In mM: NaCL137, KCL 2.7, Na2PO4 10, KH2PO4 1.8, pH 7.4). SBF was prepared in 
accordance to Kokubo et al, with ion concentrations (In mM: Na+ 142, K+ 5.0, Ca2+ 2.5, 
Cl- 148, HCO3- 4.2, HPO4 2- 1.0, SO4 2- 5.0) nearly equal to those of human blood plasma. 
SBF was buffered at ph 7.4 with tris (hydroxymethyl) aminomethane and 1M 
hydrochloric acid (HCL) at 37 °C. 
The system was characterized with respect to weight loss and water uptake. Composites 
were placed into clean wells of 24-well plates, previously washed using hydrochloric acid 
and deionized water, and completely immersed in 1 ml of buffer solution, either PBS or 
SBF. The plates were then sealed and put into an incubator of constant temperature 37 ºC. 
Both buffer solutions were changed every 3 days to compensate for cation decrease over 
the course of the in vitro studies. Two scaffolds were removed from each buffer at 
predetermined time intervals of 1, 7, 14, 21 and 28 days. These samples were gently 
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rinsed with PBS before drying for 48h in an incubator that maintained a temperature of 
37 °C and controlled relative humidity of 30 %.  The water uptakes, weight loss of the 
samples and pH of the solution were then determined. 
 
Water uptake 
In a typical test, scaffolds were wiped with a clean tissue paper to get rid of excess buffer 
solution adhering on the surface, weighed and later, dried to constant weight in order to 
determine the weight loss. Water uptake was calculated at each time point using the 
following equation [Frank, 2004]: 
% Water uptake = 100 x (Wwet –Wo)/Wo 
where, Wwet and Wo respectively, are weights of the wet and starting dry weight scaffolds 
as measured at time, t. Values obtained for duplicate samples were averaged. All weights 
were measured to an accuracy of + 0.01mg. 
 
Weight loss 
Composites’ weight losses during degradation were measured by the changes in dry 
weight after incubation for specified time periods. For such tests, the composites were 
removed, rinsed in distilled water and dried in vacuum oven for a week. Values obtained 
for duplicate samples were averaged. Percent weight loss was computed according to the 
following equation [Frank, 2004]: 
% Weight loss = 100 x (Wo-Wt) / Wo 




pH of the supernatants were measured by a calibrated pH meter every 4 days. 
 
4.2.6   Bioactivity study (for SBF-soaked samples only) 
Scanning electron microscopy 
Surface morphological changes were characterized using scanning electron microscopy 
(SEM) before and after incubation in SBF.  For the SEM experiments, samples were 
prepared as described in section 4.2.4 of this chapter. 
 
X-ray diffraction analysis 
The samples were observed under X-Ray diffraction (XRD) (Shimadzu X-ray 
diffractometer XRD-6000, Cu LFF type, 40 kV, 3°~60°) [Blaker, 2003] to identify the 
formation of crystalline apatite on the surfaces of samples treated in SBF.   
 
Von Kossa staining  
Von Kossa’s method was used to detect the mineral in apatite layer. The specimens were 
prepared according to the procedures described in section 4.2.4 of this chapter. 
 
Ionised calcium and phosphate concentrations 
The supernatants were collected and analyzed for levels of ionized calcium and 
phosphate regular time intervals for a 28-day period.  A calcium kit (Stanbio No. 150) 
and a phosphorus kit (Stanbio No. 160) were used for this purpose. 
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4.2.7   Statistical analysis 
All quantitative data were expressed as mean ± standard deviation. Statistical analysis 
was performed by Student’s t test using Instat Software (GraphPad Software, Inc., San 
Diego, CA, USA) for comparisons between different treatment groups. A value p < 0.05 
was considered to be statistically significant. 
 
4.3   RESULTS 
4.3.1   Scaffold morphology 
SEM analysis revealed the structure of empty PCL-TCP scaffolds. It consists of a fully 
interconnected network of pores, ranging from 400 to 600 µm in diameter (Fig. 4.1). The 
porosity was calculated to be 65 %.  
 
Figure 4.1: Scanning electron micrograph of empty PCL-TCP scaffolds revealed 
interconnecting pores of 400-600µm in diameter.   
 
4.3.2 Cytocompatibility study 
Cellular viability and proliferation 
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Cellular viability and proliferation were assayed via the semi-quantitative AlamarBlue 
test (Fig. 4.2). Cell proliferation causes the redox indicator to change from oxidized to 
reduced form; hence, a higher percentage of reduction is proportional to more growth. 
Interestingly, groups with rhBMP-2 exhibited an initial burst of cell growth between 3 h 
and day one. This burst was not dose-dependent as groups with 10, 100 and 1000 ng/ml 
of rhBMP-2 all showed similar percent increase in reduction respectively. Control 
without rhBMP-2 demonstrated no such initial burst of cell growth. 
However, at day 13, cell growth from all groups declined to a value not significantly 
different from control. Control and groups with 10 and 100 ng/ml rhBMP-2 stabilized to 
about 65 % reduction of AlamarBlue, i.e. a 35 % increase in cell growth as compared to 3 
h. The cell/scaffold constructs with 1000 ng/ ml of rhBMP-2 showed only a 40 % 
reduction after 13 days, i.e. only a 10 % increase in cell growth. Notably, at the end of the 
experiment, at day 28, there was no significant difference (p < 0.05) between control and 
groups with 10 and 100 ng/ml of rhBMP-2.  
 
Figure 4.2: Cell viability and proliferation was assayed by Alamar-Blue test. Cell density 
used was 3 x 105 cells/scaffold. Controls were cell/scaffold constructs without rhBMP-2. 
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The other groups constituted of cell/scaffold constructs with 10, 100 and 1000 ng/ml 




Confocal microscopy confirmed cellular viability. Viable osteoblasts as identified by 
their green fluorescence were observed to attach onto the bars of the scaffolds as early as 
3 h. However, cells were of low density and dispersed (Fig. 4.3a). This was consistent for 
all experimental groups. At day one, cell density was greatly increased for groups with 
rhBMP-2. Cells initiated spreading and spanning across the pores of the scaffolds (Fig. 
4.1.3b). At day 20, viable osteoblasts from all groups appeared to form aggregates that 
covered the bars and pores of the scaffolds entirely. Intriguingly, control showed minimal 
cell death in comparison to groups with rhBMP-2, which evinced high cell death, as 
indicated by enhanced red fluorescence (Fig. 4.3c). 
 
 
Figure 4.3: Confocal micrographs of osteoblasts stained with 2 µg/ml of FDA and 100 
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µg/ml of PI after (a) 3 h, (b) 1 and (c) 20 days. FDA stained viable cells green while PI 




Under PCLM, at 3 h, it was observed that the inoculated cells from all groups were round 
and distributed singly or in clumps in the fibrin matrix (Fig. 4.4a). Cells commenced to 
spread and migrate from day 1 onwards (Fig. 4.4b). Groups with rhBMP-2 achieved 
better confluency in fibrin glue than control. By the second week, ¾ of the pore structure 
of the scaffolds were filled with aggregates of cells for all groups. At day 20, all groups 
revealed extensive extracellular matrix with black colored mineralized nodules within the 




Figure 4.4: Phase contrast light microscopy showing osteoblasts loaded PCL-TCP 




SEM confirmed the adhesion of cells onto scaffolds. At week 1, cells from all groups 
demonstrated focal contact formation to the surface of the bars and were observed to 
branch to adjacent bars and struts. Some of the pores were completely filled with cells 
after only 2 weeks (Fig. 4.5). Both the surfaces and the pores of the scaffolds were 
heavily colonized. At the end of the experiment, the surfaces and pores were entirely 
accretions were detected. These observations were consistent for all experimental groups. 
 
 
Figure 4.5: Scanning electron micrographs of osteoblast adhering onto PCL-TCP 
scaffolds 2 weeks after cell loading. (a) Control (scaffold/cell constructs without rhBMP-
2) (b) Scaffold/cell constructs with 10 ng/ml rhBMP-2 (c) Scaffold/cell constructs with 
100 ng/ml of rhBMP-2 (d) Scaffold/cell constructs with 1000 ng/ml of rhBMP-2.   
overwhelmed by cells and what seemed to be extracellular matrix. Notably, globular  
 
Extracellular matrix production 
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In Fig. 4.6, the progression of osteocalcin is shown. For all groups, osteocalcin 
heightened 7 days after stimulation with differentiation medium, and peaked at day 14. 
Only cells/scaffold constructs with 100 ng/ml rhBMP-2 showed significant increase in 
levels of osteocalcin in comparison to control (p < 0.05). However, after reaching the 
pinnacle, osteocalcin levels decreased over several days for all groups. At day 28, the 
amount of osteocalcin attained a value similar to when non-stimulated for all groups. 
The Von Kossa assay ascertains mineralized structures that resemble calcium nodules, an 
indication of woven bone formation. The scaffolds used for this study has tricalcium 
phosphate, hence to make accurate comparisons, an additional control i.e. PCL-TCP 
scaffold alone, was included. A few, small, mineralized nodules were observed on the 
scaffolds on day 11, just 4 days after stimulation, for groups loaded with rhBMP-2. This 
was not observed for control. On day 14, the mineralized nodules were large enough to 
be observed on both culture wells and scaffold surface (Fig. 4.7). Mineralized nodules 
were apparent for control as well but in lesser amounts. The number of mineralized 
nodules did not differ significantly between day 14 and day 21 for all groups. 
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Figure 4.6: Extracellular matrix production as assessed by osteocalcin assay. The results 
are shown as osteocalcin (ng/ml) as a function of days. On day 7, cells were stimulated 
with differentiation medium (refer to text). Control was scaffold/cell constructs without 
rhBMP-2. The other groups constituted of scaffold/cell constructs with 10, 100 and 1000 
ng/ml of rhBMP-2, respectively (n = 4, ± SD). 
 
Figure 4.7: Extracellular matrix production as assessed by Von Kossa assay at day 20. 
Brownish-black deposits indicate extent of mineralization on the surfaces of culture wells 
(arrows). (a) Control (scaffold/cell constructs without rhBMP-2), (b) Scaffold/cell 
constructs with 10 ng/ml, (c) 100 ng/ml and (d) 1000 ng/ml of rhBMP-2. All pictures 
were reproduced at 4 x magnification. 
 
4.3.3   Biodegradation study 
Water Uptake 
The percentage of water absorbed by PCL-TCP scaffolds as shown in Figure 4.8 can be 
interpreted by dividing the time points into 3 phases. From day 0 to day 1, composites 
immersed in PBS showed a gradual increase to 14.4 % ± 0.20 water absorbed. Scaffolds 
immersed in SBF immediately exhibited 12.9 % ± 0.70 water uptake and maintained it at 
day one. At phase 2, which represents day 1 to day 12, a slight decrease in water uptake 
was observed for composites soaked in PBS to an average of 11.8 % ± 0.80. Scaffolds in 
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SBF maintained its percent of water uptake at 12.4 % ± 0.24. The last phase, day 12 to 
day 21, composites in PBS experienced a gradual increase in water uptake, approaching a 
final value of 14.6 % ± 0.30. Interestingly, composites in SBF showed a decline in water 













Figure 4.8: The percent of water absorbed by PCL-TCP composite scaffolds after 
immersion in simulated body fluids (SBF) and phosphate buffered saline (PBS) over a 




For both buffers, the weight loss measurements did not reveal any trend (Table 4.1). No 

























0 1 2 4 7 10 12 14 18 21 
SBF 0 -1.93 -0.17 0.4 1.44 2.2 0.53 0.34 -1.78 0.18 
std 0 0.05 0.04 0.06 0.12 0.06 0.13 0.01 0.16 0.02 
PBS 0 0.82 1.76 1.41 1.37 1.92 0.94 2.42 -1.1 0.6 
std 0 0.01 0.09 0.05 0.02 0.12 0.17 0.27 1.2 0.03 
 
Table 4.1:  The percent weight loss of PCL-TCP composite scaffolds with after 
immersion in simulated body fluids (SBF) and phosphate buffered saline (PBS)  over a 
time period of 21 days (n = 2, ± SD). 
 
pH measurements 
pH measurements for the SBF-soaked samples showed that the pH of the surrounding 
fluids remained unchanged until 17 days, after which it started to become slightly acidic 
(Fig. 4.9). PBS-soaked samples demonstrated no significant changes in the pH over the 
21 days time period. 
 
Bioactivity 
Figure 4.10 illustrates the inorganic calcium/phosphate ratio manifested by samples 
immersed in SBF over time. The Ca/P ratios of 1.30 (day 17), 1.50 (day 21) and 1.67 
(days 24 and 28) correspond to octacalcium phosphate (OCP), beta-TCP and 
hydroxyapatite (HA) respectively according to the findings of previous studies [101, 
103]. The results showed that an initial precipitation of tricalcium phosphate lead to the 
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formation of HA through the pre-deposition of octacalcium phosphate (OCP) and beta-












Figure 4.9: The pH of supernatant collected from PCL-TCP composite scaffolds 






































Figure 4.10: Calcium/phosphate ratio of the supernatant collected from PCL-TCP 
composite scaffolds immersed in simulated body fluids as a function of time (n = 2, ± 
SD). 
that HA, which closely mimics the composition of bone, started to form only after 
incubation in SBF for 17 days.  Von Kossa assay verified that calcium salts were 
increasingly deposited on the surface of the scaffolds after immersion in SBF for up to 4 
weeks (Fig 4.11).  Scanning electron microscopy monitored regularly the morphology 
and crystallization of apatite on the surface of the scaffolds after immersion in SBF for 4 
weeks (Fig 4.12).  The agglomeration of TCP particles within the PCL polymer was 
clearly evident before any treatment in SBF. The surfaces of the scaffolds were only 
slightly degraded with no obvious calcium precipitation after the first week of incubation.  
At the second week, the TCP particles partially fell off the scaffolds, leaving behind 
irregular-sized gaps that enhanced the surface contact area with the simulated body 
fluids.   
This resulted in the enhanced mineralized layer observed at week 3. Clusters of mineral 
precipitates were detected on the surfaces of the scaffolds.  After 4 weeks of incubation, 
apatite had formed continuously on the surface with a thicker precipitated layer as 
compared to week 3. Interestingly, the precipitates formed unique globoid and needle-
like structures. 
 
4.4   DISCUSSION 
4.4.1   Cytocompatibility 
Effect of rhBMP-2 on cell proliferation 
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Numerous studies have investigated the effect of BMP on various types of scaffolds both 
in vitro and in vivo. The rhBMP-2 encapsulated in biodegradable poly (DL-lactide-co-







Figure 4.11: Phase contrast micrographs of the calcium precipitates on the surface of 
a representative PCL-TCP composite scaffold after immersion in simulated body 
fluids for (a) 1 and (b) 4 weeks and stained with Von Kossa as described in 
manuscript. 
 
        
     (a)                                                                       (b) 
         
                            (c)         (d) 
Figure 4.12: Scanning electron micrographs of the calcium precipitates on the surface of 
PCL-TCP composite scaffolds immersed in simulated body fluids for (a) 2, (b) 3 and (c) 
4 weeks. Figure (d) is a higher magnification of (c) that illustrates the unique globoid and 
needle-like structures manifested by the calcium precipitates on the surface of PCL-TCP 




the regenerated bone displayed excellent mechanical properties [Mori, 2000]. It was also 
discovered that rhBMP-2 could induce bone regeneration in close apposition to dental 
implant surfaces, however bone fill and osseointegration values from groups with 
rhBMP-2 were similar as control [Sykaras, 2001]. An evaluation of the effect of rhBMP-
2 on rat bone marrow stromal cells cultured on titanium fiber mesh in vitro disclosed that 
rhBMP-2 increased cell proliferation from 4 to 8 days but after that DNA content 
decreased [Vehof, 2001]. 
The current work showed that rhBMP-2 stimulated an initial burst of cells, followed by a 
decline to a value similar as control. This corresponds with the findings of the above 
literatures. This behavior could be explained by the binding affinity of rhBMP-2 for the  
PCL-TCP scaffold and its in vitro release characteristics. It was hypothesized that growth 
factor release exists in two stages [Ziegler, 2002]. The initial burst of cells is due to 
elution of loosely bound protein. Nevertheless, the initial burst could serve to augment 
the in vivo wound healing response. The second phase of release presents a specific 
pattern dependent upon the type of material and growth factors used. 
For example, the rhBMP-2 release profiles from hyaluronic acid-based scaffolds in vitro, 
demonstrated that approximately one third of the initially loaded rhBMP-2 diffused out of 
the scaffolds over the course of 28 days, unlike the rapid release observed in collagen and 
polylactic scaffolds [Kim, 2002]. The present study did not investigate the in vivo release 
kinetics of rhBMP-2 from PCL-TCP scaffolds; hence it is recommended as future work. 
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The identification of a quantitative release carrier model is pertinent for clinical 
application. 
This research did not reveal any dose-dependent effect of rhBMP-2 on cell proliferation. 
This corroborates with the findings of Vehof et al. However, there is a possibility that the 
range of rhBMP-2 concentrations used were too wide. Perhaps a narrow range of 100– 
500 ng/ml of rhBMP-2 could exhibit dose-dependent effects on cell proliferation.  
 
Effect of rhBMP-2 on cell differentiation 
It was found that osteocalcin levels heightened at the second week, followed by 
deposition of calcified matrix. This pattern of osteocalcin expression and mineralization 
coincides with reported sequence of osteoblast differentiation observed by others 
[Salgado, 2002]. However, the strategy of combining PCL-TCP scaffold with rhBMP-2 
seemed to accelerate the process of mineralization. Mineralized nodules were observed as 
early as 4 days after stimulation for cell seeded scaffolds augmented with varied 
concentrations of rhBMP-2. Additionally, it was observed that 100 ng/ml of rhBMP-2 
was the most stimulative of differentiation as it produced the most amount of osteocalcin 
7 days after stimulation. It was reported that rhBMP-2 and glucocorticoids such as 
dexamethasone, which was a component of the differentiation medium, could act 
synergistically on osteoblast differentiation [Yamaguchi, 2000; Vehof, 2001]. This 
verifies the above observation. 
An important observation of the current research was that PCL-TCP scaffolds proved to 
be osteoconductive, osteoinductive and non-toxic to cells in vitro. Cells adhesion and 
colonization of the scaffold was proof of its osteoconductiveness. Extracellular matrix 
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production verified its osteoinductiveness and confocal microscopy confirmed cell 
viability, hence indicating its non-toxic nature. This implies great clinical applications for 
this novel scaffold. 
Intriguingly, groups with rhBMP-2 exhibited escalated cell death at day 20. This was 
perhaps due to a change in cell signaling pathway but needs to be investigated further. It 
is known that as osteoblasts undergo terminal differentiation and after the cellular matrix 
mineralizes, they undergo apoptosis. This programmed cellular death is an expected 
result of cell maturation and the blocking of rhBMP-2 actions not only arrest osteoblast 
differentiation but also prevents apoptosis [Canalis, 2003]. Hence, since the canine 
osteoblasts used in this study were already differentiated, the addition of rhBMP-2 could 
have expedited maturation into terminally differentiated state, resulting in quickened 
death of cells. 
In light of the plethora of growth factors currently known, investigating the effect of 
other growth factors with the PCL-TCP scaffolds in hope of further enhancing its 
osseointegration properties is recommended. Alternatively, rhBMP-2 could be used in 
combination with other growth factors to stimulate a microenvironment as close as 
possible to the in vivo condition. Recently, a combination of PRP and autogenous bone 
graft was advocated as a means of enhancing bone formation. PRP is an autologous 
source of concentrated platelets, when combined with thrombin and calcium chloride, 
leads to release of platelet derived growth factors and transforming growth factors 
[Shanaman, 2001; Wiltfang, 2003]. It proved effective for maxillary sinus augmentation 
[Rodriguez, 2003] and treatment of bone defects around titanium implants [Kim, 2002]. 
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Hence, this indicates that growth factors in combination can be more effective and this 
strategy will be further discussed in the next chapters. 
4.4.2   Biodegradation 
The other parameter assessed in this study was the degradation of the PCL-TCP scaffolds 
immersed in SBF and PBS. All the scaffolds retained their framework and 3-D 
morphology until the end of the experiment, which means that the degradation process 
was still in its early stage. This corresponds to other studies involving the degradation of 
composite scaffolds composed of polymers and ceramics [Maquet, 2004; Kim, 2004]. It 
is expected in tissue engineering that the degradation rate of porous polymer scaffolds 
should be slower than the bone formation rate since the mechanical properties of the 
scaffolds must be sufficient to support the bone regeneration process [Hedberg, 2005]. 
 
Water uptake 
In general, PBS- and SBF-soaked scaffolds showed a similar trend of water absorption 
from days 0-17. A maximum percent of water was absorbed by capillary action aided by 
the hydrophilic nature of TCP, followed by the saturation of scaffolds with water. 
However, from day 17 onwards, the water absorption gradually declined for SBF-soaked 
scaffolds as compared to a progressive increase for PBS-soaked scaffolds. This 
phenomenon may be attributed to the weight loss and bioactivity properties of the 




No trend was deciphered for the percent of weight loss of PCL-TCP scaffolds immersed 
in SBF and PBS, hence suggesting erosion as the cause. Approximately 1-2 % weight  
loss was observed at several time points, more for PBS- than SBF-soaked scaffolds. The 
minimal weight loss observed in this study clearly indicated that the scaffolds were 
slowly degraded. This weight loss was likely due to ionic release of TCP and perhaps to a  
smaller extent, hydrolytic degradation of PCL. The PCL polymer, like its synthetic 
polyester counterparts PPF and PLGA, degrade through hydrolysis of their ester linkages. 
However, the degradation of these two polymers was reportedly faster [Hedberg, 
2005].The increase of water absorption exhibited by PBS-soaked samples may be due to 
cavities created inside the composites because of the elution of TCP particles as 
suggested by the weight loss data. However, this postulation needs to be verified.  
The proposed mechanism of degradation manifested by PCL-TCP composite scaffolds 
are as a result of combining PCL polymer with TCP ceramic. Woodard et al have 
extensively studied the intracellular bulk degradation of PCL. For bulk degradation, 
degradation proceeds throughout the polymer matrix and the immediate drop of 
molecular weight is observed, whilst mass loss is retarded. After nine months, the 
molecular weight decreased to about 5000, followed by the onset of the second stage of 
degradation. The rate of chain scission slowed, the hydrolytic process began to produce 
short chain oligomers and weight loss was observed. Eventually the implant was 
observed to fragment into a powder. The degradation of fragmented PCL was observed 
inside the phagosomes of macrophages and giant cells. Inside these cells, the degradation 
was rapid, requiring only 13 days for complete absorption in some cases. 
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The addition of TCP is hypothesized to accelerate the degradation of the PCL polymer. 
Since the TCP particles are only physically blended into the polymer, they occupy 
random spaces in the polymer. After the scaffold is immersed in solution for awhile, the 
TCP particles being hydrophilic tend to fall off and interact with the surrounding 
medium. If in the presence of supersaturated ions, the TCP will convert to its more stable 
soluble phase that is apatite. The falling of TCP created voids within the polymer, thus 




Upon degradation, the formation of a calcium-rich surface layer was nucleated beginning 
with an initial phase of tricalcium phosphate, followed by precipitation of octacalcium 
phosphate which finally served as a template for hydroxyapatite growth.  Notably, apatite 
that is analogous to inorganic bone, developed after 17 days post-immersion in SBF.  The 
bioactivity results suggest that the weight loss and decline in water uptake observed was 
compensated by the precipitation of calcium compounds on the surface of the scaffolds at 
its early stage of degradation. The pH of the supernatant that commenced to decrease at 
day 17 further substantiates this supposition.  It can be concluded that day 17 is a turning 
point for PCL-TCP scaffolds to nucleate calcium precipitation. 
It is hypothesized that the apatite nucleation observed was via the functional groups of 
the composite scaffold. The scaffold would release positive charged ions, most likely 
Ca2+ from TCP, into SBF via an exchange with the H3O+ ions in the fluid to form 
hydroxyl groups on its surface. These hydroxyl groups would then combine with positive 
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charged ions in the fluid to form an amorphous precipitate on the glass surface. After a 
long soaking period, this precipitate combines with phosphate ions in the fluid to form an 
amorphous calcium phosphate with a low Ca/P ratio and this phase later transforms into 
bone-like apatite crystal, increasing its Ca/P ratio and incorporating minor ions such as 
Na+, Mg 2+ and Cl-. These reactions can be written as: 
4 Ca3 (PO4)2 (s)-----------Ca10 (PO4)6 (OH)2 (s) + 2 Ca2+ + 2 HPO4- 
The dissolution of TCP can result in the incorporation of organic molecules like proteins 
as well. Hence, the bone forming cells in vivo, that is, osteoblasts can preferentially 
proliferate on the apatite and differentiate to form an extracellular matrix composed of 
biological apatite and collagen. As a result, the surrounding bone comes in direct contact 
with the surface apatite layer. When this process occurs, a chemical bond is formed 
between the bone mineral and the surface apatite to decrease the interfacial energy 
between them [Kokubo, 2003]. 
Therefore, PCL-TCP scaffolds possessed a bioactive nature.  This phenomenon will have 
interesting influences on the in vitro protein delivery properties of the scaffolds as will be 
discussed in the subsequent two chapters. Future work also entails testing the efficacy of 
the scaffolds as protein delivery systems for the repair of bone defects using in vivo 










4.5    CONCLUSIONS 
Cytocompatibility 
• Novel PCL-TCP scaffolds seeded only with canine osteoblasts could sustain 
excellent osteogenic expression in vitro. The osteoblasts could attach, migrate and 
proliferate on the surfaces of the scaffolds for four weeks in culture medium 
without any significant adverse effects. 
• The rhBMP-2 enhanced the differentiated function of canine osteoblasts in a non-
dose dependent manner. This resulted in accelerated mineralization, followed by 
death of osteoblasts as they underwent terminal differentiation. 
  
Biodegradation 
• All the PCL-TCP scaffolds retained their framework and 3-D morphology until 
the end of the experiment (4 weeks), which means that the degradation process 
was still in its early stage. 
• PCL-TCP scaffolds were not only biodegradable and bioresorbable, but also 
possessed a bioactive nature. Upon degradation, the formation of a calcium-rich 
surface layer was nucleated beginning with an initial phase of tricalcium 
phosphate, followed by precipitation of octacalcium phosphate which finally 






CHAPTER 5: PCL-TCP SCAFFOLDS AS PROTEIN DELIVERY 
SYSTEMS FOR RHBMP-2 
5.1   INTRODUCTION 
In Chapter 4, the efficacy of incorporating canine osteoblasts with recombinant bone 
morphogenetic protein-2 (rhBMP-2) into 3D biodegradable polycaprolactone- 20 % 
tricalcium phosphate (PCL-TCP) scaffolds in vitro was evaluated [Rai, 2004]. We 
discovered that the scaffolds were biocompatible and when seeded only with cells, 
sustained osteogenic expression. Also, the addition of rhBMP-2 had accelerated 
mineralization. However, the inclusion of cells in this strategy has its disadvantages. 
Firstly, a surgery must be performed for the extraction of autologous cells. Secondly, the 
cells must be expanded in vitro to obtain sufficient numbers. This is both time and 
resource consuming [Saoto, 2003]. Lastly, one must be careful not to introduce any 
contaminants during the preparation process. 
These drawbacks provide the impetus to venture into an alternative strategy that requires 
the loading of the scaffold with osteoinductive factors only, prior to implantation. Here, 
the scaffold serves as a protein delivery system (PDS). Based on this concept, numerous 
groups have been focusing on developing a PDS for bone engineering [Sheridan, 2000; 
Murphy, 2000; Saoto, 2003; Tabata, 2003; Wozney, 2003]. Among the plethora of 
growth factors available, BMP-2 is reportedly the strongest osteoinductive factor 
administered therapeutically to restore form and function to bone [Mori, 2000; Yuan, 
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2001; Bessho, 2002; Jinguishi, 2002; Niedhart, 2003; Matsuo, 2003; Ruhe, 2004]. 
However, currently used carriers for BMP-2, namely collagen and ceramics are less than 
ideal and the development of a carrier for load bearing applications is highly desired from 
a clinical point of view. 
Extensive in vitro and in vivo studies on PCL-based scaffold/cell constructs have been 
performed. In vivo, the constructs exhibited bone formation, remodeling and maturation 
along with rapid vascularization in low and medium load-bearing sites [Hutmacher, 2000; 
Hutmacher, 2001; Zein, 2002; Schantz, 2002; Schantz, 2003; Endres, 2003]. In addition, 
the use of the highly reproducible and computer-controlled fused deposition modeling 
technique allows the fabrication of tissue-engineered grafts designed on the basis of 
computed tomography (CT) scans of individual defect sites [Hutmacher, 2001; Endres, 
2003]. 
Following the current trend toward bioactive composite development, novel bioactive 3D 
biodegradable composites consisting of 80 % PCL and 20 % TCP were fabricated, which 
were assessed in this study. The TCP component was reported to spontaneously bond to 
and integrate with bone, provides a pH buffering effect on the polymer degradation 
behavior [Blaker, 2003; Maquet, 2004] and enhances the mechanical properties of porous 
polymer constructs [Boccaccini, 2002]. Moreover, TCP exhibit a high binding affinity for 
proteins and are well known as carriers for BMPs [Ruhe, 2004; Niedhart, 2003]. 
Fibrin sealant was selected for the delivery system to promote the loading efficiency of 
rhBMP-2 onto the scaffolds [Orban, 2002]. The sealant has been studied in various 
applications to improve the stability and cell-attachment properties of scaffolds [Thorn, 
2004], while simultaneously delivering cells [Endres, 2003, Salgado, 2002] and/or 
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bioactive agents like angiogenic [Wong, 2003], polypeptide growth factors [Sahni, 1998; 
Elbert, 2000] and, recently, non-glycosylated BMPs [Schmoekel, 2004]. 
Here, a novel PDS consisting of three components: slow degrading PCL-based scaffolds 
with sufficient physical properties to withstand both wound contraction forces as well as 
load bearing applications, fibrin Tisseel sealant and rhBMP-2, was proposed. It must be 
noted that the various components of the PDS proposed are FDA approved and can be 
prepared simultaneously and quickly at the operation table. This makes the current 
strategy highly suited for clinical applications.  
The specific aim of this study was to investigate the suitability of PCL-TCP composite 
scaffolds in combination with fibrin tisseel sealant as PDS for rhBMP-2 at the 
concentrations of 10 and 20 µg/ml. Plain PCL scaffolds were adopted as controls. The 
protein retention, intensity of burst, spatial distribution on scaffold surface, in vitro 
release kinetics as well as the stability and bioactivity of the eluted rhBMP-2 was 
assessed over a period of 21 days. 
 
5.2   MATERIALS AND METHODS 
5.2.1   Scaffold design and fabrication 
PCL and PCL-TCP (80:20%) scaffolds, each with a lay down pattern of 0/60/120° and a 
porosity of about 70 % and measuring 5 x 5 x 3 mm were used. Scanning electron 
microscopy (SEM) revealed the structure of both PCL and PCL-TCP scaffolds to be a 
typical honeycomb array of interconnected equilateral triangles with regular porous 
morphology. It was observed that PCL scaffolds had a smooth surface unlike PCL-TCP 
scaffolds where hydrophilic TCP was evidently exposed within the hydrophobic PCL 
 94 
scaffold surface as particles (Fig 5.1). The scaffolds were soaked for 3 h at 37°C in 
Phosphate Buffered Saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 




Figure 5.1: SEM micrographs of 3-dimensional (A) PCL and (B) PCL-TCP scaffold 
structure produced by fused deposition modeling and having a 0/60/120° lay down 
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pattern. Both pictures represent the top view, displaying a typical array of equilateral 
triangles. TCP was evident as particles on the walls of the PCL scaffold. 
 
5.2.2   Loading of bovine serum albumin and calculation of percentage protein 
retention 
Forty microliters of a model protein, bovine serum albumin (BSA, 1mg/ml), was loaded 
onto PCL-TCP composite scaffolds together with twenty microliters of fibrin Tisseel 
sealant (Tisseel kit, Immuno, Austria). The loaded scaffolds were then hydrolyzed in 1 
mg of lipase (L8525, Sigma, Germany) dissolved in 20 mM Tris-HCL, pH 7.23, at 37 °C 
for 5 days. Similar procedures were used to hydrolyze 1 mg/ml of BSA standard solution. 
After hydrolysis, protein concentrations of loaded scaffolds and standard solution were 
determined by Protein BioRad method (Bio-Rad, USA). Scaffolds (n = 2) were pretreated 
in PBS and simulated body fluids (SBF) (method was described in chapter 4) for 0, 7, 14, 
21 and 28 days and subjected to the above protein loading and hydrolysis procedure. 
Subsequently, protein retention for each time point was calculated using the following 
equation [Wei, 2004]: 
PR (%) = 100 x Retained protein amount/Initially loaded protein amount 
 
5.2.3   Loading of bone morphogenetic protein-2  
The BMP used in the present study was recombinant human BMP-2 (rhBMP-2) 
(Shanghai Huigu Bio-tech Co, China) at concentrations of 10 and 20 µg/ml. A loading 
volume consisting of 30 µl rhBMP-2 at the various concentrations and 20 µl fibrin tisseel 
sealant (Tisseel kit, Immuno, Austria) was evenly pipette-loaded onto each scaffold. 
Similarly, 30 µl of rhBMP-2 free PBS with 20 µl fibrin sealant was loaded onto scaffolds 
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to serve as control. Hence, six experimental groups were created) (Table 5.1). 
 
  
Group 1: PCL-fibrin scaffolds loaded with 10 µg/ml rhBMP-2 
Group 2: PCL-fibrin scaffolds loaded with 20 µg/ml rhBMP-2 
Group 3: PCL-TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2 
Group 4: PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2 
Group 5: PCL-fibrin scaffolds (control 1) 
Group 6: PCL-TCP-fibrin scaffolds (control 2) 
 
Table 5.1: Six experimental groups were created for this study (n = 4 for each group). 
 
5.2.4   Intensity of burst and distribution of rhBMP-2 loaded on PCL-TCP scaffolds 
In addition, the percentage intensity of burst (amount of rhBMP-2 released / initial loaded 
rhBMP-2 concentration x 100 %) at 24 h was quantified for each scaffold loaded with 
rhBMP-2 at doses of 2, 4, 8, 10 and 20 µg/ml. The physical distribution of 10 µg/ml 
rhBMP-2 on the scaffolds was analyzed by SEM and confocal laser microscopy (CLM). 
For SEM, samples were fixed as described in section 4.1.2.4 of chapter 4. For CLM, 10 
µg/ml rhBMP-2 was labeled using a FluoReporter FITC protein labeling kit (Molecular 
Probes, USA) according to manufacturer’s instructions, before loading onto scaffolds as 
described in section 5.2.2 and viewed under a confocal laser microscope (Olympus 1 X 
81, FluoView 500). Three- dimensional depth projection images were constructed from 
100 horizontal slices of step size 2 µm. 
 
5.2.5   In vitro release measurements of rhBMP-2 
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The PCL and PCL-TCP-fibrin composite scaffolds loaded with rhBMP-2 at various 
concentrations were placed in 24-well plates and immersed in 2 ml of PBS. The elution 
of rhBMP-2 was examined at 2 h, followed by 1, 2, 7, 10, 14, 16, 18 and 21 days. At each 
time interval, the supernatant was completely removed and replaced with fresh buffer. 
Eluted rhBMP-2 in the removed buffer (n = 4) at each time interval was measured 
quantitatively using a sandwich enzyme-linked immunosorbent assay (ELISA). 
Monoclonal anti-human BMP-2 antibody (Mab 3552, R & D Systems) was diluted by 50- 
fold to obtain a final concentration of 10 µg/ml in PBS, then 50 µl was added to each 
well of Nunc immuno plate. After incubation overnight at 4 °C, the wells were washed 
with PBS containing 0.05 % Tween (PBST). Two hundred microliters of blocking 
solution (3 % Bovine serum albumin in PBS) was added to each well, followed by 
incubation at 37 °C for 40 min. A standard curve was plot by preparing a total of eight 
dilution points ranging from 0 to 20 µg/ml of rhBMP-2 as reference standards. Fifty 
microliters from each group (release study supernatants and reference standards) was 
transferred to a coated capture plate. After incubation for 2.5 h at 37 °C, the wells were 
washed 2 x with PBST. The anti-BMP-2-antibody was biotinylated with a biotin labeling 
kit according to manufacturer’s instructions (Roche Diagnostic, Germany) and 50 µl 
(0.5µg/ml) was added for 1.5 h. Then, 100 µl of Avidin Horse Radish Peroxidase 
(AHRP) conjugated (Pierce, USA) (1: 1000 in PBST) was added to each well for 1 h. 
After washing 2 x with PBST, 100 µl of ABTS solution (Pierce, USA) was added to each 
well for 8 min. One hundred microliters/well of 1 % sodium dodecyl sulfate stop solution 
was added before reading the plate at 405 nm [Kim, 2002]. The eluted proteins in the 
removed buffer (n = 4) at each time interval was also assayed quantitatively for total 
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protein content by BioRad protein method (Bio-Rad, USA), according to manufacturer’s 
instructions, using BSA as a standard. All raw data obtained were expressed as 
micrograms/ ml. 
5.2.6   Bioactivity and stability of eluted rhBMP-2 
In order to assess the bioactivity of rhBMP-2 eluted from the PCL/PCL-TCP-fibrin 
scaffolds, an alkaline phosphatase (ALP) assay was performed. Basically, release study 
supernatants (n = 4) from each time point were incubated for 4 days with a monolayer of 
human osteoblasts (hOB) (1 x 105 cells/ml) as previously described [Salgado, 2002], 
cultured in Dulbecco’s modified Eagle’s medium on 24-well plates. This was followed 
by rinsing twice with PBS and then staining with a Sigma ALP kit (No. 86), used 
according to the manufacturer’s instructions (Sigma Diagnostics, USA). Under the 
influence of rhBMP-2, hOB expressed enhanced osteoblast phenotype by increased ALP 
activity [Kim, 2002, Partridge, 2002]. Hence, strong staining for ALP ascertained that 
released rhBMP-2 retained its bioactivity. Sites of phosphatase activity appeared as dark 
blue-stained granules within the cytoplasm of cells. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) confirmed the 
identity of released rhBMP-2 as well as provided information about its stability [Ziegler, 
2002]. The release study supernatants were suspended in electrophoresis buffer and 
electrophoresed in 12 % SDS-PAGE under reducing conditions. SDS-PAGE followed by 
modified silver staining (BioRad, CA) showed the molecular weight of rhBMP-2 used for 
this experiment to be about 30 kDa. Hence, a band of 30 kDa observed in the release 
study supernatants would confirm presence of an intact rhBMP-2. As molecular weight 
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markers, [14 C] methylated proteins (serum albumin 66.2 kDa; ovalalbumin 45 kDa; 
carbonic anhydrase 31 kDa; trypsin inhibitor 21.5 kDa; lysozyme 14.4 kDa; aprotinin 6.5 
kDa) were used. Time points investigated for both ALP assay and SDS-PAGE were 
selected in accordance to the release profile obtained from section 5.2.5.  
5.2.7   Statistical analysis 
Four replicates were used for each experimental group and each experiment was repeated 
twice. All results were expressed as mean ± standard deviation (SD). The results were 




5.3.1   Percentage protein retention 
In order to measure the true protein retention (PR), protein loaded PCL-TCP scaffolds 
were hydrolyzed in lipase solution. SEM micrographs revealed significant and steady 
deterioration in morphology and structural integrity (Fig 5.2). Initially, scaffold surfaces 
became bumpy, with TCP particles protruding out and cracks were initiated at these sites. 
The cracks grew in length and diameter, creating holes in the rods of the scaffolds. Pore 
sizes increased as diameters of rods diminished significantly. Finally, at day 5, rods 
dissociated from each other, resulting in the collapse of the scaffold architecture. 
The initial % of protein retention by the scaffolds before pretreatment in any buffer was 
(49.1 ± 1.50) %. A progressive increase in PR of scaffolds was detected after immersion in 
PBS and SBF over 4 weeks (Fig 5.3). Notably, scaffolds pretreated in SBF manifested a 
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significantly higher PR of (88.5 ± 1.40) % as compared to the (69.1 ± 1.40) % evinced by 















Figure 5.2: SEM micrograph of PCL-TCP scaffolds before (A & C) and after 
(B & D) 




Figure 5.3: Protein retention of PCL-TCP composite scaffolds after pretreatment in 
simulated body fluid (SBF) and phosphate buffered saline (PBS) over time (n = 2, ±  SD). 
 
 
5.3.2   Intensity of burst and distribution of rhBMP-2 loaded on PCL-TCP scaffolds 
An intensity of average 27 % burst of release was observed for PCL-fibrin scaffolds 
loaded with 2, 4, 8, 10 and 20 µg/ml of rhBMP-2 at 24 h. No significant difference (p > 
0.05) was observed among the various concentrations. PCL-TCP-fibrin scaffolds loaded 
with 2, 4, 8, 10 and 20 µg/ml of rhBMP-2 at 24 h showed an average intensity of 50.1 % 
burst of release. Once again, the intensity of burst was non-dose dependent. 
SEM examination revealed cobweb-like extensions of fibrin sealant attached onto the 
surface as well as across the pores of PCL and PCL-TCP scaffolds (Fig. 5.4A). The fibrin 
sealant manifested thick fibrils with a large pore size (> 5µm). The fibrin network was 
well established on PCL-TCP scaffolds but was discontinuous on PCL scaffolds. PCL 
fibrin scaffolds loaded with 10 µg/ml rhBMP-2 showed sparse, large clumps of rhBMP-2 
particles attached to the rods’ surface of the scaffold (Fig. 5.4B). In contrast, roughly 
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spherical rhBMP-2 particles were evident and dispersed on the rods’ surface of PCL-
TCP-fibrin scaffolds (Fig. 5.4C). These findings were substantiated by confocal laser 
microscopy. Fluorescent rhBMP-2 was observed to form clumps that were non-uniform 
and sparse on the rods’ surface of PCL-fibrin scaffolds. Individual rhBMP-2 particles 
could not be discerned. PCL-TCP-fibrin scaffolds revealed clearly fluorescent rhBMP-2 
particles, approximately 6 µm in diameter, uniformly distributed on the rods’ surface of 





Figure 5.4: SEM micrographs of (A) Control (PCL-TCP-fibrin scaffolds), (B) PCL-fibrin 
and (C) PCL-TCP-fibrin scaffolds loaded with 10 µg/ml of rhBMP-2. 
 
5.3.3   Release measurements 
Fig. 5.5 illustrates the amount and Fig. 5.6 the cumulative release of rhBMP-2 from the 
experimental groups over a period of 21 days as quantified by sandwich-ELISA. Plotting 
the mean % of cumulative release from all experimental groups (y) against time (x), 
resulted in a trend-line with a polynomial equation of y = -0.0835 x2 + 5.0435 x + 31.33 
and a R2 value of 0.9746. Groups 1 and 2 showed a similar triphasic in vitro release 
profile. This consisted of an initial burst of 26.4 % or 3 and 4.8 µg/ml at 2 h, a second 
cumulative release of 68.5 % or 7.6 and 12.8 µg/ml at day 7 and a third cumulative 
release of 100 % or 11.4 and 18.2 µg/ml at day 16 respectively. No significant 
differences were observed for the intensity of burst at all three release time points. After 
day 16, no further release of rhBMP-2 was detected.  
Group 3 demonstrated a biphasic in vitro release pattern. This consisted of an initial 
cumulative release of 53.3 % or 5.7µg/ml at day 1 and a delayed second cumulative 
release of 100 % or 10.7 µg/ml at day fourteen. No significant differences were observed 
for the intensity of burst at both release time points. After day 14, no further release of 
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rhBMP-2 was detected. A triphasic in vitro release pattern was observed for Group 4. 
This consisted of an initial release of 49.1 % or 11.4 µg/ml at 2 h, a second cumulative 
release of 82.8 % or 19.2 µg/ml at day 10 and a third cumulative release of 100 % or 23.2 
µg/ml at day 21. The intensity of burst diminished significantly (p < 0.05) over the three 






Figure 5.5: The amount of rhBMP-2 released from experimental groups in vitro as a 
function of time. Released medium was removed at 2 h, followed by 1, 2, 4, 7, 10, 14 and 
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21 days and quantified by ELISA (n = 4, mean ± SD). Group 1: PCL-fibrin scaffolds 
loaded with 10 µg/ml rhBMP-2. Group 2: PCL-fibrin scaffolds loaded with 20 µg/ml 
rhBMP-2. Group 3: PCL-TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 4: 
PCL-TCP- fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Controls showed no release 









Figure 5.6: The cumulative in vitro release of rhBMP-2 from experimental groups as a 
function of time. Released medium was removed at 2 h, followed by 1, 2, 4, 7, 10, 14 and 
21 days and quantified by ELISA (n = 4, mean ± SD). Group 1: PCL-fibrin scaffolds 
loaded with 10 µg/ml rhBMP-2. Group 2: PCL-fibrin scaffolds loaded with 20 µg/ml 
rhBMP-2. Group 3: PCL-TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 4: 
PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Controls showed no release of 
rhBMP-2 at all time points. 
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Protein Bio-Rad assay revealed that all experimental groups, including controls, showed 
a similar trend, that is a progressive decline in total protein content over time (Fig. 5.7). 
Plotting the mean protein content from all experimental groups (y) against time (x), 
resulted in a trend-line with a polynomial equation of y = 0.2777 x2 – 9.0284 x + 71.378 
and a R2 value of 0.9291. There was no significant difference (p > 0.05) in the amount of 
total protein release between controls. This suggests that fibrin release from both 
scaffolds followed a similar pattern. Fibrin release from both controls lasted for only 10 
days, after which no protein could be detected in the supernatant. The amount of protein 
release at each time point for controls was significantly (p < 0.05) lower than that 
obtained by the experimental groups loaded with rhBMP-2. Protein release was detected 
for up to day 16 for Groups 1 and 2, day 14 for Group 3 and day 21 for Group 4. These 
findings correlate well with the results obtained from sandwich-ELISA. 
 
5.3.4   Bioactivity and stability  
A qualitative histochemical demonstration of alkaline phosphatase activity assessed the 
bioactivity of rhBMP-2 eluted in release study supernatants. At 2 h, all experimental 
groups loaded with rhBMP-2 manifested enhanced blue-stained granules indicative of 
phosphatase activity (Fig. 5.8A-D). Hence, the eluted rhBMP-2 retained its bioactivity at 
2 h. This was also observed at days 2, 7 and 16 for Groups 1 and 2. Blue-stained granules 
were evident for Groups 3 and 4 at days 1, 14 and 10, 21 respectively. Notably, the eluted 
rhBMP-2 could retain its bioactivity in vitro for up to 21 days. All other time points 
revealed negligible ALP activity. Control groups displayed negligible staining of 




Figure 5.7: The amount of total protein release from experimental groups in vitro as a 
function of time. Released medium was removed at 2 h, followed by 1, 2, 4, 7, 10, 14 and 
21 days and quantified by protein BioRad Assay (n = 4, mean ± SD). Group 1: PCL-
fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Group 2: PCL-fibrin scaffolds loaded 
with 20 µg/ml rhBMP-2. Group 3: PCL-TCP-fibrin scaffolds loaded with 10 µg/ml 
rhBMP-2. Group 4: PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Control 1: 















                 
                   
 
 
Figure 5.8: ALP histochemistry of hOB incubated with eluted 
supernatant from 2 h from (A) PCL-fibrin scaffolds alone, (B) PCL-fibrin 
scaffolds loaded with 10 µg/ml rhBMP-2, (C) PCL-fibrin scaffolds loaded 
with 20 µg/ml rhBMP-2, (D) PCL-TCP-fibrin scaffolds loaded with 10 
µg/ml rhBMP-2 and (E) PCL-TCP-fibrin scaffolds loaded with 20 µg/ml 
rhBMP-2. Blue-stained granules within the cytoplasm of cells represent 







SDS-PAGE verified the identity and stability of eluted rhBMP-2. Fig. 5.9A depicts eluted 
rhBMP-2 from Groups 1 and 3 at 2 h, days 2, 7, 16 and 2 h, days 1 and 14 respectively. 
Fig. 5.9B shows eluted rhBMP-2 from Groups 2 and 4 at 2 h, days 2, 7, 16 and 2 h, days 
10 and 21 respectively. At these time points, a clear 30 kDa band was detected, which 
corresponds to the molecular weight of an intact rhBMP-2. However, at all other time 
points, no bands were observed, indicating the absence of rhBMP-2 from the release 
study supernatants. Interestingly, additional multiple high and low molecular weight 
bands were evident at 2 h until day 10 for all composites. Controls also showed multiple 
high and low molecular weight bands until day 10, after which no bands could be 
discerned. These bands correspond in molecular weight to those observed in the 
experimental groups loaded with rhBMP-2. 
 
5.4   DISCUSSION 
Numerous groups are working on growth factor delivery systems for bone engineering. 
Problems inherent in the currently used delivery systems for BMP-2 include slow release, 
unfavorable architecture for vascularization and lack of mechanical strength. Hence, here 
a novel protein delivery system is proposed that consisted of three components, 
biodegradable PCL-based scaffolds, fibrin Tisseel sealant and rhBMP-2, for load bearing 
applications in bone regeneration. It must be noted that these components are FDA 
approved and can be prepared simultaneously and quickly at the operation table. This 







Figure 5.9:  SDS-PAGE represents rhBMP-2 elution from (A) PCL-fibrin and PCL-TCP-
fibrin scaffolds loaded with 10 µg/ml rhBMP-2. Lane 1: protein molecular weight 
markers. Lane 2: positive control. Lanes 3-6: eluted rhBMP-2 from PCL scaffolds loaded 
with 10 µg/ml rhBMP-2 at 2 h, days 2, 7 and 16. Lanes 7-9: eluted rhBMP-2 from PCL-
TCP scaffolds loaded with 10 µg/ml rhBMP-2 at 2 h, days 1 and 14. (B) PCL-fibrin and 
PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. Lane 1: protein molecular 
weight markers. Lane 2: positive control. Lanes 3-6: eluted rhBMP-2 from PCL scaffolds 
loaded with 20 µg/ml rhBMP-2 at 2 h, days 2, 7 and 16. Lanes 7-9: eluted rhBMP-2 from 
PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2 at 2 h, days 10 and 21. 












This work investigated specifically the in vitro efficacy of PCL-TCP-fibrin composite 
scaffolds as PDS for rhBMP-2. The first parameter measured was protein retention. PCL-
TCP scaffolds demonstrated reasonable protein retention of (49.1 ± 1.50) % as compared to 
other scaffolds before soaking in any buffer [Sheridan, 2000; Murphy, 2000]. Remarkably, after 
immersion in SBF and PBS for 4 weeks, the PR was augmented to (88.5 ± 1.40) % and (69.1 ± 1.40) 
% respectively. Various factors were responsible for this occurrence. After immersion in 
buffer over time, the hydrophilic TCP components of the composites provided a large 
amount of water and open structure to the system [Kim, 2004]. This resulted in enhanced 
protein adsorption and correlates to an investigation by [Matsumoto, 2004], which 
claimed that the adsorbed amount of protein was directly proportional to the specific 
surface area of TCP. In addition, the release of TCP particles as reported in the previous 
chapter, created holes in the scaffolds that could be occupied by the protein, thus further 
increasing the amount of protein encapsulated. 
The higher PR observed in SBF in contrast to PBS pretreated samples could be attributed 
to the innate bioactivity of PCL-TCP scaffolds in SBF. This property was observed and 
reported in the previous chapter as well. Basically, the dissolution of TCP caused an 
increase in the levels of calcium and phosphate ions in SBF, subsequently nucleating the 
precipitation of apatite crystals at the defect sites of the scaffolds [Kokubo, 2003]. These 
crystals could incorporate organic molecules e.g. proteins present in the fluid through 
electrostatic interaction between amino groups of the protein and negative charged sites 
of apatite crystals [Yamamuro, 1990; Matsumoto, 2004].  
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It was interesting to note that the controls, that is, PCL-fibrin scaffolds, retained 
significantly (p < 0.05) more rhBMP-2 than PCL-TCP-fibrin scaffolds as indicated by the 
intensity of burst results at 24 hours. The PCL-fibrin scaffolds probably retained more 
rhBMP-2 at day 1 because of its hydrophobic property that causes the delay of water 
penetration, thus retarding the diffusion of rhBMP-2 from the scaffold into the release 
medium [Jeong, 2003]. On the other hand, PCL-TCP-fibrin scaffolds have reduced 
hydrophobicity, hence allowing water penetration and diffusion of protein through 
scaffold more readily. Hence, the addition of TCP appears to have a profound effect on 
the loading efficiency or initial burst of rhBMP-2. 
The second parameter analyzed was the distribution of rhBMP-2 and fibrin sealant on the 
scaffolds. A continuous network of fibrin was observed on PCL-TCP scaffolds in 
contrast to a discontinuous array on PCL scaffolds. This resulted in a uniform distribution 
of rhBMP-2 on PCL-TCP-fibrin scaffolds, whereas rhBMP-2 was dispersed unevenly as 
clumps on PCL–fibrin scaffolds. Notably, rhBMP-2 appeared (as observed in SEM and 
CLM studies) to adhere only to the surface of fibrin network with no signs of 
encapsulation detected. This observation is further substantiated by the fact that although 
the pores of the scaffold manifested fibrin networks, no rhBMP-2 could be detected 
spanning the pores. This suggests that rhBMP-2 needs a substrate to adhere onto. Further 
experiments are required to unravel this phenomenon that will have important 
implications in the usage of fibrin sealant as PDS for growth factors. 
The third parameter measured was the in vitro release kinetics. ELISA results revealed a 
triphasic release pattern for PCL-fibrin scaffolds loaded with 10 and 20 µg/ml rhBMP-2 
and PCL-TCP-fibrin scaffolds loaded with 20 µg/ml rhBMP-2. A bi-phasic release 
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pattern was observed for PCL-TCP-fibrin scaffolds loaded with 10 µg/ml rhBMP-2. 
PCL-fibrin scaffolds loaded with 10 and 20 µg/ml rhBMP-2 exhibited a similar release 
pattern and burst intensities. Thus, the dose of rhBMP-2 affected the release profile for 
PCL-TCP but not plain PCL scaffolds. 
A minimum of 2 bursts of release emerged between 2 h and day 16 for all scaffolds, 
hence providing a physiological concentration of free protein in the vicinity of the 
implant, which may attract target cells to the implant site by chemotaxis. BMP-2 is 
endogenously produced within a few days after fracture, suggesting that BMP is 
necessary for bone formation within a few days after post trauma [Beesho, 2002]. Thus, 
the initial bursts of rhBMP-2 from PCL-fibrin and PCL-TCP-fibrin scaffolds would 
facilitate bone healing impeccably. It should be noted that PCL-TCP-fibrin scaffolds 
loaded with 20 µg/ml rhBMP-2 exhibited prolonged retention of the protein for up to day 
21. This increases the time period acting on the surrounding cells, which can lead to 
enhanced bone induction. Thus, these novel biomaterials could suffice to be reliable, 
protein delivery systems for a single growth factor. Numerous in vitro release kinetic 
studies have been conducted by other research groups but direct comparisons are 
impossible due to the plethora of growth factors, scaffold materials and experimental 
methods employed. 
SDS-PAGE and ALP assays verified the stability of eluted rhBMP-2. Two conclusions 
can be drawn from the SDS-PAGE results. Firstly, at each burst of release of rhBMP-2, 
the protein sufficed as an intact or non-degraded band. This indicates that the different 
materials did not affect the stability and activity of rhBMP-2. Secondly, additional high 
and low molecular weight bands were apparent for up to day 10 for both composites and 
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controls. We hypothesize that these bands represent the end products of the action of 
thrombin, a proteolytic enzyme, on fibrinogen. Fibrin monomers are formed that 
crosslink spontaneously to form a weak gel i.e. fibrin sealant [Doillon, 2002]. This 
implies that the initial release of rhBMP-2 was due to fibrin sealant that had adhered to 
the scaffolds. Importantly, although fibrin had disintegrated by day 10 (verified by 
Protein-BioRad assay), rhBMP-2 was still released as detected by sandwich-ELISA from 
all scaffolds. This implies that rhBMP-2 could directly attach to the PCL and PCL-TCP 
scaffolds. 
ALP assay conceded that the rhBMP-2 released still maintained its bioactivity at all time 
points. This correlates with the results obtained by Kim HD et al. They detected that 
Hyaff-11 scaffolds released active rhBMP-2 over the course of 48 days as assessed by the 
level of ALP expression in T1/2 cells. This has 2 implications. Firstly, the aggregation of 
rhBMP-2 observed upon loading onto PCL-fibrin scaffolds in the present study did not 
result in inactivation of the factor [Sheridan, 2000]. Secondly, at day 21, release study 
supernatants from PCL-TCP-fibrin scaffolds loaded with 20 µg/ml of rhBMP-2 showed 
significant ALP activity. This suggests that sufficient intact rhBMP-2 molecules were 
still present to enhance the osteoblastic phenotype and that rhBMP-2 can maintain its 
bioactivity in vitro for 21 days. 
The mechanism of release of rhBMP-2 from the scaffolds is an important consideration. 
Drugs formulated in polymeric devices are usually released by diffusion through the 
polymer barrier, by degradation of the polymer materials, or a combination of both 
mechanisms [Murphy, 2000; Tabata, 2003; Wei, 2004]. For PCL-fibrin scaffolds loaded 
with 10 and 20 µg/ml rhBMP-2, the initial burst effect was likely due to elution of fibrin 
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with surface bound rhBMP-2 attached to the outer surface of the scaffold [Ruhe, 2004]. 
The second burst of release was probably due to diffusion of the incorporated rhBMP-2 
out of the polymer scaffold or disintegration of fibrin, which brings along with it rhBMP-
2 as it falls off the scaffolds. The third burst was likely due to the diffusion of rhBMP-2 
particles that had directly attached to the scaffold or was entrapped within the scaffold 
matrix as fibrin was no longer present. Although PCL is a biodegradable polymer, 
biodegradation of the PCL is considerably slower than that of other degradable polymers. 
Therefore, since PCL is hardly degraded during the diffusion process, diffusion through 
the scaffold is the only possible mechanism of drug release [Jeong, 2003]. 
PCL-TCP-fibrin scaffolds loaded with 10 and 20µg/ml of rhBMP-2 displayed 2 and 3 
bursts of release respectively. Once again the initial release was likely due to the 
disintegration of rhBMP-2-fibrin matrix attached to surface of the scaffold. Notably, the 
addition of TCP caused a delay in the second elution of rhBMP-2, which was observed 
only at day 14 and 10 respectively. Thus these composites retained rhBMP-2 longer than 
PCL-fibrin scaffolds. This is likely due to the formation of intermolecular linkages of 
rhBMP-2 for the TCP component of the PCL scaffold [Wei, 2004]. The second elution 
was most likely caused by the degradation of TCP particles and/or by simple diffusion. 
PCL-TCP-fibrin scaffolds loaded with 20 µg/ml of rhBMP-2 manifested a third burst of 
release at day 21 which most probably represents the additional remaining rhBMP-2 
bound to TCP or entrapped within the PCL matrix due to the increased concentration of 
rhBMP-2 loaded. We hypothesize that by further increasing the concentration of rhBMP-
2, more bursts would be observed or bursts of similar intensities. Further studies are 
urged to corroborate this hypothesis. Additional work should also address the hypothesis 
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that local, controlled release of rhBMP-2 from PCL and PCL-TCP-fibrin scaffolds in vivo 
will enhance the osteoconductivity of these composites and correlate with the in vitro 
release profile determined in the current study. 
To our best knowledge, we are the first group to report on the suitability of PCL-based 
honeycomb scaffolds as protein delivery systems for a single growth factor, specifically, 
rhBMP-2. This study revealed that both the dosage of growth factor and material of 
scaffolds are important determinants of release kinetics profile. We propose the usage of 
PCL-fibrin scaffolds as short-term release carriers that could prove useful for the in vivo 
wound healing process. PCL-TCP-fibrin scaffolds are recommended as long-term release 
carriers for applications that require release of bioactive molecules throughout a long 
time period for the full biologic effect to be realized, such as for tissue regeneration. The 
next chapter will look at the applicability of the PCL-TCP scaffolds as delivery systems 













5. 5   CONCLUSIONS 
• PCL and PCL-TCP-fibrin composite scaffolds displayed protein retention 
efficiencies of 70 and 43 % respectively.  
• Fluorescence and scanning electron microscopy revealed sparse clumps of 
rhBMP-2 particles, non-uniformly distributed on the rods’ surface of PCL-fibrin 
scaffolds. In contrast, individual rhBMP-2 particles were evident and uniformly 
            distributed on the rods’ surface of the PCL-TCP-fibrin scaffolds.  
• PCL-fibrin scaffolds loaded with 10 and 20 mg/ml rhBMP-2 demonstrated a 
triphasic release profile as quantified by ELISA. This consisted of burst releases 
at 2 h, and days 7 and 16.  
• A biphasic release profile was observed for PCL-TCP-fibrin scaffolds loaded with 
10 mg/ml rhBMP-2, consisting of burst releases at 2 h and day 14. PCL-TCP- 
fibrin scaffolds loaded with 20 mg/ml rhBMP-2 showed a triphasic 
            release profile, consisting of burst releases at 2 h, and days 10 and 21. The 
addition of TCP particles caused a delay in rhBMP-2 release.  
• SDS-PAGE and ALP assay verified the stability and bioactivity of eluted rhBMP-








CHAPTER 6: PCL-TCP SCAFFOLDS AS PROTEIN DELIVERY 
SYSTEMS FOR PRP 
6.1   INTRODUCTION 
Recently, increasing attention has been paid to bioresorbable composite materials made 
of polymers and ceramics for reconstruction of multi-tissue organs, tissue interfaces and 
structural tissue including bone [Du, 2000; Maquet, 2004; Kim, 2004]. Bioactive, 
biodegradable and bioresorbable composite scaffolds, combining PCL with 20% TCP for 
bone regeneration were recently fabricated using the highly reproducible fused deposition 
modeling technique (refer to Chapter 2) [Hutmacher, 2000; Hutmacher 2001; Zein, 2002; 
Schantz, 2002; Schantz, 2003; Endres, 2003]. Chapter 4 showed that the PCL-TCP 
scaffolds were biocompatible and when loaded only with osteoblasts, sustained 
osteogenic expression [Rai, 2004]. One exciting applications for these scaffolds is protein 
or growth factor delivery and its potential was investigated briefly in chapter 5 [Maquet, 
2004; Kim, 2004; Rai, 2005]. 
The present study aimed to examine the release profile of the growth factors present in 
platelet-rich plasma (PRP) loaded onto PCL–TCP scaffolds in simulated body fluid 
(SBF). This research was initiated to expand and complement the preliminary work, 
where the release kinetics of bone morphogenetic protein-2 from PCL and PCL– TCP 
scaffolds in phosphate buffered saline (PBS) over a period of 21 days was evaluated as 
described in chapter 5 [Rai, 2005]. Unfortunately, that study overly simplified the in vivo 
clinical situation in two main ways. Firstly, multiple growth factors are present in blood 
plasma in vivo and their synergistic, antagonistic or additive interactions help bring about 
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wound healing and tissue regeneration [Pfeilschifter, 1990; Freymiller, 2004]. Constant 
delivery of one type of growth factor may be able to elicit a favorable outcome but may 
not represent an efficient method in terms of time needed and amount of growth factor 
used. Furthermore inappropriate amounts loaded may have adverse effects [Rai, 2004; 
Raiche, 2004] and are considered non-physiological.  
With this in mind, PRP was selected for its source of multiple growth factors; namely, 
platelet derived growth factor (PDGF), transforming growth factor (TGF), vascular-
endothelial growth factor (VEGF) and insulin-like growth factor (IGF). Its application 
has been reported as an effective way to induce both vascular and bone tissue repair and 
regeneration, mostly in oral and maxillofacial surgery [Marx, 1998; Schleiphake, 2002; 
Tozum, 2003; Marx, 2004]. PRP was specifically chosen for this study in light of is its 
proven effectiveness, safety, cost effectiveness and availability in an easy to develop 
manner [Kim, 2002; Kim, 2002; Kawase, 2003; Lucarelli, 2003; Oyama, 2004]. 
The second issue to circumvent was the buffer solution selected for release profile 
determination. Previous work [Rai, 2005] and other in vitro drug delivery studies [Frank, 
2004; Wei, 2004] adopted PBS as the released supernatant. However, PBS does not 
accurately emulate bodily fluids in terms of the composition of its ions. SBF, on the other 
hand, depicts a closer match [Kokubo, 2003]. The type of buffer employed is crucial as it 
influences the degradation of the delivery system that in turn modulates the release 
kinetics. 
To address the above concerns, an investigation was designed that focused on the in vitro 
protein delivery properties of PCL-TCP scaffolds, specifically the release kinetics of 
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multiple growth factors TGF-β1, PDGF-BB and IGF-1, present in PRP as a function of 
hydrolysis time in PBS and SBF in normal physiological conditions. 
6.2   MATERIALS AND METHODS 
6.2.1   Scaffold design and fabrication 
PCL–TCP (80%:20%) composite scaffolds, purchased from Osteopore International Pte 
Ltd, Singapore, were fabricated by fused deposition modeling as described in previous 
chapters. Each scaffold manifested a lay-down pattern of 0/60/120° and porosity of about 
70 %. Dimensions of 5 x 5 x 3 mm were used.  
 
6.2.2   Preparation of PRP 
Platelet-rich plasma was prepared from whole blood collected from one pig source 
(Duroc/Yorkshire cross, 45 kg, 16 weeks old). In brief, 10 ml heparinised blood was 
centrifuged at 2 400 rpm for 10 min to separate PRP and platelet-poor plasma (PPP) 
portions from the red blood cell fraction. The PRP and PPP portions were again 
centrifuged at 3 600 rpm for 15 min to concentrate PRP (0.8 ml) [Marx, 1998; Tozum, 
2003]. Two hundred microliters of PPP was retained with PRP, making the final volume 
1 ml and this mixture was stored at -20 °C until loading. 
 
6.2.3   Characterization of PRP 
Before analysis, the PRP mixture prepared was thawed and centrifuged for 10 min at 
10000 rpm in a microcentrifuge. PRP was then diluted 100 fold and 20 µl of this dilution 
was placed onto the counting chambers of a hemocytometer for a platelet count (number 
of platelets/µl). Commercially available enzyme-linked immunosorbent assay kits and 
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polyclonal antibodies that have been validated for measuring their respective growth 
factors were used according to the manufacturer’s instructions to quantify the 
concentrations of TGF-β1 (#KAC1688, Biosource International Inc, USA), PDGF-BB 
(#AB-23-NA, R&D Systems, USA) and IGF-1 (IGF-1 ELISA, IBT, Germany). All 
growth factor measurements were performed in duplicates. Since a larger proportion of 
the TGF-β1 in biological samples is often present in latent form, TGF-β1 was converted 
to its active form as directed by the manufacturer in order to estimate the total TGF-β1 
content. Finally, the amount of total protein in the supernatant was measured by BioRad 
Protein assay according to manufacturer’s instructions (Bio-Rad, USA). Bovine serum 
albumin was used as a standard. 
 
6.2.4    Loading of PRP onto PCL-TCP scaffolds 
A loading volume consisting of 10 µl activating solution, that is, thrombin (4 IU/ml, 
Tisseel Kit, Baxter Immuno, Austria) in 10 % CaCl2 (Merck, Germany), and 40 µl of 
PRP mixture was sequentially pipette loaded onto each PCL–TCP scaffold placed in a 
well of a 24-well plates. The PRP clotted upon contact with the thrombin–calcium 
chloride solution on the scaffold at 37 °C. Thirty minutes after the initiation of clotting, 1 
ml of PBS or SBF was added into each well. Similarly, 40 µl of PRP-free PBS or SBF 
with 10 µl thrombin–CaCl2 solution was loaded onto scaffolds to serve as control. Four 
samples were adopted for each experimental group and each experiment was repeated 
twice. 
Phase contrast and scanning electron microscopy (SEM) were used to verify the 
attachment of PRP onto the PCL–TCP scaffolds. As described elsewhere [95, 107], SEM 
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samples were fixed in 2.5 % gluteraldehyde (Sigma, Germany) at 4 °C overnight. They 
were then dehydrated in a graded ethanol series of 25 %, 50 %, 75 %, 95 % and 100 %, 
air-dried and gold sputtered with JFC-1200 fine-coater for 70 s at 30 mA under high 
vacuum. The specimens were viewed with a Jeol JSM 5660LV SEM operating at 10 kV 
under high vacuum mode. 
 
6.2.5    Release measurements of platelet-derived growth factor, transforming 
growth factor and insulin-like growth factor present in PRP 
The PCL–TCP scaffolds loaded with PRP were placed in 24-well plates and immersed in 
1 ml of PBS or SBF. The elution of proteins was examined at 2 h, followed by 1, 2, 4, 7, 
10, 14, 17 and 21 days. At each time interval, the supernatant was completely removed 
and replaced with fresh buffer. The released supernatant from each time point was stored 
at -20 °C until analyzed for total protein, TGF-β1, PDGF-BB and IGF-1 concentrations 
by their respective methods as described in Section 6.2.3.  
 
6.2.6   Statistical analysis 
All quantitative data were expressed as mean ± standard deviation. Statistical analysis 
was performed by unpaired and paired Student’s t test using Instat Software (Graph- Pad 
Software, Inc., San Diego, CA, USA) for comparisons between SBF and PBS treatments 
as well as statistical differences with time in the elution profiles. A value p < 0.05 was 
considered to be statistically significant. 
 
6.3   RESULTS 
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6.3.1   Characterization of PRP 
To characterize platelet-rich plasma (PRP) extracted from whole blood, aliquots were 
measured for total number of platelet per microliter, total protein count in micrograms per 
milliliter and TGF-β1, PDGF-BB and IGF-1 concentrations in nanograms per milliliter. 
A similar analysis was carried out for PRP after activation (PAC) by thrombin in calcium 
chloride solution. The results have been tabulated in Table 6.1. It is observed that PRP 
contained significantly more TGF-β1 and PDGF-BB than IGF-1. TGF-β1 and PDGF-BB 
levels were almost similar. The number of platelets increased 4-fold to reach a value 
of468 000/µl after activation. TGF, PDGF and IGF amounts escalated by 8, 8 and 3 fold 
respectively. 
 
Table 6.1: Characterization of platelet-rich plasma (PRP) and PRP after activation (PAC) 
(n = 4, ± SD). 
 
 
6.3.2   Morphology of PRP loaded on PCL-TCP scaffolds 
Phase contrast and SEM examination displayed cobweb like extensions of fibrin network 
present in the PRP mixture (Fig. 6.1). These extensions were attached to the rods and 
spanned across the pores of the scaffolds. Thus, the adhesion of PRP onto the scaffolds 
was verified. 
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Figure 6.1: Scanning electron (A) and phase contrast (B) micrographs of platelet-rich 
plasma loading onto PCL–TCP composite scaffolds. PRP mixture formed an 
interconnected network that extended across the pores, while remaining rooted to the rods 
of the composites. 
 
6.3.3   Release measurements 
Protein Bio-Rad assay revealed that both experimental groups showed a similar trend that 
is a progressive decline in total protein content over time (Fig. 6.2). No release of protein 
was observed for control, which was thrombin in calcium chloride solution. It should be 
noted that the initial burst of release at 2 h was significantly higher for PBS- than SBF-
soaked scaffolds. However after day 1, protein release from SBF-soaked samples was 
noticeably higher than PBS soaked samples until day 7 where protein release in 
micrograms per milliliter was not detected. Table 6.2 shows the overall in vitro release 
data. The release of TGF-β1 from PCL–TCP scaffolds after immersion in SBF and PBS 
over a period of 21 days is illustrated in Fig. 6.3. SBF-soaked scaffolds displayed 53.5 % 
drop in TGF release from 19.1 ng/ml ± 1.1 at 2 h to 8.88 ng/ml ± 2.3 at day 7 ( p < 0.05). 
From day 7 to day 21, a sustained release of 9.19 ng/ml ± 1.08 was evident. No burst-like 
release was noticed. Plotting the mean amount of release (y) against time (x), resulted in  
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Figure 6.2: Amount of total protein release from platelet-rich plasma-
loaded PCL–TCP composite scaffolds  immersed in simulated body fluid 
(SBF) and phosphate buffered saline (PBS) as a function of time (days). 
Control, that is PCL–TCP composite scaffolds loaded with thrombin 




Table 6.2: The amounts of TGF-β1, PDGF-BB and IGF-1 released from PCL-TCP 
composite scaffolds immersed in simulated body fluids and phosphate buffered saline (n 




a trend-line with the polynomial equation y = -0.006 x3 + 0.244 x2-2.976 x +19.5 (R2 = 
0.89). Only 64.4 % of total TGF was released from PAC by day 21. 
Interestingly, a disparate pattern of TGF-β1 release, specifically a triphasic burst-like 
profile, from PCL–TCP scaffolds submerged in PBS was noticed. Three burst-like 
releases were observed at 2 h, days 7 and 14. The intensity of bursts (25 ng/ ml ± 0.97) 
was not statistically different from each other (p < 0.05). The differences in the amount 
released at the remaining time points were statistically significant (p < 0.05) except day 
17. Total release from PAC was achieved at day 21. At each time point, there was more 
TGF release in PBS- than SBF-soaked samples. Fig. 6.4 illustrates the release of PDGF-
BB from PCL–TCP scaffolds after immersion in SBF and PBS over a period of 21 days 
in vitro. SBF-soaked scaffolds demonstrated a sustained release of 9.6 ng/ml ± 0.73 from 
2 h until day 4. A linear increase of 82.8 % in PDGF release was discerned from day 4 
(9.63 ng/ml ± 1.70) until day 14 (17.6 ng/ml ± 1.75) (p < 0.05). After day 14, a sustained 
release of 18 ng/ml ± 0.05 was observed (p < 0.05). No burst-like release was detected. 
Plotting the mean amount of release (y) against time (x), resulted in a trendline with the 
polynomial equation y =-0.005 x3 + 0.158 x2 - 0.698 x + 10.2 (R2 = 0.99). Only 60.5 % of 
total PDGF was released from PAC by day 21. 
Intriguingly, a triphasic burst-like profile was again identified for PCL–TCP scaffolds 
immersed in PBS. The bursts of release were observed at 2 h, days 7 and 16. The 
intensity for the first 2 bursts was not significantly dissimilar (36.8 ng/ml ± 1.94) (p < 
0.05). However, the third burst was 37 % less (23.2 ng/ml ± 2.5). The differences in the 




Figure 6.3: Amount of TGF-β1 released from PRP-loaded PCL–TCP composite scaffolds 
immersed in simulated body fluid (SBF) (A) and phosphate buffered saline (PBS) (B) as 
a function of time (days). Control, that is PCL–TCP composite scaffolds loaded with 
thrombin solution alone, showed no release (n = 4, ± SD). A trendline with polynomial 





Total release of PDGF from PAC was achieved at day 21. There was more release in 
PBS- than SBF-soaked samples at most time points. 
The final growth factor monitored was IGF-1 (Fig. 6.5). A similar release profile was 
observed for PCL– TCP scaffolds immersed in PBS and SBF. Only one burst-like release 
of 3.9 ng/ml ± 0.1 was evident at day 1. A progressive decline in IGF-1 amounts was 
observed after day 1 which persisted until days 7 and 14 for SBF- and PBS-soaked 
samples respectively, after which further release was not observed. The differences in the 
amount released at all time points were statistically significant (p < 0.05). Total release of 
IGF-1 from PAC was realized at the end of the experiments. 
 
6.4   DISCUSSION 
Biodegradable and bioresorbable PCL–TCP composite scaffolds were recently developed 
to serve as templates for guided bone regeneration as well as protein delivery systems to 
enhance cell growth. This research was evoked to expand the preliminary work 
(described in chapter 5) on PCL–TCP scaffolds as delivery systems for rhBMP-2 [Rai, 
2005], with two issues in mind. Firstly, bone formation and repair are affected by 
temporal and spatially varying concentrations of numerous growth factors. Secondly, the 
buffer selected for analysis should resemble body fluids as intimately as possible to 
facilitate any inherent degradation and/or bioactivity of the composite scaffolds.  
The present work aimed to elucidate the release profile of the multiple growth factors 
present in PRP loaded onto the scaffolds immersed in SBF and PBS and ultimately 
identify the determinants of release. The proposed system attempted to imitate the release 




Figure 6.4: Amount of PDGF-BB released from PRP-loaded PCL–TCP composite 
scaffolds immersed in simulated body fluids (SBF) (A) and phosphate buffered saline 
(PBS) (B) as a function of days. Control, that is PCL–TCP scaffolds loaded with 
thrombin solution alone, showed no release (n = 4, ± SD). A trend-line with polynomial 




Figure 6.5: Amount of IGF-1 released from PRP-loaded PCL–TCP composite scaffolds 
immersed in simulated body fluid (SBF) and phosphate buffered saline (PBS) as a 
function of time (days). Control, that is PCL–TCP composite scaffolds loaded with 
thrombin solution alone, showed no release (n = 4,  ± SD). 
 
to an insoluble network of fibrin by the addition of thrombin in 10% calcium chloride 
solution. This network entraps the growth factors released from PRP and facilitates their 
attachment onto PCL–TCP scaffolds for sustained release.  
Several exciting observations were realized from this study. Briefly, the elution of the 
individual growth factors appeared to be dependent on the size [Wei, 2004] and amount 
of protein loaded as well as the type of buffer used for analysis [Murphy, 2000]. PRP-
loaded scaffolds immersed in SBF evinced a disparate release pattern for all three growth 
factors. TGF-β1 levels declined for the first week and then were constant until the end of 
the experiments. On the contrary, PDGF-BB levels heightened for the first two weeks 
and then were constant until the end of the experiments. IGF-1, on the other hand, 
exhibited a progressive reduction in levels over the entire experimental period.  
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TGF-β1 and PDGF-BB are both basic, homodimeric proteins of molecular weights 25 
and 30 kDa respectively [Pfeilschifter, 1990]. IGF-1 is a basic, single chain peptide of 70 
amino acids and has a molecular weight of 7.5 kDa [Schliephake, 2002]. The amounts 
present in PRP after activation were 164.7 ± 24.8, 194 ± 43 and 18.3 ± 4.75 ng/ml for 
TGF-β1, PDGF-BB and IGF-1 respectively. It should be noted that TGF and PDGF 
levels were not significantly different whereas IGF levels were considerably lower. This 
relationship was also observed by Ref. [Apornmaeklong, 2004]. Two possible reasons 
why PDGF-BB was increasingly released, while TGF-β1 was decreasingly released in 
the initial stages are its larger size and higher amounts. A larger size would mean reduced 
surface area to volume ratio, which implies that fewer proteins could adhere onto the 
scaffolds, resulting in more release over time. The eventual invariable release 
experienced by both growth factors was presumably due to electrostatic interactions 
between the positively charged growth factors and the negatively charged apatite formed 
as described in the previous paragraph. The exact mechanism involved is stimulating 
future work. IGF-1 was present in too minute amounts to engage in any intermolecular 
linkages with apatite, thus was released continuously by diffusion through the pores of 
the scaffolds over time. 
PRP loaded scaffolds immersed in PBS demonstrated a similar release pattern for TGF-
β1 and PDGF-BB but a dissimilar one for IGF-1. TGF-β1 and PDGF-BB release 
followed a triphasic burst-like profile, while IGF-1 exhibited a progressive reduction in 
levels over the entire experimental period. The triphasic burst-like profile is probably a 
consequence of release of growth factor bound loosely to inner pore surfaces of the 
scaffolds, diffusion of incorporated factors out of the scaffold and degradation of the TCP 
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component of the scaffolds [Murphy, 2000; Wei, 2004]. The release was not growth 
factor mediated. 
A similar tri-phasic release profile was obtained for BMP-2 loaded PCL–TCP scaffolds 
in PBS [Rai, 2005]. IGF-1, being small and present in minute amounts, was released 
continuously by diffusion through the pores of the composites over time. The buffers 
used for analysis played an important role in determining the release profile of TGF-β1 
and PDGF-BB. The most significant difference being the absence of a burst-like profile 
in SBF as compared to PBS-soaked scaffolds. This can be partially accredited to the 
dissimilar degradation properties in terms of water uptake and weight loss displayed by 
the composites immersed in the two buffers. Furthermore, SBF has the capability to 
facilitate the formation of apatite on PCL–TCP scaffolds’ surfaces, unlike PBS, and this 
would surely affect the release kinetics.  
SBF-soaked scaffolds had delayed release of growth factors and total release was not 
obtained (64.4 % for TGF and 60.5 % for PDGF) in this study. This corresponds to Ref. 
[Murphy, 2000], where slowed release of vascular endothelial growth factor was 
observed when poly (lactide-co-glycolide) scaffolds were immersed in SBF. Since 
composition of SBF is almost similar to our bodily fluids in terms of its composition of 
ions [Babensee, 1998; Kokubo, 2003], the release profiles obtained from SBF-soaked 
samples is expected to be a more accurate prediction of the in vivo situation. Thus, 
researchers must be more vigilant when interpreting results from protein release 
experiments carried out in PBS, particularly for bioactive composites. It should be noted 
that both PBS and SBF are devoid of plasma proteins as well as enzymes like proteases 
that may alter the release of growth factors entrapped in the fibrin clot initially. 
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Examining the effect of SBF supplemented with such proteins on release profile is 
meaningful future work. 
In conclusion, the elution profiles of the growth factors were determined by the size and 
amount of protein loaded and the type of buffer used for analysis. The next chapters 
illustrate the implantation of PRP-loaded PCL–TCP scaffolds into femoral and 
mandibular defect sites in rats and dogs respectively. Ultimately, it is hoped that the in 
vitro release profile in SBF mimics the true in vivo situation and more importantly the 

















6.5    CONCLUSIONS 
• The original protein retention of the scaffolds was (49.1 ± 1.50) %. After 
immersion in SBF and PBS for 4 weeks, the amount of protein retention was 
augmented to 88.5 % ± 1.40 and 69.1 % ± 1.40 correspondingly.  
• Microscopic analysis verified the attachment of PRP (in the form of a cobweb-
like network) to the rods and pores of the scaffolds.  
• The buffers played an important role in determining the release profiles of TGF 
and PDGF. PBS-soaked scaffolds manifested a tri-phasic burst-like profile that 
was absent in SBF. SBF-soaked scaffolds experienced delayed release of the 
growth factors and total release was not achieved (64.4% for TGF and 60.5% for 
PDGF), whereas total release was realized for PBS-soaked scaffolds.  
• The release profiles for SBF-soaked scaffolds were growth factor mediated in 
terms of their amounts and sizes. This was not observed for PBS samples.  
• IGF-1, on the other hand, exhibited a progressive reduction in levels over the 
entire experimental period for both buffers.  
• Since SBF is analogous to our body fluids in terms of its ionic constituents, we 
expect the elution profiles derived from SBF-soaked samples to more accurately 







CHAPTER 7: PRP DELIVERY BY PCL-TCP SCAFFOLDS AS 
TREATMENT FOR CRITICAL-SIZED RAT FEMORAL DEFECTS 
7.1    INTRODUCTION 
A bone regenerative strategy consisting of PCL-20 % TCP composite scaffolds loaded 
with PRP was proposed in the previous chapter. The three-dimensional honey-combed-
shaped scaffolds were designed and fabricated by fused deposition modeling techniques 
(refer to Chapter 2) [Zein, 2002; Thorn, 2004]. The inclusion of 20 % TCP provided the 
composites with bioactivity by nucleating a hydroxyapatite layer on its surface as 
revealed in chapter 4 [Yang, submitted], as well as enhanced stiffness [Rodriguez, 2003; 
Kim, 2004]. Notably, these scaffolds were also proven as viable in vitro delivery systems 
for rhBMP-2 [Rai, 2004; Rai, 2005] and PRP [Rai, 2005] (refer to chapters 5 and 6), thus 
deeming them capable of an osteoinductive nature as well.  
The body’s natural repair of critical size bone defects due to trauma or disease is 
inadequate. This accentuates the need for bone substitutes to help restore a new vascular 
and bone architecture with biological and mechanical properties analogous to the native 
ones. In spite of the overwhelming studies that explore novel biomaterials as potential 
bone substitutes [Hutmacher, 2000; Endres, 2003; Ratner, 2004; Karageorgiou, 2005], 
considerable challenges persist. Improvements are especially required to rectify 
associated inflammatory responses [Rubin, 1997; Karageorgiou, 2005; Liu, 2005], 
unsatisfactory load bearing properties [van Luyn, 1992; Lee, 1994; Ito, 2005] as well as 
deprived angiogenesis within the implanted scaffold [Jin, 2000].  
PRP is an autologous concentration of human platelets in a small volume of plasma 
[Marx, 1998]. Platelets contain numerous proteins such as platelet-derived growth factor 
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(PDGF), transforming growth factorβ (TGFβ), insulin like growth factor (IGF) and 
vascular endothelial growth factor (VEGF). Several excellent reviews on PRP aver the 
merits of PRP to be its proven effectiveness, safety, cost effectiveness and availability in 
an easy to develop manner [Tozum, 2003; Marx, 2004; Freymiller, 2004]. Interestingly, 
PRP has been extensively investigated for oral and maxillofacial applications [Ito, 2005; 
Aghaloo, 2005; Fennis, 2005], however researchers from the orthopedic field have yet to 
tap on this autologous source of multiple growth factors. To the author’s best knowledge, 
the current study was the first to directly quantify the role of PRP delivered by PCL-TCP 
scaffolds in inducing neovascularization in critical-sized femoral defects.  
Potential strategies for enhancing bone regeneration must be tested in challenging in vivo 
test bed models in combination with quantitative assessment of functional integration and 
repair. Oest and co-workers recently introduced an adaptation of the rat femoral 
segmental defect model that allows rigorous evaluation of 3D bone formation via 
microcomputed tomography (micro-CT) imaging and subsequent biomechanical testing 
of the same samples [Oest, submitted]. Furthermore, in combination with perfused 
contrast agents and non-destructive micro-ct imaging techniques, it represents a 
controlled approach for the quantitative evaluation of blood vessel networks 
[Holdsworth, 2002; Bentley, 2002; Duvall, 2004] and mineralized matrix [Cartmell, 
2004; Jones, 2004; Gauthier, 2005] within implanted bone substitutes. It is also clinically 
relevant to investigate the mechanical strength of the regenerated bone. It would be ideal 
for the yield strength to correlate with the amount of newly formed bone as detected with 
the micro-CT [Jones, 2004]. Furthermore, PCL-TCP scaffolds have not yet been studied 
for mechanical competence after implantation.  
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Hence, the objectives of this study were: (1) to test the effects of local PRP delivery on 
early (3 weeks) revascularization of large bone defects in vivo and (2) to quantify the 
ability of PCL-TCP composite scaffolds with or without PRP delivery to promote longer-
term (12 weeks) bone bridging and functional integration. 
   
7.2   MATERIALS AND METHODS 
7.2.1   Scaffold design and fabrication 
PCL-TCP composite scaffolds, purchased from Osteopore International Pte Ltd, 
Singapore, were fabricated by fused deposition modeling formerly described. Each 
scaffold manifested a lay-down pattern of 0/60/120°, porosity of 70 % and pore diameter 
of 0.515 mm as determined by micro-CT analysis. Cylinders with dimensions of 8 mm in 
height and 4 mm in diameter were used. The scaffolds were sterilized as described in 
section 4.2.1. 
 
7.2.2   Preparation of PRP 
A needle was inserted into the aorta of two rats (female, Sasco Sprague-Dawley, 8 weeks 
old) under isoflurane anesthesia and ten millimeters of blood was extracted into a syringe 
containing 1 ml heparin (1000 U/ml). The heparinized blood was first centrifuged at 2400 
rpm for 10 min under sterile conditions to separate PRP and platelet poor plasma (PPP) 
portions from the red blood cell fraction. Then, the PRP and PPP portions were 
centrifuged at 3 600 rpm for 15 min to concentrate PRP (~1 ml) [Tozum, 2003; Marx, 
1998; Rai, 2005]. Five hundred microliters of PPP was retained with PRP, making the 
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final volume 1.5 ml.  This mixture contained 600 x 103 platelets/µl as determined by 
manual counts using a hemocytometer. 
$ ORDGLQJYROXPHFRQVLVWLQJRIO KXPDQ O\RSKLOL]HG WKURPELQ  ,8PO6LJPD
USA), reconstituted in 10 % CaCl2VROXWLRQ0HUFN*HUPDQ\DQGORI353PL[WXUH
was sequentially pipette loaded onto each PCL-TCP scaffold placed in a well of a 24-well 
plate. PRP clotted upon contact with the thrombin-CaCl2 solution in the scaffold after 
thirty minutes incubation at 37 °C.  
 
7.2.3   Rat segmental defect model 
The research protocol was approved by the Institutional Animal Care and Use 
Committee, following all appropriate guidelines. Twelve female, Sasco Sprague-Dawley 
rats were adopted for this study. The age of the rats was approximately 13 weeks and 
their body weight was between 230-260 g. All surgical procedures were performed under 
general anesthesia and sterile conditions. Anesthesia consisted of isoflurane delivered via 
induction chambers and facemasks. After exposing the femur via a longitudinal incision 
over the proximal hindlimb, femurs were stabilized with custom modular fixation plates 
and 7.5 mm bilateral segmental defects were created with a miniature oscillating saw. 
 
7.2.4   Experimental design 
Two treatment groups were created, namely PRP loaded PCL-TCP scaffolds and control 
scaffolds of PCL-TCP alone. Each animal received a PRP-containing PCL-TCP construct 
in one leg with the contralateral defect receiving a plain PCL-TCP scaffold. Twelve rats, 
thus 24 femurs, were assessed non-destructively for mineral formation at week 3. In 
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addition, six of the rats were sacrificed for vascular analysis at week 3. The remaining 7 
rats were evaluated non-destructively for mineral formation at week 12. Finally, 12 
samples were subjected to biomechanical testing and 2 samples were processed for 
histological study. 
 
7.2.5   Two-dimensional radiographic evaluation 
A Faxitron MX-20 Specimen Imaging Radiographic System together with its software 
(Specimen Imaging version 3.1.1, Faxitron X-ray Corporation) was used to capture 2D 
images of the femoral defects immediately after the surgery and at weeks 3, 8 and 12. 
Scans were done under general anesthesia. 
 
7.2.6   Three-dimensional microcomputed-tomographic evaluation 
7.2.6.1   Characterization of scaffolds 
Scaffold architecture was imaged using a high resolution micro-CT imaging system (viva 
CT 40, Scanco Medical, Basserdorf, Switzerland). The scanner was set at a voltage of 
55kVp and a current of 145A. Resolution was set to medium, which created a 1024 × 
1024 pixel image matrix. Isotropic slice data were obtained by the system and 
reconstructed into 2D images. These slice images were compiled and analyzed to render 
3D images and obtain quantitative architectural parameters. A total of 206 micro-
tomographic slices were acquired using a slice increment of 20 µm. Regions of interest 
were selected in each slice and a Gaussian filter (sigma = 1.2; support = 1) was used to 
partly suppress the noise in the volumes. A threshold of 25 was used to distinguish 
polymer material from pore space [Lin, 2003].  
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7.2.6.2   Evaluation for vasculature 
Imaging vascular preparation. Tissues were prepared in accordance with previously 
described methods [Duvall, 2004]. After the animals were anesthetized, the abdominal 
aorta was catheterized and the inferior vena cava severed. The vasculature was flushed 
with 0.9 % normal saline and subsequently pressure fixed with 10 % neutral buffered 
formalin. Formalin was flushed from the vessels using saline, and the vasculature was 
injected with a radiopaque silicone rubber compound containing lead chromate (Microfil 
MV-122, Flow Tech, Carver, MA). The Microfil was allowed to polymerize for 2 hours 
before the hindlimbs were removed and stored in formalin for 2 weeks to ensure proper 
fixing of tissues. 
Decalcification of hindlimbs. The fixed femurs 
were decalcified in 30 % buffered formic acid at 
room temperature. At the end of each day, the 
solution was chemically tested for the presence of 
calcium using the ammonium oxalate (5 %) 
precipitation assay. Once fully decalcified, the 
femurs were rinsed and transferred to formalin 
before micro-CT imaging. 
Micro-CT imaging. Hindlimb vasculature was imaged using the micro-CT imaging 
system with parameters similar to as described in section 7.2.6.1. A threshold of 100 was 
chosen to evaluate the vascular network. A total of 300 slices were acquired for each 
femur using a slice increment of 20 µm. PRP and control limbs were evaluated 
individually to quantify the vascular volume fraction. 
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7.2.6.3   Evaluation for bone 
Mineralization in the hindlimbs was imaged using the micro-CT imaging system [138], 
with parameters similar to as described in section 7.2.6.1. Thresholding was done to 
differentiate between mature bone, immature bone, TCP particles and PCL polymer.  A 
total of 100 and 300 slices were acquired for each femur using a slice increment of 20 µm 
for survival and post-mortem scans respectively. 
 
7.2.7   Histological evaluation 
One representative femur from each group at week 12 was fixed in 10 % neutral buffered 
formalin for 2 weeks and then subjected to histological processing. Dehydration was 
accomplished using a graded series of ethyl alcohols (Harleco, USA ) and clearing with 
xylene substitute (Thermo Electron Corporation, USA). Infiltration was performed using 
a graded series of methyl metacrylate solutions (ACROS Organics, USA). Embedding 
was performed using a catalyzed mixture of Osteo-Bed resin solution containing 2.5 g of 
benzoyl peroxide (Sigma, USA) per 100 ml. Specimens were embedded in catalyzed 
resin mixture in vacuum for at least 48 hours. After polymerization, specimens were 
placed in a freezer for 24 h. Specimens were trimmed of excess plastic (Isomet 1000, 
Buehler, USA), ground to expose relevant portions (Ecomed 3, Buehler, USA) and 
longitudinally sectioned (3-4 microns thick) using a microtome (Microm HM355S, 
Richard Allan Scientific, USA). Sections from each specimen were then stained with 
Hematoxylin and Eosin, Masson’s Trichrome and Von Kossa to detect nucleus of cells, 




7.2.8   Biomechanical evaluation 
Femora from six rats were removed after sacrifice at 12 weeks postsurgery, wrapped in 
PBS-soaked gauze, and frozen at -20°C until µCT scanning and torsional testing.  
Samples were thawed in PBS and excess soft tissue was removed prior to µCT scanning.  
After scanning, femora ends were potted in melted Wood’s metal (Alfa Aesar, Ward Hill, 
MA) up to the polymer plate.  The Wood’s metal, contained within custom stainless steel 
blocks, was allowed to solidify, thus securing the bone ends.  Holes were drilled through 
the bone and blocks, and a 0.7 mm diameter metal pin was inserted through the bone to 
further enhance fixation of the bones.  Bones were wrapped in PBS-soaked gauze to 
maintain moisture until testing.  Femora were mounted in an MTS 858 Mini Bionix® II 
testing system (MTS, (GHQ3UDLULH01) with the defects coaxially aligned with the system 
axis of rotation. The system incorporates a TestStarIIm controller.  Polymer plates and 
gauze were carefully removed prior to testing.  Each specimen was then tested to failure 
in torsion and the resulting torque-angular displacement curves were recorded on an 
oscilloscope.  The rotation rate used was 3 degrees per second and data were collected at 
100 Hz.  The stiffness, maximum torque and angle at failure were recorded for each 
specimen, with the stiffness being measured as the slope of the linear portion of the 
torque-angular displacement curve [Oest, submitted; Kokubo, 2003]. 
 
7.2.9   Statistical analysis 
All data were presented as mean ± standard error of the mean (SE). Statistical analyses 
were performed with Minitab software. Tukey’s method was used for post-hoc analyses, 
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and a general linear model was used to evaluate the effect of time post-surgery on all 
response variables. A p-value of less than 0.05 was interpreted as significant in all 
analyses and p < 0.1 was considered as a statistical trend. 
 
7.3   RESULTS 
7.3.1   Two dimensional x-ray radiographs at weeks 3, 8 and 12 
Radiographs taken immediately after surgery revealed an empty defect site with a faint 
outline of the composite spanning the region of interest. Blood clots were noted as black 
patches around the defect area. All 24 femurs appeared qualitatively similar. At week 3, 
the hematoma cleared up and the skeleton of the scaffolds was less obvious (Fig 7.1A and 
D). Bone creeping from the proximal periphery towards the center of the defect was 
observed in some of the groups. Visual differences between PRP-treated and control 
femurs were not evident. Radiographs from weeks 8 and 12 showed analogous results 
(Fig 7.1B-C and 7.1E-F). All groups manifested enhanced bone formation spreading 
throughout the entire defect site when compared to week 3. Five out of the six PRP-
treated femurs exhibited bone unions. In contrast, bone union was only detected in two 
out of the six control femurs. 
 
7.3.2   Micro-CT evaluation of vasculature at week 3 
One rat suffered abscess formation around the defect sites on both legs and was 
euthanised. Healing was otherwise uneventful in the remaining rats. Figure 7.2 illustrates 
the vascular volume fraction (VVF) as quantitated by micro-CT analysis at a threshold of 
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100. PRP-treated femurs (0.009675 ± 0.001) displayed 70.3 % higher VVF than control 




















Figure 7.1: Two dimensional radiographs of both control (PCL-TCP scaffold alone)(A-C) 
and treated (PRP-loaded PCL-TCP scaffolds) (D-F) femurs, at three weeks after surgery 
(A and D), eight weeks after surgery (B and E) and 12 weeks after surgery (C and F). 









The augmented vascularity, namely a more established network of blood vessels, was 
apparent in the micro-CT images (Fig 7.3). Vascular volume increased as voxel size 
decreased or at lower thresholds due to the contribution of smaller, densely packed 
vessels that could not be resolved when larger voxel sizes were used. The larger vessels 
appeared dilated at lower thresholds. PRP-treated femurs, however, maintained their 










Figure 7.2: Quantitative assessment of vascular volume fraction (VVF) at week 3 as 
determined by micro-CT analysis at a threshold of 100. N = 5 for each treatment group. 
Results are expressed as mean ± standard error. § indicates a statistical trend (P = 0.08). 
 
7.3.3   Micro-CT evaluation of bone at weeks 3 and 12 
The bone volume fraction (BVF) represents the amount of mineral present at the defect 
site. A statistically significant higher BVF was obtained by control (0.01412 ± 0.002) as 
compared to PRP-treated femurs (0.005893 ± 0.001) at week 3 (Fig 7.4A). When the 
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threshold was reduced from 100 to 75, the difference in mineralization between the 2 
groups was no longer significant but BVF augmented to 0.029583 ± 0.003 and 0.018675 
± 0.005 for control and PRP-treated femurs respectively (Fig 7.4B). It was noted from the 
3D images that the bony ingrowth was either continuous from the outer periphery or 
discontinuous with bone islands throughout the scaffold. The images for PRP-treated 
femurs showed minimum periosteal bone ingrowth from the defect margins, while 
control femurs manifested denser bone spanning the defect site (Fig 7.3).  
At week 12, one rat had developed an abscess and was euthanised. Six rats or 12 femurs 
remained to be tested. There was no statistical difference in BVF between the two groups 
at both thresholds. Comparing BVF at weeks 3 and 12, a statistically significant 
enhancement was noted (Fig 7.5). PRP-treated femurs experienced a 7-fold increase in 
BVF, while control femurs manifested a 3-fold increase. Complete bone bridging was 
detected in two out of the six control femurs (Fig 7.6A-B). In contrast, five out of the six  
PRP-treated femurs exhibited newly formed bone bridging the entire defect site as 
observed from the micro-CT images (Fig 7.6C-D). Callus formation was observed at the 
sides of the fully formed bone bridges, which is indicative of bone remodeling. It should 
be noted that the new bone had imprints of the pores of the PCL-TCP scaffolds, which 
















































Figure 7.3: Representative week 3 post-surgery micro-CT images of control (PCL-TCP 
alone) (A-C) and treated (PRP-loaded PCL-TCP) (D-F) femurs. A and D: bone and 










Figure 7.4: Quantitative assessment of bone volume fraction (BVF) at week 3 as 
determined by micro-CT analysis at a threshold of (A) 100 and (B) 75. N = 11 for each 
treatment group. Results are expressed as mean ± standard error. * indicates statistical 











Figure 7.5: Quantitative comparison of bone volume fraction (BVF) at weeks 3 and 12 as 
determined by micro-CT analysis at a threshold of 100. N = 11 for each treatment group 
at week 3. N = 6 for each treatment group at week 12. Results are expressed as mean ± 
standard error. * indicates statistical significance (P < 0.05). 
 








































7.3.4   Biomechanical evaluation at week 12 
Biomechanical testing was performed to quantitatively assess the structural properties of 
the healed femora. Figure 7.7 illustrates a plot of torque against angular displacement 
obtained for a PRP-treated femur that had demonstrated both high BVF and bone union. 
Information on maximum and yield torque as well as stiffness was extrapolated from 
such a plot. Femurs that had no bone union and low BVF demonstrated typical flat-curve 
patterns of soft tissue and polymer, reflecting discontinuity. Femurs that were tested 
mainly failed just proximal or distal to the healed defect site. There was one femur that 
failed in the middle of the defect site.  
PRP-treated femurs failed with significantly higher stiffness (0.0049 ± 0.003 Nm/deg) 
than controls (0.0036 ± 0.003 Nm/deg). However, both yield and maximum torque were 
similar for both groups (0.0706 ± 0.02 Nm). The correlation between stiffness and torque 
with BVF from all 10 femurs are displayed in Fig 7.8. Plotting the stiffness (y) against 
BVF (x) resulted in a trend-line with the linear equation y = 0.572 x2 + 0.0117 (R2 = 
0.66). An exponential relationship with the equation y = 1E-04e21.52x (R2 = 0.83) was 












































Figure 7.6: Representative week 12 post-surgery micro-CT images of control (PCL-TCP 
alone) (A-B) and treated (PRP-loaded PCL-TCP) (C-D) femurs. Note the bone union and 



























Figure 7.7: A plot of torque against angular displacement obtained for a representative 







































Figure 7.8: The correlation between (A) maximum torque and (B) stiffness with bone 
volume fraction (BVF) as determined by biomechanical evaluation. The data was pooled 
























































7.3.5   Histological Evaluation at week 12 
Fig 7.9A depicts the post-surgery histological images of a PRP-loaded PCL-TCP treated 
defect. Connective tissue (CT) and newly formed bone (NB) were found in direct contact 
at the scaffold-bone interface and at the periphery of the scaffolds. Within the connective 
tissue, numerous vascular structures and collagen fiber deposition were seen. Dense NB 
was observed to span most of the defect site, suggesting the unrestricted infiltration of the 
scaffold with new tissue. Bone marrow tissue occupied some cavities between this newly 
formed bone. Resorption cavities and vascular structures were interspersed in NB as well. 
It should be noted that the struts of the PCL-TCP scaffold are seen as regular-sized gaps 
in the CT and NB. Similar observations were noted for control femurs (Fig 7.9B). The 
only qualitative difference was the less extensive connective tissue at the periphery of the 
new bone with less collagen fibers in control femurs as compared to PRP-treated femurs.  
 
7.4   DISCUSSION 
Tissue engineering has immense potential to provide significantly improved therapies to 
patients needing functional restoration of damaged or degenerated bone.  The strategies 
being developed are numerous and diverse, reflecting the broad range of potential clinical 
applications and patient-specific limiting factors.  For certain applications or patients, 
revascularization is a potential rate limiting factor and therefore a rationale therapeutic 
target.  For example, the clinical use of structural allografts for treatment of large 
segmental bone defects is limited by a lack of revascularization and remodeling, resulting 
in a high incidence of refracture [Koefoed, 2005; Zhang, 2005].  Therefore, this study 




























Figure 7.9A: Representative week 12 post-surgery histological images of PRP-loaded 
PCL-TCP treated femurs. Sections 1: New bone spanning the entire defect site 
(brown/black) at 4 x magnification. Sections 2: Connective tissue with vasculature (red) 
and collagen fibers (blue). Sections 3: Active resorption sites in new bone. Sections 4: 
Vascular structures interspersed between new bone. Sections 5: Bone marrow filled up 








































Figure 7.9B: Representative week 12 post-surgery histological images of control (PCL-
TCP alone) femurs. Sections 1: New bone spanning the entire defect site (brown/black) at 
4 x magnification. Sections 2: Connective tissue with vasculature (red) and collagen 
fibers (blue). Sections 3: Active resorption sites in new bone. Sections 4: Vascular 
structures interspersed between new bone. Sections 5: Bone marrow filled up cavities 















improve revascularization and provide a clinically feasible alternative approach to bone 
grafts for treatment of segmental bone defects. 
A scaffold-based protein delivery vehicle has several advantages including localized 
protein delivery. One such system adopts biodegradable polycaprolactone physically 
blended with 20 % bioresorbable tricalcium phosphate. The PCL-TCP scaffolds were 
shown to support osteoblast proliferation and differentiation into mineralized tissue in 
chapter 4 [Rai, 2004]. The scaffolds’ degradation behavior, unique bioactive nature 
[Yang, submitted] and efficacy as delivery systems for bone morphogenetic protein-2 
[Rai, 2005] and PRP [Rai, 2005] have all been documented recently and described in 
detail in the previous chapters. The scaffolds were capable of sustained release of growth 
factors that maintained their bioactivity throughout the 1-month experimental period.   
The sustained delivery and concerted actions of multiple growth factors more closely 
mimic the natural regenerative processes. PRP serves as a potential autologous source of 
these factors and upon contact with thrombin and calcium ions, results in a large release 
of prepackaged growth factors into the immediate local environment [Tozum, 2003; 
Tsay, 2005]. Previous studies and case reports indicate that PRP has favorable effects on 
promotion of early craniofacial bone healing [Marx, 1998; Oyama, 2004; Ito, 2005; 
Fennis, 2005]. However, other studies, primarily animal models, have yielded 
contradictory results showing no effects of PRP delivery [Marx, 2004; Freymiller, 2004]. 
Revascularization may be a limiting factor in some but not all bone repair settings, 
perhaps explaining the apparently contradictory previous reports on the efficacy of PRP 
delivery.   
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Well-designed, reliable and reproducible animal models are needed to provide solid 
evidence of PRP’s capacity (in combination with bone grafts) for tissue reconstruction. 
Micro-CT combined with perfused contrast agents and bone decalcification enables 
quantification of 3D vascular architecture and volume fraction [Bentley, 2002; Duvall, 
2004]. Our study applied these techniques to quantify neovascularisation within PCL-
TCP scaffolds implanted in rat femoral defects. After 3 weeks in vivo, PRP-treated 
femurs displayed 70.3 % higher vascular volume fraction than control femurs. To our 
knowledge, this is the first study to demonstrate the beneficial effect of PRP on 
angiogenesis within 3D tissue-engineered scaffolds. PRP works via degranulation of α 
granules in the platelets that release the prepackaged growth factors including the potent 
angiogenic stimulant vascular endothelial growth factor (VEGF). The secreted growth 
factors from PRP bind to the transmembrane receptors of cells including adult 
mesenchymal stem cells, osteoblasts, fibroblasts, and endothelial cells. The binding 
activates endogenous internal signal proteins that induce the expression of genes involved 
in neovascularisation [Tozum, 2003; Marx, 2004]. The results from the current study 
corresponds to previous work which showed that PLGA scaffolds delivering VEGF 
resulted in an increase in blood vessel formation [Huang, 2005; Sun, 2005]. 
The architecture of the bony ingrowth was defined by the scaffold, giving it a regular 
porous structure [Jones, 2004]. At week 3, both continuous ingrowth from the outer 
periphery as well as discontinuous ingrowth with bone islands throughout the entire 
scaffolds was noted. This observation corroborates recent literature that reported that 
scaffolds with similar sized pores and porous walls result in both types of bone ingrowth 
[Karageorgiou; 2005]. It was hypothesized that early angiogenesis would promote 
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accelerated bone regeneration. However, bone volume fraction values were significantly 
higher for controls than PRP-treated femurs at week 3. This may be due to the inherent 
osteoconductive properties of the plain PCL-TCP scaffolds or perhaps a transient 
physical barrier to cell ingrowth due to the presence of PRP in the scaffold pores.  At 
week 12, the PRP-treated femurs obtained a BVF value not significantly different to 
controls. There was higher BVF at week 12 compared to week 3 for both groups (p < 
0.05).   
These findings correlate to recent work [Murphy, 2004], who reported that angiogenesis 
can enhance bone regeneration by speeding up the differentiation and/or maturation of 
infiltrating osteoblasts and osteoblast precursor cells during neo-bone development. It 
would be interesting to investigate if at a later time point, the PRP-treated femurs would 
exhibit more amounts of bone than their controls. It should be noted that in our study the 
honey-combed structured PCL-TCP scaffolds with a pore size of 400-600 µm and 
porosity of 70 % allowed for the infiltration of blood vessels and new bone that was 
found deep within and not just on the outer surface of the material. A higher oxygen 
tension and supply of other nutrients due to neovascularization must have favored direct 
viable tissue formation in the interior of the scaffold [Karageorgiou, 2005].  
At week 12, although maximum torque was similar for both groups, PRP-treated femurs 
failed with higher stiffness than controls. The higher stiffness obtained by PRP-treated 
femurs can also be attributed to the observation that 83 % of these femurs achieved bone 
union in contrast to only 33 % of controls. The non-unions did not have the remodeling 
callus around the fracture site. It must be emphasized that the present study adopted an 
8mm critically-sized femoral defect that does not result in bony union in the absence of 
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treatment [Oest, submitted]. No empty defect groups were needed as controls for this 
study. Thus, the high percentage of bone unions observed in our study is a significant 
finding.  
The mechanical properties of newly formed bone are still substantially less than those of 
intact bone.  A possible explanation is that the new bone is immature and just in its first 
stage of remodeling. Only after extensive remodeling does bone mature and manifest its 
true mechanical properties. Longer-term studies are advised to corroborate this 
hypothesis. Alternatively, there may not have been much bone present in the healed 
defects as would constitute a normal intact bone. There were still large open pores in the 
newly deposited bone, which are not found in normal cortical bone. The remaining 
unresorbed scaffold may have contributed to the low mechanical properties as well. 
According to histological evaluation, it was evident at higher magnifications that collagen 
organized into fibers permeated connective tissue adjacent to new bone. The 
composition, abundance and organization of fibers are known to influence the mechanical 
properties of the tissue [Fratzl, 2004; Liu, 2005]. The growth factors released from PRP 
most likely induced the deposition of collagen. Platelet-derived growth factors and 
transforming growth factors were previously shown to stimulate the synthesis of type I 
collagen, fibronectin and bone matrix [Tozum, 2003]. The in vitro release profile 
revealed that TGF-B1 was predominantly present in early phase, followed by PDGF-BB 
and IGF-1 was present in minute amounts throughout the 3-week time period [Rai, 2005].  
The findings from the current study indicated that the PCL-TCP scaffolds are an effective 
scaffold. Bone tissue was deposited not only in the immediate vicinity of construct, but 
also directly on the scaffold surfaces. Bone marrow, which contains immunocompetent 
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cells that are extremely sensitive to foreign material [Liu, 2005], was observed in direct 
contact with the polymer. These results correspond to previous in vitro experiments 
where PCL-TCP scaffolds facilitated osteoblast proliferation and differentiation [Rai, 
2004]. Notably, besides an initial hematoma that was observed in the 2D x-rays, no 
inflammatory mediators, giant cells, or fibrous encapsulation were detected.  
A number of stimulating future studies are recommended. Firstly, the experiments 
presented in the current work should be repeated but analysis should be made at later 
time points to evaluate the long-term effects of PRP, especially on bone formation. 
Secondly is the application of our bone regenerative study to a large animal model and 
for longer-time periods. A larger animal model is vital for advancement into clinical 
trials. A longer time period is required to acquire useful insights of the in vivo 
degradation properties of the scaffolds and the time required for mature bone deposition 
and remodeling to occur. The third recommendation is to test the efficacy of PRP-loaded 
PCL-TCP scaffolds in various bone defect sites other than the femur.  The bone 
colonization rate of a macroporous ceramic was found to be higher in the femur of rabbits 
(48.5%) than in the tibia (12.6%) and calvaria (22.9%) defect sites [Guehennec, 2005]. 
An investigation is currently being carried out for dog mandibular defects. 
A fourth possible study entails evaluating this bone replacement biomaterial in a more 
complex or deficient bone environment, such as osteoporotic or an atrophic non-union 
model with destroyed periosteum as developed by [Kokubo, 2003] as well as in milieu of 
compromised vascularity such as the ischemic hindlimb model [Sun, 2005]. Lastly, the 
addition of marrow stromal cells to PRP before loading onto PCL-TCP scaffolds may 
further augment bone formation and should be investigated.  It was recently reported that 
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marrow stromal cells with PRP exhibited better bone formation than autogenous bone in 
dog mandibular defects [Ito, 2005] and the concerted delivery of bone morphogenetic 
protein-4, VEGF and marrow stromal cells promoted greater bone formation relative to 
any single factor or a combination of two factors [Huang, 2005]. 
Hence, a controlled study was conducted that provides evidence of PRP’s beneficial 
effect in stimulating neovascularization and bone bridging when combined with PCL-
TCP composite scaffolds implanted in rat critical-sized femoral defects. It was also 
verified that micro-CT imaging is a useful technique for the simultaneous monitoring of 
both angiogenesis and osteogenesis within three dimensional bone engineering scaffolds. 
It must be noted that this model and imaging techniques are limited to small animal 
experiments. This is mainly because of the amount and cost of perfusion agent required if 
the animal was a larger one. The next chapter reveals the effects of PRP delivery by PCL-
TCP scaffolds in the repair of critical-sized mandibular defects. The motivation was to 
evaluate if PRP delivery by the scaffolds could circumvent current obstacles faced by 
surgeons in clinics during the placement of dental implants. There is a vast market for 















7.5     CONCLUSIONS 
• At week 3, PRP-treated femurs displayed 70.3 % higher vascular volume fraction 
than control femurs but bone volume fraction was significantly higher for the 
control-treated defects.  
• Both 2D X-ray and 3D micro-CT images revealed regions of bony ingrowth 
within the scaffolds and a continuous sheath around the scaffold periphery.  
• At 12 weeks post implantation, there was no statistical difference in bone volume 
fraction between PRP- and control- treated femurs. However, a greater proportion 
of PRP-treated femurs (83%) achieved bone union as compared to controls (33%).  
• A significantly higher torsional stiffness observed for PRP-treated defects 
compared to empty scaffolds, although no differences were found in maximum 














CHAPTER 8: PRP DELIVERY BY PCL-TCP SCAFFOLDS AS 
TREATMENT FOR CRITICAL-SIZED DOG MANDIBLE DEFECTS 
8.1   INTRODUCTION 
The most recent graft materials developed are bioactive composite scaffolds comprising 
of a biodegradable polymeric phase and a bioactive phase that spontaneously bond to and 
integrate with bone in the living bone [Kokubo, 2003]. This thesis introduced novel PCL-
20 % TCP composite scaffolds that were fabricated by a form of rapid prototyping 
technology called fused deposition modeling [Hutmacher, 2000; Hutmacher, 2001; Zein, 
2002]. The previous chapter showed that these scaffolds have fully interconnected matrix 
architecture and mechanical properties suitable for rapid vascularisation and maintenance 
of the structural integrity of bone grafts in load bearing applications respectively  
[Endres, 2003; Rai, submitted]. In addition, the use of the highly reproducible and 
computer controlled FDM technique allowed the custom-made fabrication of tissue-
engineered bone based on computed tomographic scans of individual defect sites [Endres, 
2003]. Thus, PCL-TCP scaffolds can be tailored to fit complex maxillofacial defects. 
Chapter 2 stated that a pre-requisite for the placement of dental implants is that sufficient 
amount of bone must be present to fully cover the implant and for the implant to support 
a fixed prosthetic restoration [Kim, 2002]. Thus, the ideal bone graft material must 
initially stabilize the implants and then induce bone regeneration at the defect site for the 
permanent fixation and osseointegration of the implants. This serves to improve the long-
term prognosis of the implant and decrease healing time substantially [Shanaman, 2001; 
Kim, 2002]. 
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Several methods have been proposed to improve and accelerate the healing of dental 
implants and bone grafts. One way is the application of platelet-rich plasma (PRP) as 
described in chapters 2, 6 and 7. Just to recap, PRP is an autologous source of 
concentrated platelets that releases its prepackaged growth factors, namely transforming 
growth factor (TGF), platelet-derived growth factor (PDGF) and vascular endothelial 
growth factor (VEGF) upon contact with thrombin and calcium [Marx, 1998; Tozum, 
2003]. These growth factors assist in soft tissue healing, osteogenesis and angiogenesis 
and can be readily blended with the grafting materials before implantation into the defect 
site [Kim, 2002; Choi, 2004; Fennis, 2005]. PRP also improves the handling properties of 
the graft material and decreases bleeding at donor and recipient sites [Tozum, 2003]. 
Presently, numerous contradicting results exist for the therapeutic effects associated with 
PRP alone and in combination with bone substitutes. Two excellent reviews touch on 
these controversial issues [Marx, 2004; Freymiller, 2004]. Our group has been active in 
establishing the PCL-TCP scaffolds not only as graft materials but also as potential 
delivery systems for PRP. The in vitro release profile of the growth factors released from 
PRP loaded on PCL-TCP scaffolds immersed in simulated body fluids was reported in 
chapter 6 [Rai, 2005]. Subsequently, the system was implanted into rat nonunion femoral 
defects as described in chapter 7 [Rai, submitted]. This properly controlled 3-month study 
provided solid evidence of PRP’s beneficial effect in stimulating neovascularisation and 
bony bridging in combination with PCL-TCP scaffolds. 
The next natural step would be the application of this novel bone regenerative strategy to 
a large animal model and for a longer-term period. A larger animal model is vital for 
advancement into preclinical trials and a longer time period is required for the acquisition 
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of the in vivo degradation properties of the scaffolds and the time required for mature 
bone deposition and remodeling to occur. It would also be interesting to note the efficacy 
of PRP delivery by PCL-TCP scaffolds in bone defect sites other than the femur.  With 
this in mind, the current study was aimed at investigating the efficacy of PRP loaded 
PCL-TCP composite scaffolds in facilitating the placement of dental implants and 
stimulating bone regeneration in critical-sized mandibular defects in mongrel dogs after 
an implantation period of six and nine months.  
 
8.2   MATERIALS AND METHODS 
8.2.1   Scaffold design and fabrication 
Polycaprolactone- 20 % tricalcium phosphate composite scaffolds were purchased from 
Osteopore International Pte Ltd, Singapore. Each scaffold manifested a lay-down pattern 
of 0/60/120°, porosity of 65 % and measured 18 x 10 x 7 mm. The scaffolds were 
custom-made to contain two holes for the insertion of implants as described below. 
 
8.2.2   Dental implants 
The implants have a cone-shaped design, were provided with a porous surface geometry 
and were inserted by tapping. They were 10 mm in length and 4 mm in diameter and 
made of commercially pure titanium (Endopore, Innova Technologies Corporation, 
Canada). Two titanium implants were inserted into the respective prefabricated holes in 
each scaffold just before implantation. 
 
8.2.3   PRP preparation and characterization 
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The animal study was approved and performed in accordance to the animal care and 
ethics regulations as determined by the Agri-Food and Veterinary Authority of 
Singapore. Platelet rich plasma was prepared from whole blood collected from each dog 
(Mongrel, 14-20 kg, 1-2 years old). In brief, 10 ml of heparinized blood was centrifuged 
at 2 400 rpm for 10 min to separate PRP and platelet poor plasma (PPP) portions from the 
red blood cell fraction. The PRP and PPP portions were again centrifuged at 3 600 rpm 
for 15 min to concentrate PRP (0.8-0.9 ml) [Tozum, 2003; Rai, 2005]. Five hundred 
microliter of PPP was retained with PRP, making the final volume 1.3-1.4 ml and this 
mixture was stored at –20 °C until loading.  For characterization purposes, the PRP was 
diluted 100-fold and twenty microliters of this dilution was placed onto the counting 
chambers of a hemocytometer. The average number of platelets counted from all eight 
dogs (one sample each) was 485 x 103 ± 110 /µl. The amount of total protein in PRP was 
38.2 ± 9.17 mg/ml as measured by Bio-Rad Protein assay according to manufacturer’s 
instructions (Bio-Rad, USA). Bovine serum albumin was used as standard. 
 
8.2.4   Experimental design 
A total of forty-eight dental implants were used as the experimental implants. In each 
dog, three defects sites was created and treated with one of the two treatment modalities: 
(1) grafting with scaffold and two implants (control) or (2) grafting with scaffold, two 
implants and PRP (Figure 8.1). In addition, some dogs received an extra defect site that 
was not treated and served to confirm that critical-sized defects were used in the study. A 
total of eight dogs was used, two males and two females for each time point. Samples 
were collected at six and nine months. 
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Figure 8.1: Digital photographs of implanted PCL-TCP scaffolds with titanium implants 
(A) loaded with platelet-rich plasma (PRP), (B) without PRP and empty defect (controls). 
 
8.2.5   Surgical procedures 
The mongrel was given the premedical drugs, atropine sulphate (0.05 mg/kg) and 
buprenorphine (0.01 mg/kg). Anesthesia was induced with zoletil (5 mg/kg) and 
isoflurane. The general anesthetic was delivered and monitored under the supervision of 
an experienced animal technician. Briefly, the jaw was shaved to expose the surgical site, 
followed by administration of the local anesthetic adrenaline (1 in 8000). Iodine was 
swabbed onto the shaved area. Ethanol was then applied. The skin was carefully slit open 
and soft tissues were excised. Any obstructing blood vessel was cut and sutured. One 
defect site was created at the upper and lower mandible of the right jaw respectively. Two 
implants were knocked into the prefabricated holes of a PCL-TCP scaffold and the 
construct was dropped into a centrifuge tube containing 1 ml of PRP. Using a 
micropipette, the construct was flushed with PRP several times, followed by the addition 
of thrombin (500 IU/ml, Tisseel Kit, Baxter Immuno, Austria) in 10 % calcium chloride 
(0.5 ml) that immediately formed a neat, gluey matrix that encapsulated the scaffold. 
Each defect site received one scaffold and was knocked into position until it was 
completely in fixture with the mandible cavity. An additional defect site was created at 
$ %
 168 
the lower mandible of the left jaw for the placement of the control group. Wound closure 
was performed in layers (subcutaneous, muscle and skin) using a silk suture that ensured 
complete coverage of the alveolar bone. 
 
8.2.6   Three-dimensional microcomputed-tomographic evaluation 
At 6 and 9 months after implantation, the mongrel dogs were anaesthetized, followed by 
euthanasia via perfusion with formalin through the left ventricle of the heart. The 
implants and surrounding tissue were immediately rinsed in saline solution and fixed in 
10 % neutral buffered formalin for at least two weeks. The extracted samples were then 
subjected to micro-CT analysis (SMX-100CT, Shimadzu, Japan). The specimens were 
placed in a sample holder and scanned through 180 Û DW D VSDWLDO UHVROXWLRQ RI P
which allowed the evaluation of the tissue architecture and material interphase as well as 
the degree of anisotropy. Regions of interest were selected in each slice image obtained 
from the scanned planes and globally thresholded to eliminate background noise. 
Reconstruction and subsequent analyses were done using VGStudio Max 1.1 and CT Analyzer software 
(Volume Graphics GmbH, Wieblinger Weg 92 A, 69123 Heidelberg, Germany) 
according to manufacturer’s instructions. The bone volume fraction (BVF) was recorded 
that represents the percentage of a volume of interest which was mineralized. Thresholds 
were applied to differentiate between implants, mature bone and PCL polymer. Metal plate 
filters minimized beam hardening effect caused by the titanium implants. 
   
 
8.2.7   Histological evaluation 
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After the non-destructive micro-CT analysis, the specimens were dehydrated in 
ascending series of alcohol rinses and embedded using a process that produced ground 
sections with the glycol metacrylate resin.  Once polymerized, the block was trimmed to 
remove excess plastic with an industrial vertical band saw and cut along its long axis with 
a diamond band saw (EXAKT standard saw). Ground polished sections of 100 µm 
thickness were made using the EXAKT micro grinder system from EXAKT 
Technologies, Inc., Oklahoma City, OK. This thickness was needed to determine the 
integration of the implant with the scaffold. Two slides were created for each scaffold. 
The slides were stained with Hematoxylin & Eosin and Von Kossa to detect nuclei of 
cells, extracellular matric and mineral deposits. The amount of degradation of scaffolds 
was also determined. The middle section (the area between the two implants) of each 
slide was divided into squares of equal volume. The % of scaffold remaining was 
calculated by dividing the number of squares containing remnants of the scaffold by the 
total number of squares in the cross-section. The mean of 3 sections was taken for each 
time-point. 
 
8.2.8   Statistical analysis 
All data were presented as means ± standard deviations (SD). Statistical analyses were 
performed with GraphPad Software, California, US. The results were compared using 
Student’s t-test and a p-value of less than 0.05 was interpreted as significant in all 
analyses. 
 
8.3   RESULTS 
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8.3.1   Gross examinations 
It was noted that one dog suffered abscess formation around the defect sites on one side 
and was excluded from further analysis. Healing was otherwise uneventful in the 
remaining dogs, which demonstrated that the PCL-TCP scaffolds exhibited good 
biocompatibility. Upon gross examination, the implants appeared well integrated into the 
surrounding scaffold and host tissue. There was no change in size of all implants to the 
original dimension of the PCL-TCP scaffolds. 
 
8.3.2   Micro-CT evaluation 
The three regions of each defect site that were bone, scaffold and implants were 
successfully segmented and separated by VGStudio Max (Figure 8.2). 
 
                                                                          
Figure 8.2: Segmentation using VGStudio Max software. (A) Segmented bone (light 






Figure 8.3A illustrates the bone volume fraction (BVF) of all samples over six and nine 
months.  PRP-treated groups had significantly higher BVF compared to controls at both 
time points (p < 0.05). PRP-treated groups had 98.3 % and 58.3 % higher BVF than 
controls at six and nine months respectively. Control groups showed a significant 
increase in BVF from 5.07 ± 2.13 to 9.78 ± 1.11 (92.8 %) from six to nine months. 
Similarly, PRP-treated groups displayed an increase in BVF from 10.1 ± 3.24 to 15.5 ± 
1.89 (53.9 %) from 6 to 9 months. 
Next, the BVF values for the PRP-treated groups situated at frontal or caudal sites, with 
respect to the mandible, were contrasted (Figure 8.3B). At both time points, no 
significant difference between the frontal and caudal specimens was detected (p > 0.05). 
Frontal specimens demonstrated an increase in BVF from 10.9 ± 3.99 to 15.5 ± 1.89 
(41.6 %) but this was only a statistical trend (p < 0.1). Caudal samples manifested a 
significant 68.5 % increase in BVF from 9.20 ± 2.85 to 15.5 ± 2.19 (p < 0.05). 
Another parameter compared was the BVF values for PRP-treated groups in male and 
female dogs (Figure 47C). At six months, there was no significant difference in BVF 
values between male (8.72 ± 0.63) and female (10.7 ± 3.94) dogs. A statistically 
significant higher BVF was noticed for male (17.1 ± 0.43) and female (13.8 ± 0.97) dogs 
at nine months (p < 0.05). Male dogs showed a significant 96.5 % increase in BVF values 
from six to nine months. This was not observed for the females (p > 0.05). However, a 
larger sample number is required to corroborate this finding. 
Representative three-dimensional micro-CT images of a PRP-treated group at nine 
months were examined slice by slice to determine if bony ingrowth penetrated the defect 
area (Fig 8.4). It must be noted that the images were captured at a density that only  
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A comparison of bone volume fraction between 
frontal and caudal situated PRP-loaded PCL-


















Figure 8.3: Quantitative assessment of bone volume fraction (BVF) at 6 and 9 months as 
determined by micro-CT analysis. (A) shows the differences between PRP loaded PCL-
TCP scaffolds and controls. (B) illustrates the differences between frontal and caudal 
situated PRP-loaded PCL-TCP scaffolds. Results are expressed as mean ± standard error. 






picked up implants and bone, and not scaffolds. Fig 8.4A demonstrates the proximal view 
of a defect site. New bone was observed at the periphery and in close apposition to the 
dental implants. Bone was also detected creeping up into the defect site from native bone 
at the sides and bottom. The entire height of the defect was not fully occupied with bone. 
But the amount of bone seemed adequate to hold the implants in place. Regular sized 
gaps were evident in the new bone that corresponded to the scaffold porous architecture.  
Figure 8.4B shows a distal view of the same defect site. Similar observations were noted 
as the frontal image except that new bone spanned ¾ of the defect site, including the 
cavity between the implants. Finally, fig 8.4C represents a thin section directly in the 
middle of the defect site with the implants sliced vertically into half. The entire area 
surrounding the implants was almost completely covered with new bone, indicating bony 
ingrowth into the center of the scaffold. The implants appeared to be sufficiently secured. 
Control groups experienced new bone deposition around the titanium implants but there 
was minimal bone filling the defect site that correlates with the lower BVF values 
obtained.  
 
8.3.2   Histological evaluation 
The middle sections of one sample from each group at each time-point were subjected to 
histological evaluation. Figures 8.5 and 8.6 shows representative histological 
micrographs of PRP-loaded PCL-TCP scaffolds with two implants at 6 months post-
implantation. The sides and middle section of figure 8.5 were stained light pink by H & 























Figure 8.4: Representative three-dimensional micro-CT images of a PRP-treated group at 
9 months examined slice by slice to determine if bony ingrowth was present throughout 











   
 
Figure 8.5: Representative histological section of platelet-rich plasma-treated defect at 6 
months. The two dental implants and scaffold remnants appeared black and dark brown 
respectively. The section was stained with Haematoxylin and eosin, which stains nuclei 
blue-purple, erythrocytes bright pink to red and cytoplasm and other tissue elements 
various shades of pink. I: Implant, S: Scaffold. (Original magnification: (A) x 20, (B and 











Figure 8.6: Representative histological section of platelet-rich plasma-treated defect at 6 
months. The two dental implants and scaffold remnants appeared black and dark brown 
respectively. The section was stained with Von Kossa, which stains calcium salts brown 
and non-mineralized tissue pink. Implant = I, Scaffold = S. (Original magnification: (A) x 
20, (B and C) x 40). 
S 
S 




abundant as well. It must be noted that 80.1 ± 2.4 % of the cross-sectional area was 
occupied by the scaffold which appeared brown and exhibited the shape of either the 
radial or horizontal structure of the rods. Direct contact between the scaffold and implants 
with bone tissue was observed. This implies (1) good osseointegration of implants which 
were held in place and (2) the non-restricted infiltration of remaining scaffold material 
with new tissue. 
Similar observations were evident from figure 8.6 which displays the section stained with 
Von Kossa for mineral detection. The entire section was stained a uniform bright brown, 
indicating the presence of bone trabeculae. In addition, some red counter-stain (non-
mineralized osteoid) was detected mainly at the periphery of the implants and scaffold 
remnants. The scaffold debris occupied most of the volume which was consistent with the 
results from H & E. Control scaffolds displayed very minimal and light pink staining 
with H & E, with random streaks of purple stain. The scaffold debris occupied 80.1 ± 
1.96 % of the cross-sectional area. Von kossa staining revealed dull-brown and red 
counter-stain patches throughout the section. 
Figures 8.7 and 8.8 show representative histological micrographs of PRP-loaded PCL-
TCP scaffolds with two implants at nine months post-implantation. The right and left 
sides of the implants that correspond to the defect margins were stained a uniform and 
dense bright pink with H & E, which resembled woven bone formation (Fig 8.7). The 
middle section was interestingly messy with bright pink staining at the bottom and dense, 
random streaks of purplish-brown (immature bone) occupying the remaining space. This 
suggests a dynamic process of bone remodeling. The rods of the scaffold were not as 
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Figure 8.7: Representative histological section of platelet-rich plasma-treated defect at 9 
months. The two dental implants and scaffold remnants appeared black and dark brown 
respectively. The section was stained with Haematoxylin and eosin, which stains nuclei 
blue-purple, erythrocytes bright pink to red and cytoplasm and other tissue elements 
various shades of pink. Implant = I, Scaffold = S. (Original magnification: (A) x 20, (B 
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Figure 8.8: Representative histological section of platelet-rich plasma-treated defect at 9 
months. The two dental implants and scaffold remnants appeared black and dark brown 
respectively. The section was stained with Von Kossa, which stains calcium salts brown 
and non-mineralized tissue pink. Implant = I, Scaffold = S. (Original magnification: (A) x 










area, resulting in more space filled with connective tissue. There was no separation layer 
between the scaffolds and implants with bone tissue. 
Von Kossa results (Fig 8.8) corresponded to the H & E stained sections. The right and 
left sides of the implants were stained a uniform and dense bright brown, indicating the 
presence of mature bone trabeculae at nine months. No counterstain or non-mineralized 
osteoid was detected. The middle section was messy and manifested discontinuous light 
brown staining (disturbed mineralization) with some pink counter-stain. Control scaffolds 
showed messy patches of light pink and purple throughout the H & E stained sections. 
Remnants of remaining scaffold occupied only 46.9 ± 0.49 % of the cross-sectional area. 
Most of the areas in the von kossa stained sections for control scaffolds were counter-
stained pink, specifying the presence of a non-mineralized matrix. 
 
8.4   DISCUSSION 
Large bone defects and insufficient bone volume pose many difficulties in the application 
of dental implants. In occlusal restoration with dental implants, oral and maxillofacial 
surgeons must wait until the end of the healing period to allow good osseointegration, 
which requires typically six months for the maxilla and three months for the mandible. 
These periods required for osseointegration constitute a burden for the patient [Ito, 2005]. 
Here, we adopt a tissue engineering strategy combining osteoconductive PCL-TCP 
scaffolds and osteoinductive PRP. The approach was targeted at the immediate and stable 
placement of implants into critical-sized defect sites while simultaneously inducing the 
regeneration of bone. This would obviate the need for a second surgery, which not only 
increases time demands and cost of therapy but may give rise to complications as well 
[Suba, 2004]. 
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The current study monitored the process of bone regeneration at both a qualitative and 
quantitative level. Micro-ct analysis revealed that the bone volume fraction (BVF) for 
PRP-treated defects was higher than controls at both six and nine months. The enhanced 
BVF displayed by PRP-treated defects can be explained by several reasons. Firstly, PRP 
is autologous plasma rich in growth factors that can serve as a local regulator of bone 
regeneration and hence exert a beneficial effect on bone healing in critical-size defects 
[Raghoebar, 2005]. Upon clotting to form an insoluble fibrin network, platelets in PRP 
release numerous growth factors inside the wound, of which platelet-derived growth 
factor (PDGF), insulin-like growth factor (IGF) and transforming growth factor-beta 
(TGF-β) play the most important roles. PDGF possess mitogenic, angiogenic and 
macrophage activation properties during wound healing [Schliephake, 2002; Tozum, 
2003]. TGF-β stimulates chemotaxis and mitogenesis of osteoblast precursors, promotes 
their differentiation toward mature osteoblasts and stimulates the deposition of collagen 
[Linkhart, 1996; Schliephake, 2002; Tozum, 2003]. On the other hand, PRP could have 
also acted like a blood clot and resulted in the filling of the gaps around the scaffold. As a 
consequence, this will result in guidance of bone cells into the scaffold. 
The second reason for the augmented BVF observed in PRP-treated defects can be 
attributed to the properties of the scaffold itself. Scaffolds for mandibular reconstruction 
must provide at least a temporary load sharing, if not load bearing, to withstand the forces 
of mastication. The scaffolds must have similar elastic properties to bone to avoid 
fracture and separation at the bone implant interface. There should be permeability to the 
scaffolds, both for seeding it with bioactive substances and for cellular and vascular 
ingrowth when implanted [Feinberg, 2005]. The architecture of the scaffolds was 
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designed to act as a blotting media to soak and trap the hematoma and subsequently 
promote blood clotting, a process necessary for normal wound healing.  
The PCL-TCP scaffolds used sufficed as suitable grafts for mandibular reconstruction 
and their main advantages as highlighted from this study were (1) it eliminated the need 
for an autogenous donor site, (2) it was available in unlimited quantity and consistent 
quality, (3) its’ highly porous and honeycomb-like architecture facilitated osteogenesis 
and angiogenesis, (4) it did not evoke a significant inflammatory response and (5) it 
withstood mechanical loading and held the implants in place for up to nine months. 
The present research showed that the scaffolds experienced 30 % degradation from 6 to 9 
months, finally occupying only 46.9 % of the cross-sectional area.  This indicates that 
significant degradation occurred at this time period. We hypothesize that both surface 
erosion by hydrolysis and enzymatic bulk degradation were active mechanisms at work, 
with resulting molecular weight and weight loss initiated slightly before 9 months. We 
predict that the scaffolds would be entirely degraded shortly after. However, this needs to 
be confirmed by longer in vivo experiments. The anticipated degradation time of PCL-
TCP scaffolds is less than that displayed by the first generation pure PCL scaffolds that 
degraded only after 2 years in vivo [Pitt, 1981; Smith, 1990]. The onset of degradation 
exhibited by PCL-TCP scaffolds may have resulted in the disturbed mineralization seen 
in the middle section (which contained the bulk of the scaffold) between the two implants 
after histological analysis at nine months. Notably, no adverse biological responses were 
detected. A longer time period is needed to assess the effect of complete degradation of 
the scaffolds on bone regeneration and tissue response. 
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The PRP-treated defects did not manifest faster scaffold degradation rates as compared to 
controls, implying that the disintegration of the scaffolds was not cell or growth factor-
mediated, but instead a combination of enzyme and chemical hydrolysis. This 
supposition has to be verified and in vitro and in vivo experiments are currently being 
carried out by our research group to fulfill this purpose. The above findings are consistent 
with [Wiltfang, 2003], who did not observe a faster degradation rate of ceramic bone 
substitutes with the addition of PRP. 
The disturbed mineralization present between the implants of the PRP-treated defects at 9 
months may also be attributed to the fact that the middle section of the defect was 
exposed to minimal native bone only at the top and bottom and not from the sides. This 
could have resulted in reduced access to pre-osteoblastic cells, which PRP requires in 
order to perform its osteoinductive functions. Another suggested explanation is that 
primary woven bone that was observed at six months was undergoing secondary 
remodeling to form mature bone at nine months. Any of the above explanations or a 
combination of these could have resulted in the region of disturbed mineralization. 
Although the PRP-treated groups had significantly higher BVF than controls at nine 
months, the difference was not as pronounced as it was at six months. The measured BVF 
included both the mature new bone observed at the sides and the disturbed mineralization 
observed in the middle section at nine months. These results were not surprising as PRP 
was found to have a significant outcome only in the early phases of wound healing 
[Zechner, 2003; Rai, submitted]. Platelets and growth factors are known to act in the 
earlier stage during the bone regenerative process because of the lifespan of the platelets 
and the direct effects of the growth factors that lasts less than five days. PRP is 
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hypothesized to induce bone formation by promoting the proliferation of osteoprogenitor 
cells early in the regenerative process [Ogino, 2005 ]. 
It is perceived that since growth factors within platelets exhibit their effect by binding to 
specific cell surface receptors, the use of PRP together with autogenous bone with 
inherent osteogenic cells, and not bone substitutes, would be effective [Wiltfang, 2003; 
Ito, 2005]. The use of PRP in combination with autogenous bone transplants was 
reportedly successful [Marx, 1998; Wiltfang, 2003], while the use of PRP in combination 
with bone substitutes like collagen and ceramics did not display favorable results [Ito, 
2005]. In other words, the efficacy of PRP seems dependant on the presence of 
osteogenic cells. PRP was shown to promote the in vitro proliferation of rat bone marrow 
cells [Ogino, 2005] and osteoblasts [Ferreira, 2005] with a corresponding decrease in the 
expression of alkaline phosphatase. Ten percent of PRP added to culture medium was 
apparently sufficient to induce evident cell proliferation.  
Our group believes that PRP in combination with bone substitutes should not be ruled out 
too quickly as a potential mode of treatment. The field of PRP requires reproducible and 
reliable animal models as well as methodology for assessing its true benefits. We recently 
proved the beneficial effect of PRP loaded PCL-TCP scaffolds (without cells) in 
augmenting vascularisation and bone unions in the early stages of tissue regeneration in a 
rat femoral defect model as reported in chapter 7 [Rai, submitted]. In that model, PRP 
loaded PCL-TCP scaffolds evoked the establishment of a neo-vascular network after only 
three weeks prior to stimulating mature bone formation which followed shortly at twelve 
weeks. The present study revealed significantly higher bone volume fraction for PRP-
treated defects as compared to controls at both six and nine months. In addition, 
 185 
continuous bone trabeculae with surrounding connective tissue containing capillarization 
were noted in PRP-treated defects. 
Moreover, the osteoinductive efficacy of PRP should not be underestimated. PRP is a 
physiological phenomenon and if blended with the right delivery system may prove to be 
very effective. The sustained elution of individual growth factors released by platelets 
loaded onto PCL-TCP scaffolds was measured in previous in vitro work (chapter 6) [Rai, 
2005]. The elution kinetics seemed to have provided sufficient signal to the osteoblasts or 
osteoprogenitor cells present at the defect margins to stimulate their migration into the 
defect and lay down the osteoid, followed by woven bone as observed in previous [Rai, 
submitted] and present in vivo studies. The sustained release was previously attributed to 
the scaffolds’ degradation and bioactive nature; both properties contributed mainly by the 
tricalcium phosphate component (chapter 4) [Rai, 2005a; Yang, submitted; Rai, 2005b]. 
The results of the experiments obtained hitherto by our research group using PCL-TCP 
scaffolds for delivery of PRP are very promising. A more extensive investigation that 
focuses on the in vivo protein release of such structural scaffolds is recommended. 
The present study investigated the efficacy of PCL-TCP scaffolds together with PRP in 
facilitating the placement and stability of dental implants in critical-sized defects of the 
canine mandible. The implants were held in place for up to 9 months. PRP-treated defects 
displayed enhanced bone volume as compared to controls at both 6 and 9 months. The 
PRP-loaded scaffolds stimulated the deposition of connective tissue with alveolar bone 
trabeculae. Hence, the delivery of PRP by PCL-TCP scaffolds sufficed as a promising 
alternative treatment for mandibular defects. This large animal work brings the proposed 
bone regenerative strategy a step closer to clinical trials. 
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8.5     CONCLUSIONS 
• The results showed that PRP-treated defects had 98.3 and 58.3 % more bone 
volume fraction than controls at 6 and 9 months respectively (p < 0.05).  
• No significant difference was noted between caudal and frontal situated PRP-
treated defects.  
• The deposition of osteoid and new bone trabeculae were discerned throughout the 
section at 6 months.  
• The scaffolds experienced 33 % degradation from 6 to 9 months, finally 
occupying only 46.9 ± 0.49 % of the cross-sectional area. PRP treatment had 
negligible effect on the degradation of the scaffolds.  
The sides of the implants that correspond to the defect margins were filled with mature 













CHAPTER 9: FINAL CONCLUSIONS AND RECOMMENDATIONS 
9.1   FINAL CONCLUSIONS 
This research has stumbled upon several exciting discoveries. The general aim of the 
study was to evaluate the protein delivery properties of a novel biomaterial for bone 
tissue engineering applications. The novel biomaterial was a bioactive composite scaffold 
consisting of polycaprolactone physically blended with 20 % tricalcium phosphate. It 
represents the second generation scaffold manufactured specially by the fused deposition 
modeling technique. The first generation scaffolds were plain PCL scaffolds. The reasons 
for developing bioactive scaffolds were described in detail elsewhere in this thesis.  
 
9.1.1   Cytocompatibility of PCL-TCP scaffolds 
The first set of testing conducted targeted the cytocompatibility, specifically the cellular 
compatibility properties of the polymer in vitro. It is crucial to prove for any potential 
biomaterial with medical-related applications that the material facilitates the attachment 
of host cells, followed by their proliferation and then differentiation into neo tissue. At no 
instance in this process should the scaffold material or its degradation by-products cause 
the apoptosis or necrosis of the cells.  Our study showed that PCL-TCP scaffolds seeded 
only with canine osteoblasts sustained excellent osteogenic expression in vitro. The cells 
adhered well onto the rods of the scaffolds as well as across the pores. There was 
adequate and unrestricted infiltration of scaffold architecture with cells and eventually 
mineral deposit.  
Some experimental groups had rhBMP-2 loaded onto the scaffolds as well to stimulate 
the differentiation of the osteoblasts. It was evident that rhBMP-2 enhanced the 
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differentiated function of canine osteoblasts in a non-dose dependent manner. The 
addition of rhBMP-2 resulted in accelerated deposition of mineral by cells on the 
scaffolds which was observed as early as week two. This was considered very fast in 
contrast to other scaffolds presently investigated by other groups. Another interesting 
observation was that the group with the largest concentration of rhBMP-2 loaded (1000 
ng/ml) had resulted in significant death of the osteoblasts as they were forced to undergo 
hastened terminal differentiation. This implies that the concentration of growth factor has 
to be optimal, not in excess such that death is induced and not too little such that bone 
mineralization is not stimulated. Thus, concentration of growth factor to be delivered for 
bone regeneration applications has to be carefully considered. 
 
9.1.2   Biodegradation of PCL-TCP scaffolds 
The next series of experiments were aimed at characterizing the degradation behavior of 
the material. The PCL-TCP scaffolds were immersed in phosphate buffered saline (PBS) 
and simulated body fluids (SBF) and periodically samples were removed for analysis. 
The degradation nature of the biomaterial is crucial as it determines both biocompatibility 
as well as the protein release kinetics.  The scaffolds were shown to be slow degrading 
and degraded via random hydrolysis of its ester bonds. It is hypothesized that the TCP 
particles fell off the PCL polymer, leaving gaps in the structure and thus a small percent 
of weight loss. These gaps increased surface area for attack of now exposed ester bonds 
by the surrounding water molecules.  
For SBF-immersed scaffolds, the fallen or degraded TCP actually served as nucleation 
sites for the formation of calcium precipitates. Several interesting isomers of precipitates 
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were formed on the surfaces of the scaffolds as observed under scanning electron 
microscopy and verified by x-ray diffraction analysis. After three weeks of immersion in 
SBF, the calcium/phosphate ratio revealed that a hydroxyapatite (Hap) layer had 
established. These were very exciting results as it is the first time that these scaffolds 
were shown to possess a bioactive nature and the findings has several implications. 
Firstly, a Hap layer would allow the scaffold to integrate directly to bone tissue in vivo. 
This will help rectify problems of fibrous capsule formation that is often observed with 
implanted synthetic scaffolds and prevents direct bonding to bone. Secondly, the active 
chemical surface displayed by the Hap layer would result in the creation of electrostatic 
interactions with positive-charged osteoinductive factors. This will enhance protein 
absorption by the scaffolds as was proven true in a following study.  
PCL is considered a polyester and its degradation by-products are acidic. TCP however is 
hydrophilic and can neutralize these acidic by-products. The pH measurements showed 
no significant change over time for PBS-soaked samples. This indicates that the scaffolds 
were hardly degraded in PBS. The pH dropped slightly by 0.1 for SBF-soaked scaffolds 
at week three. This was probably due to the degradation of TCP which was accelerated in 
SBF that resulted in faster degradation of PCL polymer. The slight pH drop was 
insignificant though and not likely to induce an inflammatory response. Week three 
appears to be the turning point for degradation of PCL-TCP scaffolds immersed in SBF. 
Hence, taken altogether, the second phase of experiments demonstrated that PCL-TCP 
scaffolds were bioactive and the surface that contacts the cells were non-toxic.   
9.1.3   PCL-TCP scaffolds as delivery system for a single growth factor 
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The objective of the following phase of work was to characterize for the first time the 
suitability of these novel three-dimensional PCL-TCP scaffolds as protein delivery 
systems for a single growth factor in vitro. Fibrinogen was used to aid in the initial 
loading of proteins onto the scaffold. PCL scaffolds were tested on as well so that we 
could confirm the effect specifically TCP had on the protein delivery profile. Many 
exciting observations were made from this study. Firstly, the percent protein retention by 
the scaffolds was greatly enhanced by pre-treatment in PBS and even more so in SBF. 
This has interesting applications. Should we always pre-treat the scaffolds before they are 
used? Should the scaffolds then be packaged and sold immersed in buffer? Secondly, the 
adhesion characteristics of the fibrin network and rhBMP-2 on the surface of the PCL and 
PCL-TCP scaffolds were different. TCP seemed to have resulted in the uniform 
distribution of rhBMP-2 on the surface of the scaffolds.  
Thirdly, both the dosage of growth factor and material of the scaffold sufficed to be 
determinants of the protein release kinetics for PCL-TCP scaffolds when PBS was used 
as the release buffer. Intriguing bursts-like release profiles were obtained which 
corresponded to protein release from diffusion, degradation of the fibrin network from 
the scaffolds and degradation of TCP. The addition of TCP had prolonged the release of 
rhBMP-2 as compared to plain PCL scaffolds. Another significant conclusion of this 
investigation was that the rhBMP-2 released at each time-point (twenty-one day period) 
retained its bioactivity and its protein structure was stable as well. This means that the 
scaffolds did not interfere in the desired properties of the released protein.  
Based on the results of this study, the PCL-fibrin scaffolds are recommended as short-
term release carriers that could prove useful for the in vivo wound healing process. PCL-
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TCP-fibrin scaffolds on the other hand, are recommended as long-term release carriers 
for applications that require sustained release of osteoinductive factors throughout a long 
time period for the full biologic effect to be realized, such as for bone and vascular tissue 
regeneration.  
 
9.1.4   PCL-TCP scaffolds as delivery system for multiple growth factors 
Once the scaffolds were proven to be suitable delivery systems for a single growth factor, 
they were investigated for applications requiring the release of multiple growth factors. It 
is widely known that multiple growth factors interact with each other synergistically or 
antagonistically to bring about in vivo processes like wound healing and bone 
regeneration. Thus, we wanted to establish PCL-TCP scaffolds as carriers of multiple 
growth factors. Platelet-rich plasma (PRP) was selected as the source of growth factors 
and the release kinetics of individual growth factors present were determined after PRP-
loaded scaffolds were immersed in PBS and SBF. It was discovered that the elution 
profiles of the growth factors were determined by their size and amount loaded as well as 
the type of buffer used for analysis. 
SBF-soaked scaffolds did not achieve total release of its growth factors at 21 days. No 
bursts-like release were observed either unlike their counterparts in PBS. Instead, 
sustained release persisted. These scaffolds evinced a disparate release pattern for all 
three growth factors. TGF-β1 levels declined for the first week and then were constant 
until the end of the experiments. PDGF-BB levels heightened for the first two weeks and 
then were constant until the end of the experiments. IGF-1, on the other hand, exhibited a 
progressive reduction in levels over the entire experimental period. In contrast PBS-
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soaked samples exhibited total release and bursts-like release profiles that were not 
growth factor mediated. The proposed reason for disparity between PBS and SBF-soaked 
samples is the ability of the PCL-TCP scaffolds to form the Hap layer in SBF which 
participated in growth factor binding and release. It would be meaningful to monitor how 
these unique release patterns result in wound healing and bone regeneration in vivo. Thus, 
PCL–TCP scaffolds emerged as suitable delivery systems for multiple growth factors 
release in vitro.  
 
9.1.5    Rat femoral defect model 
The next stages of experiments were focused on evaluating PRP delivery by PCL-TCP 
scaffolds for treatment of bone defects in animal models. The first animal model was the 
rat. This was a study conducted in collaboration with the Georgia Institute of 
Technology. Several significant findings were reported. Notably, state of the art in vivo 
imaging technology was used that could detect and quantify both vascularization and 
bone mineralization. We successfully detected augmented neovascularization stimulated 
by PRP-loaded PCL-TCP scaffolds after three weeks post-implantation. Current literature 
only focused on the effect of PRP on bone mineralization and the works were mainly of 
semi-quantitative nature only. Furthermore, the benefit of PRP in an orthopedic 
application has not been published before. Our study revealed that eighty-three percent 
bone unions across critical-sized femoral defects were achieved when treated with PRP 
delivered by PCL-TCP scaffolds after twelve weeks of implantation.  
In addition, there were interesting comparisons made between treatment with controls 
(plain scaffolds) and PRP-loaded PCL-TCP scaffolds. At week three, controls manifested 
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significantly more mineralization but less vascularization than PRP-treated femurs. At 
week twelve however, there was no significant difference between the groups in the 
amount of mineral. The 3D images revealed that control femurs had random bone islands 
throughout the defect site, while PRP-treated femurs achieved bone unions with callus 
formation. This resulted in the higher stiffness obtained by PRP-treated femurs. 
These results suggest strongly that our proposed strategy, that is, PRP delivery by PCL-
TCP scaffolds, were capable of stimulating angiogenesis, followed by osteogenesis in a 
rat critical-sized femoral defect model.  This is on par with the body’s natural healing 
response where a vascular network must be established first to provide nutrients and 
gaseous exchange to facilitate the initial deposition and preceded by maintenance of bone 
repair and remodeling processes. The scaffolds architecture and porosity allowed for the 
infiltration of blood vessels as well as minerals. Another important conclusion was that 
the scaffolds were biocompatible as no significant inflammatory response was observed. 
It was also verified that micro-CT imaging is a useful technique for the simultaneous 
monitoring of both neovascularization and mineralization within three-dimensional bone 
tissue engineered scaffolds. 
 
9.1.6    Dog mandible defect model 
The second animal model adopted was the dog. The PRP loaded PCL-TCP scaffolds 
were implanted in critical-sized mandibular defects and specimens were analyzed for 
bone regeneration after six and nine months. A significant aim of this study was to 
explore if the scaffolds were capable of facilitating the initial placement of dental 
implants while concurrently stimulating bone repair and regeneration to promote 
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osseointegration of the implants. This would reduce wound healing time substantially. 
Usually, a clinician has to wait for three to six months before there is bone of sufficient 
quality and quantity for the fixation of implants. Implant fixation is necessary for the 
placement of a replacement tooth, braces and most other oral and maxillofacial surgery 
related devices. Thus, with our strategy, the implant can be fixed immediately after 
trauma and the patient can lead a normal life almost immediately. An additional goal of 
this research was to investigate if the proposed strategy will work at a site other than the 
femur and the consequences of implantation in bodily fluids to the degradation of the 
scaffolds for longer time periods. 
PRP-treated groups exhibited significantly higher BVF compared to controls at both time 
points, but the difference was not as pronounced as it was at six months.  An increase in 
BVF was detected for PRP-treated and control groups from six to nine months. 
Compared to the previous rat study, the BVF values obtained were higher as was 
anticipated due to the longer implantation times. No significant difference between the 
frontal and caudal specimens was reported at both time points. A statistically significant 
higher BVF was observed for male and female dogs at nine months. Looking at the 
innermost section of defect site, it was noted that the entire area surrounding the implants 
was mostly covered with new bone, indicating bony ingrowth into the center of the 
scaffold. Hence, PCL-TCP scaffolds together with PRP facilitated the placement and 
subsequent stability of the dental implants for up to nine months.  
Histological analysis showed that PCL-TCP scaffolds experienced 33 % degradation 
from six to nine months, finally occupying only 46.9 % of the cross-sectional area.  This 
indicates that significant degradation occurred at this time period. The PRP-treated 
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defects did not manifest faster scaffold degradation rates as compared to controls, 
implying that the disintegration of the scaffolds was not cell or growth factor-mediated. 
New bone trabeculae with surrounding connective tissue containing capillarization were 
noted throughout PRP-treated defects at six months. At nine months, interestingly, the 
sides of the implants had continuous bone trabeculae but disturbed mineralization was 
observed in the region between the implants.  
In conclusion, the work presented in the thesis proved that PCL-TCP scaffolds offers 
outstanding promise as protein delivery systems for bone regeneration applications. 
 
9.2   RECOMMENDATIONS FOR FUTURE WORK 
9.2.1   Physical and mechanical properties of PCL-TCP scaffolds as it undergoes 
hydrolytic degradation after immersion in different fluids  
The in vitro degradation properties of the scaffolds were not thoroughly studied in this 
thesis as it was not the focal point. In particular, further mechanical and physical 
characterizations are needed and for a longer time period.  Mechanical strength data is 
important as it regulates the biodegradability of the composites in vivo and hence 
determines the scaffold’s ability to provide structural support for bone mineralization. It 
should also be noted that the mechanical properties of the scaffolds prior to implantation 
would be distinct from post-implantation due to the inherent aggressive body fluids. 
Furthermore, mechanical strength of plain PCL scaffolds have been extensively reported 
but no such studies have been conducted for the second generation PCL-TCP scaffolds. 
Physical properties that should be monitored include volume, porosity, molecular weight 
and weight loss of scaffolds. Ph measurements are also needed to examine the acidity of 
 196 
the degradation by-products. We suggest immersing PCL-TCP scaffolds in phosphate 
buffered saline and cell culture medium used for growth of osteoblasts in vitro. The 
culture medium is representative of the in vivo body fluids environment where the 
scaffolds will be implanted. Then samples should be analyzed for at least eight time-
points over a period of twenty-four weeks or six months.  The in vitro data obtained will 
serve as a useful indicator of the true situation in vivo. The ultimate significance of this 
work lies in its contribution to the understanding of guided bone regeneration observed in 
our previous in vivo experiments involving the treatment of femoral and mandibular 
defects in a rat and dog model respectively by PCL-TCP composite scaffolds. 
 
9.2.2   In vivo degradation of PCL-TCP scaffolds 
Our initial work has shown that PCL-TCP scaffolds possess many of the desired 
characteristics for use as a biodegradable scaffold, including in vitro biocompatibility, 
bioactivity and mechanical integrity. In order for a biomaterial to be successful over the 
long term, the implant material must have a rate of degradation that acts in concert with 
the ingrowth of new bone. Ideally the scaffold would degrade slowly enough to maintain 
structural support during the initial stages of bone formation, but fast enough to allow 
space for continuous growth of new bone. 
To ensure sufficient statistical power for testing the scaffolds, the recommended study 
should be carried out using a rat model with two samples implanted subcutaneously in 
their abdominal cavity per animal and evaluation at two relevant implantation time 
points. Thus, a total of eight rats, that is sixteen scaffolds, should be used for the 
experiments. At twelve and twenty-four weeks post-operative, samples should be 
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retrieved and polymer degradation and tissue response within the pores of the scaffold 
can be assessed via micro-computed tomography, mechanical testing and histological 
techniques. Parameters evaluated should include changes in the scaffolds’ surface 
morphology, porosity, dimensions, mechanical properties and the presence of tissue 
and/or inflammatory mediators. These evaluations will provide data regarding the in vivo 
biocompatibility and biodegradation of the scaffold which is a crucial preclinical 
criterion. In addition, the results will be contrasted with the ones from the previous in 
vitro experiments and conclusions can be made on the respective contribution of 
hydrolytic and enzymatic modes of degradation. 
 
9.2.3   Evaluation of PRP-loaded PCL scaffolds in the repair of rat femoral defects 
The goal of bone repair constructs is to restore new vascular and bone architecture with 
biological and mechanical properties analogous to intact bone. To achieve this, our group 
had previously implanted PRP-loaded PCL-TCP composite scaffolds into rat femoral 
defects as described in chapter seven. Here we recommend using pure polycaprolactone 
scaffolds instead but in the similar rat model. The PRP-loaded PCL scaffolds will be 
implanted into 7.5 mm critical-sized, rat femoral defects for the investigation of fracture 
healing. A total of twelve Sprague-Dawley rats can be utilized. Each rat should receive a 
PRP-loaded PCL scaffold in one leg with the contralateral defect receiving a plain PCL 
scaffold.  In combination with perfused contrast agents, bone decalcification and non-
destructive micro-ct imaging techniques, the quantitative evaluation of blood vessel 
networks and mineralized matrix within implanted bone substitutes should be performed 
periodically for three months. It is also clinically relevant to investigate the mechanical 
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strength of the regenerated bone. It would be ideal for the yield strength to correlate with 
the amount of newly formed bone as detected with the micro-CT. The final analysis 
recommended is histological to determine the cellular distribution within the bone defect. 
This study will reveal: (1) the efficacy of PCL scaffolds in the treatment of rat femoral 
defects, (2) the applicability of the newly developed rat nonunion model in combination 
with phase enhanced micro-CT imaging techniques in evaluating tissue regrowth in 3D 
scaffolds and (3) more importantly, the results of this study will be compared to that 
obtained previously when PCL–20 % TCP scaffolds were used. The contribution of the 
bioactive TCP component to the bone regeneration process observed formerly can then 
be deduced. 
 
9.2.4   Analysis of PCL-TCP scaffolds as bone grafts in a sheep segmental femoral 
defect model 
The investigations are directed at confirming that the three-dimensional, bioactive 
polycaprolactone scaffolds can serve simultaneously as effective scaffolding material and 
growth factor delivery systems for the repair of bone defects. Our bone regenerative 
approach was recently tested in a rat femoral defect model that provided preliminary 
evidence for the efficacy of the PRP-loaded PCL-TCP scaffolds. The next natural step 
would then be to evaluate the strategy in a larger animal model and for a longer period of 
time. Here, we propose the implantation of PRP-loaded PCL-TCP scaffolds in sheep 
femoral defects for 6 months. Plain PCL-TCP scaffolds, intact femurs and empty defects 
will serve as controls. The bone volume fraction, bone union formation, mechanical 
strength and cellular distribution will be assessed at six and nine months.  
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The key research objective is to establish that the PRP-loaded PCL-TCP composite 
scaffolds can stimulate bone repair and regeneration upon implantation into large 
segmental bone defects for a long-term period. A large animal model is vital for 
advancement into clinical trials. The sheep is chosen as the experimental animal. A long 
time period is required to acquire useful insights of the in vivo degradation properties of 
the scaffolds and the time required for mature bone deposition and remodeling to occur. 
Specific objectives include elucidating (1) the amount and quality of bone formed in 
terms of the bone volume fraction, bone union formation and mechanical properties, (2) 
the amount and type of cellular and vascular infiltration into the defect site, (3) the long-
term effects of the material on host tissue, (4) the long-term effects of the host 
environment on the material biodegradation and (5) the correlation between previous 
results from the rat femoral defect study with results from the current study. The 
realization of the aims of this research proposal could result in the advancement of this 
novel bone substitute to clinical trials.  
 
9.2.5   Quantitative assessment of the in vivo release kinetics of growth factors from 
PCL-based scaffolds in rats 
The aim would be to address the hypothesis that local, controlled release of rhBMP-2 
from PCL-TCP scaffolds in vivo will enhance the osteoinductivity of the scaffolds as well 
as correlate with in vitro release profile determined previously. The in vivo environment 
is more aggressive and variable than any simulated in vitro medium. Thus, the most 
accurate measurement of the release profile has to be conducted and verified in an in vivo 
model. It is also interesting to compare the concentration of growth factor released at the 
 200 
local site of implantation against the amount that is transported in the bloodstream and 
excreted in urine. Two experimental groups consisting of six rats each and one control 
group with 6 rats will be needed. Experimental rats will receive either 10 or 20 ug/ml 
radiolabeled BMP-2 loaded PCL-TCP scaffolds. Control rats will receive plain scaffolds 
as well as BMP-2 loaded pure PCL scaffolds. These scaffolds will be implanted into 
experimentally created calvarial defects. The amount of radioactivity will be measured at 
predetermined time points at the application site itself as well for serum and urine 
samples. Specimens should be analyzed by histology as well to detect the tissue 
regeneration process within the area of BMP-2 release. We hypothesize that sustained 
delivery of BMP-2 will show better bone healing than any immediate release of BMP-2. 
Once again, the effect of the addition of TCP to the PCL polymer on protein release and 
eventually bone healing will be revealed. 
 
9.2.6   A PCL nanofiber scaffold fabricated by electrospinning and its potential for 
bone tissue engineering 
An alternative scaffold fabrication technique namely electrostatic fiber spinning or 
electrospinning was recently introduced. This method produces highly porous non-woven 
fabrics consisting of fibers in the nanometer range. Due to the small fiber diameters and 
the overall porous structure, electrospun fabrics have an extremely high surface area to 
volume ratio that is beneficial for the attachment of growth factors and cells within the 
scaffold. One exciting idea is to deposit growth factor-impregnated electrospun fibers as 
a thin layer onto the PCL or PCL-TCP scaffolds. In addition, the high surface area 
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facilitates the absorption of fluid molecules which result in stable blood clot formation, 
hence aiding in the initial wound healing processes at the defect site.  
The fabrication method of polycaprolactone nanofibers by electrospinning is simple yet 
interesting. The PCL polymer solution is delivered at a constant flow rate (Q = 0.1 
ml/min) to a metal capillary (1.6 mm OD, 1 mm ID, 50 mm length) connected to a high-
voltage power supply. Upon applying a high voltage such as 13 kV, a fluid jet is ejected 
from the capillary. As the jet accelerates towards a grounded collector, the solvent 
evaporates and a charged polymer fiber is deposited on the collector in the form of a non-
woven fabric. The fabric is stored in a dessicator for several days, and then cut into 
squares of desired dimensions. For sterilization, the scaffolds are placed in 70 % ethanol 
for three hours. These nanofiber scaffolds may very well represent the next generation of 
synthetic biomaterials used as protein delivery systems. The extent of nanofiber 
deposition as well as its porosity can be tailored to achieve the best protein loading and 
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